
<html lang="en"     class="pb-page"  data-request-id="02fb4530-f3d6-4d2e-b3e2-136e4e12e8e8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b01256;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain" /></meta><meta name="dc.Creator" content="Mónica  García" /></meta><meta name="dc.Creator" content="Marina  Virgili" /></meta><meta name="dc.Creator" content="Mònica  Alonso" /></meta><meta name="dc.Creator" content="Carles  Alegret" /></meta><meta name="dc.Creator" content="Begoña  Fernández" /></meta><meta name="dc.Creator" content="Adriana  Port" /></meta><meta name="dc.Creator" content="Rosalía  Pascual" /></meta><meta name="dc.Creator" content="Xavier  Monroy" /></meta><meta name="dc.Creator" content="Alba  Vidal-Torres" /></meta><meta name="dc.Creator" content="María-Teresa  Serafini" /></meta><meta name="dc.Creator" content="José Miguel  Vela" /></meta><meta name="dc.Creator" content="Carmen  Almansa" /></meta><meta name="dc.Description" content="The synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are..." /></meta><meta name="Description" content="The synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 19, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01256" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01256" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01256" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01256" /></link>
        
    
    

<title>4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01256" /></meta><meta property="og:title" content="4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0016.jpeg" /></meta><meta property="og:description" content="The synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported. The different positions of the central scaffold, designed using a merging strategy of both target pharmacophores, were explored using a versatile synthetic approach. Phenethyl derivatives in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles. One of the best compounds, 15au, showed a balanced dual profile (i.e., MOR agonism and sigma antagonism) and a potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice. Contrary to oxycodone, as expected from the addition of σ1R antagonism, 15au showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084. At equianalgesic doses, 15au showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R antagonism may be a useful strategy for obtaining potent and safer analgesics." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01256"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01256">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01256&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01256&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01256&amp;href=/doi/10.1021/acs.jmedchem.9b01256" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2434-2454</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01407" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01436" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ<sub>1</sub> Receptor Antagonists for the Treatment of Pain</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Mónica García</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mónica García</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M%C3%B3nica++Garc%C3%ADa">Mónica García</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marina Virgili</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marina Virgili</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Carrer Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Virgili">Marina Virgili</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mònica Alonso</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mònica Alonso</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Carrer Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M%C3%B2nica++Alonso">Mònica Alonso</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carles Alegret</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carles Alegret</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Carrer Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carles++Alegret">Carles Alegret</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Begoña Fernández</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Begoña Fernández</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bego%C3%B1a++Fern%C3%A1ndez">Begoña Fernández</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adriana Port</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adriana Port</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adriana++Port">Adriana Port</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1881-6449" title="Orcid link">http://orcid.org/0000-0003-1881-6449</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rosalía Pascual</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rosalía Pascual</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rosal%C3%ADa++Pascual">Rosalía Pascual</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2535-0272" title="Orcid link">http://orcid.org/0000-0002-2535-0272</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xavier Monroy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xavier Monroy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xavier++Monroy">Xavier Monroy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alba Vidal-Torres</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alba Vidal-Torres</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alba++Vidal-Torres">Alba Vidal-Torres</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">María-Teresa Serafini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">María-Teresa Serafini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa-Teresa++Serafini">María-Teresa Serafini</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">José Miguel Vela</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">José Miguel Vela</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+Miguel++Vela">José Miguel Vela</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Carmen Almansa</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carmen Almansa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 0034934466148. E-mail: <a href="/cdn-cgi/l/email-protection#caa9aba6a7aba4b9ab8aafb9beafbcafe4a9a5a7"><span class="__cf_email__" data-cfemail="81e2e0edece0eff2e0c1e4f2f5e4f7e4afe2eeec">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carmen++Almansa">Carmen Almansa</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5665-4685" title="Orcid link">http://orcid.org/0000-0001-5665-4685</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01256&amp;href=/doi/10.1021%2Facs.jmedchem.9b01256" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2434–2454</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 19, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 August 2019</li><li><span class="item_label"><b>Published</b> online</span>19 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01256" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01256</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01256"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2333</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01256" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mónica&quot;,&quot;last_name&quot;:&quot;García&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Virgili&quot;},{&quot;first_name&quot;:&quot;Mònica&quot;,&quot;last_name&quot;:&quot;Alonso&quot;},{&quot;first_name&quot;:&quot;Carles&quot;,&quot;last_name&quot;:&quot;Alegret&quot;},{&quot;first_name&quot;:&quot;Begoña&quot;,&quot;last_name&quot;:&quot;Fernández&quot;},{&quot;first_name&quot;:&quot;Adriana&quot;,&quot;last_name&quot;:&quot;Port&quot;},{&quot;first_name&quot;:&quot;Rosalía&quot;,&quot;last_name&quot;:&quot;Pascual&quot;},{&quot;first_name&quot;:&quot;Xavier&quot;,&quot;last_name&quot;:&quot;Monroy&quot;},{&quot;first_name&quot;:&quot;Alba&quot;,&quot;last_name&quot;:&quot;Vidal-Torres&quot;},{&quot;first_name&quot;:&quot;María-Teresa&quot;,&quot;last_name&quot;:&quot;Serafini&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;Miguel Vela&quot;},{&quot;first_name&quot;:&quot;Carmen&quot;,&quot;last_name&quot;:&quot;Almansa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2434-2454&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01256&quot;},&quot;abstract&quot;:&quot;The synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported. The different positions of the central scaffold, designed using a merging strategy of both target pharmacophores, were explored using a versatile synthetic approach. Phenethyl derivatives in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles. One of the best compounds, 15au, showed a balanced dual profile (i.e., MOR agonism and sigma antagonism) and a potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice. Contrary to oxycodone, as expected from the addition of σ1R antagonism, 15au showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084. At equianalgesic doses, 15au showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R an&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01256&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01256" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01256&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01256" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01256&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01256" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01256&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01256&amp;href=/doi/10.1021/acs.jmedchem.9b01256" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01256" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01256" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01256%26sid%3Dliteratum%253Aachs%26pmid%3D31743642%26genre%3Darticle%26aulast%3DGarc%25C3%25ADa%26date%3D2020%26atitle%3D4-Aryl-1-oxa-4%252C9-diazaspiro%255B5.5%255Dundecane%2BDerivatives%2Bas%2BDual%2B%25CE%25BC-Opioid%2BReceptor%2BAgonists%2Band%2B%25CF%25831%2BReceptor%2BAntagonists%2Bfor%2Bthe%2BTreatment%2Bof%2BPain%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D2434%26epage%3D2454%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290663" title="Pharmacophores">Pharmacophores</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the sigma-1 receptor (σ<sub>1</sub>R) and the μ-opioid receptor (MOR) are reported. The different positions of the central scaffold, designed using a merging strategy of both target pharmacophores, were explored using a versatile synthetic approach. Phenethyl derivatives in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles. One of the best compounds, <b>15au</b>, showed a balanced dual profile (i.e., MOR agonism and sigma antagonism) and a potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice. Contrary to oxycodone, as expected from the addition of σ<sub>1</sub>R antagonism, <b>15au</b> showed local, peripheral activity in this test, which was reversed by the σ<sub>1</sub>R agonist PRE-084. At equianalgesic doses, <b>15au</b> showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ<sub>1</sub>R antagonism may be a useful strategy for obtaining potent and safer analgesics.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The adequate management of pain constitutes an important challenge because currently available treatments provide in many cases only modest improvements, leaving many patients unrelieved<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and leading to important productivity losses and socio-economical burden.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Existing pain therapies include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid agonists, calcium channel modulators, and antidepressants, but all of them show limited efficacy and a range of secondary effects that can preclude their use, especially in chronic settings.</div><div class="NLM_p">Opioids are among the most effective therapies when addressing severe pain states. They act through three different types of opioid receptors (μ, κ, and δ), which are transmembrane G-protein coupled receptors (GPCRs), although the main analgesic action is attributed to the activation of the μ-opioid receptor (MOR). However, the use of MOR agonists is limited by their important side effects, such as constipation, respiratory depression, emesis, dependence,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and tolerance.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> As a consequence, long-term treatment with MOR agonists usually require substantial increases in dosing in order to maintain a clinically satisfactory pain relief, which finally results in either unacceptable side effects, leading to poor patient compliance, or alternatively in addiction, as revealed by the recent opioid crisis affecting the USA.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Three of the most widely used MOR agonists, morphine (<b>1</b>), oxycodone (<b>2</b>), and fentanyl (<b>3</b>) are depicted in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative MOR agonists (<b>1</b>–<b>3</b>) and σ<sub>1</sub>R antagonists (<b>4</b>, <b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several approaches have attempted to improve the benefit-risk balance of opioids (i.e., to enhance or maintain their analgesic efficacy without increasing or, ideally, reducing their adverse effects). These include developing allosteric<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> MOR ligands, targeting different opioid receptor subtypes<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> or MOR receptor isoforms,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and reducing central nervous system (CNS) penetration.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> More recently, the development of biased ligands has attracted much attention and the G-protein biased (cAMP versus β-arrestin pathway) MOR agonist (GPB-MOR) oliceridine<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> was developed by Trevena on the basis of its improved side effects profile.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, currently prevailing evidence suggests that GPB-MOR will retain opioid-like abuse potential<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and the U.S. Food and Drug Administration recently declined to approve oliceridine.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">An alternative approach is the development of multimodal compounds exhibiting activity at both MOR and additional relevant target/s in the same molecule. This was the strategy behind the development by Grünenthal of cebranopadol,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> a highly potent dual MOR and nociceptin/orphanin FQ peptide ligand that reached phase 3 clinical trials, although progression to the market has not been reported.</div><div class="NLM_p">As a new approach to obtain potent but safer opioids, we devised dual compounds targeting both the MOR and the sigma-1 receptor (σ<sub>1</sub>R). The goal was to enhance the opioid analgesia component by adding unique analgesic properties provided by the σ<sub>1</sub>R antagonist component while reducing side effects. Accordingly, consistent with a role of the σ<sub>1</sub>R in chronic pain sensitizing conditions<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and modulation of opioid-induced efficacy- and safety-related outcomes,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> we reasoned that a dual MOR agonist and σ<sub>1</sub>R antagonist could provide analgesics with (i) similar efficacy to opioids, (ii) activity in chronic pain conditions with no/reduced pharmacodynamic tolerance, (iii) activity in pain of neuropathic origin, where opioids are poorly effective, and (iv) a better safety profile. This strategy also addressed the intrinsic multimodal nature of pain, which is often treated in the clinic by combination of available drugs.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Combination of two mechanisms of action in a single molecule is a major challenge, but as compared with drug cocktails or multicomponent drugs, multiple (dual) ligands offer the potential advantages of a better efficacy, superior treatment compliance (one instead of various pills at potentially different dosage intervals/frequency), lowering the risk of drug–drug interactions, simpler pharmacokinetics, and less variability, both in drug exposure and response to treatment among patients.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">The σ<sub>1</sub>R gene encodes a 24 kDa protein of 223 amino acids anchored to the endoplasmic reticulum (ER) and plasma membranes.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The σ<sub>1</sub>R sequence has no homology with other mammalian proteins and is structurally and functionally different from other target classes because it acts as a molecular chaperone that interacts with diverse proteins to modulate their functions. The first link of the σ<sub>1</sub>R to analgesia was established by Chien and Pasternak,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> who described it as an endogenous antiopioid system based on the finding that σ<sub>1</sub>R agonists counteracted opioid receptor-mediated analgesia, while σ<sub>1</sub>R antagonists, such as haloperidol (<b>4</b>), potentiated it. Many additional preclinical studies support a role of the σ<sub>1</sub>R in the treatment of pain.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The development of the σ<sub>1</sub>R knockout mice (σ<sub>1</sub>R-KO),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> which shows no obvious phenotype and perceives normally sensory stimuli, was a key milestone in this endeavor. In physiological conditions the responses of the σ<sub>1</sub>R-KO to mechanical and thermal stimuli were undistinguishable from wild-type mice, but they do not develop attenuated pain behaviors when pain pathways become sensitized following capsaicin or formalin injection or in neuropathic pain conditions after nerve injury (i.e., sciatic nerve ligation) or secondary to chemotherapy (i.e., paclitaxel-induced neuropathy). Many of these actions were confirmed by the use of σ<sub>1</sub>R antagonists and led to the advancement of one compound, S1RA (E-52862, <b>5</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> into clinical trials for the treatment of different pain states.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Interestingly, compound <b>5</b>, when administered in combination with morphine, potentiated its analgesia in models of nociceptive pain, but not its adverse effects, and reduced its addictive/rewarding effects as revealed in the conditioned place preference test paradigm.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Potentiation of opioid analgesia was reproduced combining other σ<sub>1</sub> antagonists and different μ-opioid reference agonists and has been evidenced in several animal pain models, including nociceptive, visceral, inflammatory, and neuropathic pain.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Clinical data support preclinical findings, as administration of compound <b>5</b> produced a clinically relevant reduction of opioid-associated adverse events (nausea, vomiting, and dizziness) and a meaningful reduction for the need of concomitant antiemetic medication, meaning that an enhancement of the benefit–risk of the opioid (morphine) overall clinical profile was obtained.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> All these preclinical and clinical results support the potential therapeutic value of a dual MOR agonist/σ<sub>1</sub>R antagonist compound for the treatment of pain.</div><div class="NLM_p">The design of dual drugs is a complex process because achieving good affinity at an appropriate ratio, the right agonistic/antagonistic pharmacological activity at each molecular target and selectivity for only two targets, while avoiding many others, is a significant challenge. An additional issue is getting the good ADME and physicochemical properties required for in vivo activity as the room for optimization is reduced by the need of keeping both activities.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Combining in the same molecule a MOR agonist and σ<sub>1</sub>R antagonist profile adds to this complexity also because there is no high throughput in vitro test for unambiguously establishing the functionality of σ<sub>1</sub>R ligands, often functionally designated only after in vivo testing.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Several approaches have been used for the design of dual compounds.<a onclick="showRef(event, 'ref18 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref29">(18,29)</a> The conceptually most simple is the mutual prodrug approach, where two active molecules are linked through a labile bond that cleaves in vivo to give the two unaltered compounds, which then act individually on their respective targets.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> A different approach is the design of bivalent ligands (or conjugates), where two pharmacophores are linked via a long spacer of variable chemical nature and are designed to span across homo- or heterodimeric GPCRs and target two individual receptors simultaneously.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Representative examples have been developed in the opioid field by the Portoghese group.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> This strategy usually provides high in vitro affinities but compounds not able to achieve oral activity and CNS penetration due to their high molecular weight and flexibility. Shortening the linker up to a point when the pharmacophores are touching provides the so-called “fused” dual compounds. However, the best scenario in relation to obtaining the desired drug-like properties, is provided by “merging” the two pharmacophores by taking advantage of commonalities in their structures, as exemplified by the aforementioned cebranopadol.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">As a first exploration to a new multimodal approach to potent and safer analgesics, we report here the synthesis and structure–activity relationships (SAR) studies that were designed using a merging approach and led to the identification of a new series of 4-aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives <b>15</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) with dual affinity toward the MOR and the σ<sub>1</sub>R.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TMSOI, NaH, DMSO, rt to 50 °C, 1 h; (b) EtOH–water 9:1, 100 °C, 16 h; (c) TEA, DCM, 0 °C, 2 h; (d) <sup>t</sup>BuOK, THF, −78 to −30 °C, 1–4 h; (e) TFA, DCM, rt or reflux; (f) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h.</p></p></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of the compounds described herein was accomplished as depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a> and indicated in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Starting from <i>N</i>-Boc-piperidone <b>6</b>, a highly versatile route was devised to prepare derivatives <b>15</b>, following a similar strategy previously described from <i>N</i>-Cbz-piperidone<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Epoxide <b>7</b> was prepared using Corey–Chaykovsky reagent,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> followed by thermal ring opening with arylamines <b>8</b>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> leading to aminoalcohols <b>9</b> in good yields. Acylation with an adequate acyl halide, <b>10</b>, and final intramolecular cyclization by treatment with potassium <i>tert</i>-butoxide at low temperatures rendered spirocyclic compounds <b>12</b>. Finally, Boc-deprotection followed by <i>N</i>-alkylation provides the target compounds <b>15</b> in good yields. In particular, this method was used for the preparation of compounds <b>15ah</b>–<b>aj</b> and <b>15an</b>–<b>aq</b> using the appropriate reagents, aniline <b>8</b>-<b>1</b>, 2-chloropropionyl chloride <b>10</b>-<b>1</b>, and the corresponding alkylating agents <b>14</b>.</div><div class="NLM_p">Although <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> is of general application, some variations were used in particular cases. In the case of simple R<sub>3</sub> groups, such as benzyl and phenethyl, the <i>N</i>-substituted piperidones (<b>16</b>) were commercially available and were used to prepare compounds <b>15</b> bearing the substituent R<sub>3</sub> right from the start. This allowed diversification in substituents R<sub>1</sub>-R<sub>2</sub> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) by building the spirobicyclic core following a similar strategy to that described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The related spiro compound <b>20</b> was prepared from aminoalcohol <b>18</b>-<b>1</b> (where R<sub>1</sub> is H and <i>n</i> is 1) upon treatment with carbonyldiimidazole (CDI).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TMSOI, NaH, DMSO, rt to 50 °C, 1 h; (b) EtOH–water 9:1, 100 °C, 16 h; (c) TEA, DCM, 0 °C, 2 h; (d) <sup>t</sup>BuOK, THF, −78 to −30 °C, 1–4 h; (e) CDI, THF, reflux, 16 h.</p></p></figure><div class="NLM_p">In an analogous way to that described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, the pyrrolidinyl derivative <b>21</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was prepared starting from <i>N</i>-benzylpyrrolidin-3-one with final exchange of R<sub>3</sub> group to install the phenethyl chain present in compound <b>21</b> by conventional <i>N</i>-debenzylation followed by <i>N</i>-alkylation, as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Activity of Reference Compounds <b>2</b>, <b>4</b>, and <b>5</b> and Compounds <b>15a</b>, <b>15b</b>, <b>20</b>, and <b>21</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0010.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) in a MOR binding assay using [3H]-DAMGO as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">MOR functionality (EC<sub>50</sub>) measuring cyclic AMP (cAMP) on CHO-K1 cells. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Efficacy of 100% is defined as the maximum effect induced by stimulation with DAMGO. It is provided for compounds showing EC<sub>50</sub> below 1000 nM in the functional assay.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) to human σ<sub>1</sub>R in transfected HEK-293 membranes using [<sup>3</sup>H](+)-pentazocine as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Less than 50% inhibition at 10 μM.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Less than 50% inhibition at 1 μM.</p></div></div><div></div></div><div class="NLM_p">Alternatively, the aryl or heteroaryl group in R<sub>1</sub> was installed in the last step of the sequence (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Epoxides <b>17</b> were treated with methanolic ammonia to render aminoalcohols <b>22</b>. Subsequent acylation and cyclization were conducted under modified reaction conditions regarding those shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, to minimize formation of byproducts derived from the amide NH present in compounds <b>24</b>. Thus, acylation was best performed under a biphasic system (ethyl acetate–water) and final cyclization to spirocyclic compounds <b>26</b> was carried out at higher temperatures and with inverse addition (acyl compound <b>24</b> was added over a solution of <i>tert</i>-butoxide). Finally, arylation with aryl halides <b>28</b> under Ullmann or Buchwald–Hartwig coupling conditions rendered target compounds <b>15n</b>–<b>p</b>, <b>15v</b>–<b>z</b>, and <b>15aa</b>–<b>ag</b>. Compounds <b>15ar</b>–<b>15at</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) were synthesized following a similar approach but starting from <i>N</i>-Boc protected epoxide <b>7</b>. It was transformed to key intermediate <b>27</b>, that was either converted into <b>26</b> or, alternatively, it was first arylated to render key precursor <b>12</b> and then substituent R<sub>3</sub> was incorporated as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>3,</sub> MeOH, rt, 16 h; (b) K<sub>2</sub>CO<sub>3</sub>, EtOAc–water, 0 °C, 30 min; (c) <sup>t</sup>BuOK, THF, rt, 16 h; (d) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>trans</i>-1,2-cyclohexanediamine, 1,4-dioxane, 110 °C, 16 h; (e) for compounds <b>15ab</b>, <b>15as</b>, <b>15ar</b>, and <b>15at</b>: Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 16 h; (f) TFA, DCM, rt, 3 h; (g) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h.</p></p></figure><div class="NLM_p">Compounds bearing a spirocyclopropyl group in position 2 were synthesized (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) using 4-methoxybenzyl (PMB) as <i>N</i>-protecting group. The key step was the acylation of aminoalcohol <b>30</b> with a conveniently functionalized acid chloride <b>31</b>,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> followed by treatment with excess of potassium <i>tert</i>-butoxide, which provided two concomitant cyclizations to yield the spirocyclopropyl compound <b>33</b> in 48% yield (two steps). Boc deprotection and introduction of the phenethyl chain was performed as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> to render <b>36</b>. Finally, PMB group removal using cerium ammonium nitrate (CAN) and arylation under Ullmann or Buchwald–Hartwig coupling conditions provided compounds <b>15m</b> and <b>15au</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH–water 9:1, 100 °C, 16 h; (b) TEA, DCM, 0 °C, 2 h; (c) <sup>t</sup>BuOK, THF, 0 °C, 2 h; (d) TFA, DCM, rt, 3 h; (e) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h; (f) CAN, acetonitrile–water, rt, 16 h; (g) Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 16 h; (h) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>trans</i>-1,2-cyclohexanediamine, 1,4-dioxane, 110 °C, 16 h.</p></p></figure><div class="NLM_p">Additionally, some compounds were obtained by functional group transformations over final derivatives. Compound <b>15g</b> was obtained by debenzylation of <b>15h</b>, while hydrolysis of <b>15i</b> afforded the acid <b>15j</b>, which was coupled with dimethylamine to provide <b>15k</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compounds <b>15q</b>, <b>15s</b>, and <b>15u</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) were obtained by demethylation of their methoxy precursors with boron tribromide, as described for <b>15q</b> in the experimental part. Compounds <b>15ak</b>, <b>15al</b>, and <b>15am</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) were obtained by acetylation of the corresponding anilines <b>40</b> that in turn were prepared by reduction of their nitrophenyl precursors, <b>39</b>, synthesized using the procedure describe in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of Substituents in R<sub>2</sub></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0011.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>2</sub>,R<sub>2′</sub></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub><b>i</b></sub> MOR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> MOR<a class="ref internalNav" href="#t2fn7" aria-label="b">b</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> MOR<a class="ref internalNav" href="#t2fn8" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> σ<sub>1</sub>R<a class="ref internalNav" href="#t2fn9" aria-label="d">d</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t2fn2" aria-label="e">e</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">α<sub>1</sub>AR<a class="ref internalNav" href="#t2fn3" aria-label="f">f</a> % inh (1  μM)</th><th class="colsep0 rowsep0" align="center">M<a class="ref internalNav" href="#t2fn4" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15c</b></td><td class="colsep0 rowsep0" align="center">Me, H</td><td class="colsep0 rowsep0" align="center">7 ± 6</td><td class="colsep0 rowsep0" align="center">14 ± 2</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">6 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="center">0.4</td><td class="colsep0 rowsep0" align="center">72</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15cS</b></td><td class="colsep0 rowsep0" align="center">Me, H (<i>S</i>)</td><td class="colsep0 rowsep0" align="center">69 ± 33</td><td class="colsep0 rowsep0" align="center">264 ± 128</td><td class="colsep0 rowsep0" align="center">83</td><td class="colsep0 rowsep0" align="center">14 ± 0.2</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="center">0.3</td><td class="colsep0 rowsep0" align="center">68</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15cR</b></td><td class="colsep0 rowsep0" align="center">Me, H (<i>R</i>)</td><td class="colsep0 rowsep0" align="center">8 ± 0.5</td><td class="colsep0 rowsep0" align="center">16 ± 7</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">21 ± 8</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="center">75</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15d</b></td><td class="colsep0 rowsep0" align="center">Et, H</td><td class="colsep0 rowsep0" align="center">3 ± 2</td><td class="colsep0 rowsep0" align="center">1 ± 0.3</td><td class="colsep0 rowsep0" align="center">99</td><td class="colsep0 rowsep0" align="center">6 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="center">0.4</td><td class="colsep0 rowsep0" align="center">75</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15e</b></td><td class="colsep0 rowsep0" align="center">Pr<sup>i</sup>, H</td><td class="colsep0 rowsep0" align="center">1 ± 0.1</td><td class="colsep0 rowsep0" align="center">0.2 ± 0.1</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="center">10 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="center">65</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15f</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>OMe, H</td><td class="colsep0 rowsep0" align="center">13 ± 3</td><td class="colsep0 rowsep0" align="center">32 ± 5</td><td class="colsep0 rowsep0" align="center">90</td><td class="colsep0 rowsep0" align="center">32 ± 10</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">1.9</td><td class="colsep0 rowsep0" align="center">63</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15g</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>OH, H</td><td class="colsep0 rowsep0" align="center">46 ± 12</td><td class="colsep0 rowsep0" align="center">125 ± 41</td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="center">209 ± 77</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">55</td><td class="colsep0 rowsep0" align="center">from <b>15h</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15h</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>OBn, H</td><td class="colsep0 rowsep0" align="center">40 ± 5</td><td class="colsep0 rowsep0" align="center">107 ± 37</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="center">40 ± 8</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">94</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15i</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>CO<sub>2</sub>Me, H</td><td class="colsep0 rowsep0" align="center">92 ± 36</td><td class="colsep0 rowsep0" align="center">181 ± 33</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">54 ± 17</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="center">0.2</td><td class="colsep0 rowsep0" align="center">72</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15j</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>CO<sub>2</sub>H, H</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t2fn5" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t2fn5" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t2fn5" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t2fn6" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t2fn6" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">from <b>15i</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15k</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>CONMe<sub>2</sub>, H</td><td class="colsep0 rowsep0" align="center">636 ± 172</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t2fn5" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">275 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t2fn6" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t2fn6" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">from <b>15j</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15l</b></td><td class="colsep0 rowsep0" align="center">Me, Me</td><td class="colsep0 rowsep0" align="center">3 ± 1</td><td class="colsep0 rowsep0" align="center">4 ± 1</td><td class="colsep0 rowsep0" align="center">98</td><td class="colsep0 rowsep0" align="center">13 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">92</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15m</b></td><td class="colsep0 rowsep0" align="center">spirocyclopropyl</td><td class="colsep0 rowsep0" align="center">15 ± 2</td><td class="colsep0 rowsep0" align="center">11 ± 4</td><td class="colsep0 rowsep0" align="center">93</td><td class="colsep0 rowsep0" align="center">9 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="center">4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) in a MOR binding assay using [3H]-DAMGO as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t2fn7"><sup><sup>b</sup></sup><p class="last">MOR functionality (EC<sub>50</sub>) measuring cyclic AMP (cAMP) on CHO-K1 cells. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t2fn8"><sup><sup>c</sup></sup><p class="last">Efficacy of 100% is defined as the maximum effect induced by stimulation with DAMGO. It is provided for compounds showing EC<sub>50</sub> below 1000 nM in the functional assay.</p></div><div class="footnote" id="t2fn9"><sup><sup>d</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) to human σ<sub>1</sub>R in transfected HEK-293 membranes using [<sup>3</sup>H](+)-pentazocine as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t2fn2"><sup><sup>e</sup></sup><p class="last">Whole-cell patch clamp hERG blockade.</p></div><div class="footnote" id="t2fn3"><sup><sup>f</sup></sup><p class="last">Percentage inhibition of α1A receptor at 1 μM ligand concentration.</p></div><div class="footnote" id="t2fn4"><sup><sup>g</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t2fn5"><sup><sup>h</sup></sup><p class="last">Less than 50% inhibition at 1 μM.</p></div><div class="footnote" id="t2fn6"><sup><sup>i</sup></sup><p class="last">Not tested.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exploration of Substituents in the Phenyl Ring of Position 4 (R<sub>1</sub>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0012.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1′</sub></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> MOR<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> MOR<a class="ref internalNav" href="#t3fn4" aria-label="b">b</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> MOR<a class="ref internalNav" href="#t3fn5" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>i</sub> σ<sub>1</sub>R<a class="ref internalNav" href="#t3fn6" aria-label="d">d</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t3fn7" aria-label="e">e</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">α<sub>1</sub>AR<a class="ref internalNav" href="#t3fn8" aria-label="f">f</a> % inh (1  μM)</th><th class="colsep0 rowsep0" align="center">M<a class="ref internalNav" href="#t3fn9" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15n</b></td><td class="colsep0 rowsep0" align="center">2-Cl</td><td class="colsep0 rowsep0" align="center">3 ± 1</td><td class="colsep0 rowsep0" align="center">1 ± 0.1</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15o</b></td><td class="colsep0 rowsep0" align="center">2-F</td><td class="colsep0 rowsep0" align="center">8 ± 2</td><td class="colsep0 rowsep0" align="center">4 ± 1</td><td class="colsep0 rowsep0" align="center">94</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15p</b></td><td class="colsep0 rowsep0" align="center">2-OMe</td><td class="colsep0 rowsep0" align="center">57 ± 7</td><td class="colsep0 rowsep0" align="center">144 ± 28</td><td class="colsep0 rowsep0" align="center">81</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t3fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15q</b></td><td class="colsep0 rowsep0" align="center">2-OH</td><td class="colsep0 rowsep0" align="center">535 ± 13</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t3fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">51 ± 12</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t3fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="center">from <b>15p</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15r</b></td><td class="colsep0 rowsep0" align="center">3-OMe</td><td class="colsep0 rowsep0" align="center">126 ± 71</td><td class="colsep0 rowsep0" align="center">304 ± 91</td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 5</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15s</b></td><td class="colsep0 rowsep0" align="center">3-OH</td><td class="colsep0 rowsep0" align="center">727 ± 583</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t3fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">55 ± 8</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t3fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">67</td><td class="colsep0 rowsep0" align="center">from <b>15r</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15t</b></td><td class="colsep0 rowsep0" align="center">4-OMe</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t3fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t3fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">14 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t3fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15u</b></td><td class="colsep0 rowsep0" align="center">4-OH</td><td class="colsep0 rowsep0" align="center">606 ± 367</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t3fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">122 ± 13</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t3fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="center">from <b>15t</b></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">See corresponding footnotes of <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</p></div><div class="footnote" id="t3fn4"><sup><sup>b</sup></sup><p class="last">MOR functionality (EC<sub>50</sub>) measuring cyclic AMP (cAMP) on CHO-K1 cells. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t3fn5"><sup><sup>c</sup></sup><p class="last">Efficacy of 100% is defined as the maximum effect induced by stimulation with DAMGO. It is provided for compounds showing EC<sub>50</sub> below 1000 nM in the functional assay.</p></div><div class="footnote" id="t3fn6"><sup><sup>d</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) to human σ<sub>1</sub>R in transfected HEK-293 membranes using [<sup>3</sup>H](+)-pentazocine as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t3fn7"><sup><sup>e</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t3fn8"><sup><sup>f</sup></sup><p class="last">Percentage inhibition of α1A receptor at 1 μM ligand concentration.</p></div><div class="footnote" id="t3fn9"><sup><sup>g</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t3fn2"><sup><sup>h</sup></sup><p class="last">Not tested.</p></div><div class="footnote" id="t3fn3"><sup><sup>i</sup></sup><p class="last">Less than 50% inhibition at 1 μM.</p></div></div></div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h; (b) Pd/C, MeOH, 3 bar H<sub>2</sub>, rt, 16 h; (c) AcCl, TEA, DCM, rt, 16 h.</p></p></figure><div class="NLM_p last">Enantiopure compounds <b>15</b> were obtained by chiral preparative HPLC separation of the corresponding racemic mixtures, as indicated in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>. The absolute configuration of the eutomers was assigned as (<i>R</i>) as established by chiral synthesis of compounds <b>15cR</b> and <b>15asR</b>. Starting from (<i>S</i>)-2-chloropropionyl chloride (<b>10–1S</b>, 95% ee) and following the procedure described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, with modified acylation conditions, the corresponding (<i>S</i>)-acyl derivative <b>19–1S</b> was obtained. This was cyclized assuming inversion of configuration to give compound <b>15cR</b> with 91% ee, as determined by chiral HPLC. In turn, compound <b>15asR</b> was prepared from <b>10–1S</b> using the procedure described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. However, it was only obtained with a 67% ee as determined by chiral HPLC due to partial epimerization in the metal catalyzed arylation step under the standard coupling conditions.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17873" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17873" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For the design of the dual MOR and σ<sub>1</sub>R ligands, we envisaged a merging approach, i.e., combining the two target pharmacophores in the same central core. As at the time we initiated the project there were no crystal structures available of any of the two receptors, the design was based on pharmacophore models generated from known available ligands for each of them. The MOR pharmacophore was generated with the “Auto Pharmacophore Generation” protocol within Discovery Studio,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> using morphine (<b>1</b>) as input ligand, chosen because of its structural rigidity. The protocol enumerates all pharmacophores compatible with the input molecule considering the following features: Hydrogen Bond Acceptor (HBA), Hydrogen Bond Donor (HBD), Hydrophobic (HYD), Negative Ionizable (NI), Positive Ionizable (PI), and Aromatic ring (AR). It then chooses those pharmacophores with the highest selectivity as predicted by a Genetic Function Approximation built from a training set of 500 pharmacophore models. Of the resulting selected pharmacophores, we prioritized the one having two HBA features (HBA1 and HBA2). The HBD generated on account of the two hydroxyl groups of morphine were discarded because other MOR agonists lacked these groups. As several opioid agonists, i.e., fentanyl (<b>3</b>), contain a HYD at the other site of the basic amine, a HYD was added (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), not as a requirement but as a potentially tolerated feature. In the case of the σ<sub>1</sub>R a new model was built using Langer pharmacophore<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> as starting point. On the basis of our in house SAR data,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> one of its four hydrophobic features, HYD1, was omitted as it was not deemed necessary for σ<sub>1</sub>R binding, and HYD3 and HYD4 were merged into one single HYD (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) MOR pharmacophore with aligned morphine (<b>1</b>); (B) σ<sub>1</sub>R pharmacophore with aligned E-52862 (<b>5</b>); (C) superposition of both models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With these results in hand, a merging approach seemed indeed feasible: both pharmacophores require a basic amine, i.e., a PI, and the AR of MOR may as well match a HYD present in the σ<sub>1</sub>R pharmacophore. Accordingly, both σ<sub>1</sub>R and MOR models were aligned by the PI, the HYD, and the HYD–AR pair. Their superposition is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C. On the basis of this model several bicyclic scaffolds were proposed (<b>15a</b>,<b>b</b>, <b>20</b>, and <b>21</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and the new series of dually active 4-aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives <b>15</b> was identified.</div><div class="NLM_p">The compounds synthesized were evaluated in a primary human σ<sub>1</sub>R binding assay using [<sup>3</sup>H]-(+)-pentazocine<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> as a radioligand and in a human MOR binding assay using [<sup>3</sup>H]-DAMGO<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> as a radioligand. The MOR functional assay was carried out by measuring cyclic AMP (cAMP) on CHO-K1 cells,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> providing EC<sub>50</sub> as well as <i>E</i><sub>max</sub> data (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Generally speaking, a full agonist profile is suggested for compounds active at the MOR with <i>E</i><sub>max</sub> above 80%. However, a cell line overexpressing the MOR with a high receptor reserve<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> is used in this assay, and thus no unequivocal determination of the functional nature (i.e., full vs partial agonism) can be established.</div><div class="NLM_p">The active compounds were also evaluated at 1 μM in a selectivity panel constituted by the guinea-pig sigma-2 receptor (σ<sub>2</sub>R) and the following human protein targets: 5-HT<sub>1A</sub> receptor, 5-HT<sub>2B</sub> receptor, α<sub>1</sub>A adrenoreceptor (α<sub>1</sub>AR), α<sub>2</sub>A adrenoreceptor, dopamine transporter, δ-opioid receptor, κ-opioid receptor, histamine H<sub>1</sub> receptor, norepinephrine transporter, and serotonin transporter. This panel includes targets validated for pain and others associated with undesirable side effects, in order to rule out off target activities that could interfere with the analgesic response of the compounds. In addition, we assayed from the beginning the blockade of the human ether-a-go-go-related gene (hERG), the well-known potassium channel linked to cardiac toxicity<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> because hERG inhibition was a recurrent issue in our previous σ<sub>1</sub>R programs.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The results obtained in a patch-clamp assay are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</div><div class="NLM_p">The initial compounds prepared contained the naked central scaffold and a benzyl (<b>15a</b>) or phenethyl (<b>15b</b>) tail (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Both of them showed an interesting σ<sub>1</sub>R affinity, but <b>15b</b> was superior regarding MOR agonism. Two modifications of the central scaffold, the 1-oxa-3,8-diazaspiro[4.5]decan-2-one derivative <b>20</b> and the 6-oxa-2,9-diazaspiro[4.5]decan-8-one derivative <b>21</b>, were also synthesized. Both of them showed good σ<sub>1</sub>R affinity but were poorly active at MOR. This could be explained by a worse compliance of <b>20</b> and <b>21</b> with the MOR pharmacophore because the ether oxygen in both scaffolds was not able to match HBA2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). On these bases, we decided to focus our SAR study on compound <b>15b</b>, which also showed affinity for two additional receptors of the selectivity panel (inhibitions at 1 μM of 85% for the α<sub>1</sub>AR and 69% for the 5-HT<sub>2B</sub> receptor). Because the α<sub>1</sub>AR activity was a constant throughout the series its binding results (% at 1 μM) are also reported in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Fitting of compounds <b>15b</b> (A), <b>20</b> (B), and <b>21</b> (C) into the overlapped MOR and σ<sub>1</sub>R pharmacophores. <b>20</b> and <b>21</b> do not match HBA2, as shown by the unhighlighted green spheres, automatically set by the Discovery Studio Ligand–Pharmacophore Mapping protocol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Exploration of substitution in position 2 of the central scaffold (R<sub>2</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) showed that methylation afforded a substantial increase in affinity on both primary targets. However, compound <b>15c</b> retained activity for the α<sub>1</sub>AR and the hERG channel. Hence, efforts in this program were mainly directed to reduce these off-target activities. Interestingly, while the σ<sub>1</sub>R affinity of the two enantiomers of <b>15c</b> was similar, the <i>R</i> enantiomer (<b>15cR</b>) showed an improvement on MOR agonism of 1 order of magnitude over the <i>S</i> counterpart. This enantiospecific increase in MOR affinity obtained with alkyl substitution in position 2 might be due to a favorable lipophilic interaction with the receptor near the HBA2 feature, not covered by the MOR pharmacophore model. A 4-fold difference in hERG inhibition also favored <b>15cR</b>, while α<sub>1</sub>AR affinity remained similar. Elongation of the alkyl chain to ethyl (<b>15d</b>) or isopropyl (<b>15e</b>) increased MOR activity, but the higher affinity for MOR versus the σ<sub>1</sub>R was not considered a desirable balance. The desired ratio of in vitro affinities for the MOR and σ<sub>1</sub>R receptors is complex to establish, and in fact this is one of the main challenges in the design of this particular class of dual compounds. However, a predominant affinity for MOR would not make evident the enhancement of the opioid analgesia provided by the σ<sub>1</sub>R antagonist component. Note that enhancement of opioid analgesia in combination studies was obtained using lower doses of opioids than of σ<sub>1</sub>R ligands (example morphine at 2.5–5 mg/kg and E-52862 at 40 mg/kg) and that maximal enhancement occurs when opioids are combined at low doses (around ED<sub>25</sub> if administered alone).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Introduction of a polar group, such as methoxy, provided a more balanced derivative (<b>15f</b>). However, its clogP decrease did not afford a significant improvement in hERG inhibition, and the same was observed for the hydroxymethyl derivative <b>15g</b>. Benzylation of this group (<b>15h</b>) was tolerated by both targets, but it was clearly detrimental regarding hERG inhibition, probably due to the its increased lipophilicity. Introduction of carboxyl derivatives (<b>15i</b>–<b>k</b>) decreased affinity for both primary targets. Altogether these results indicate that the introduction of carboxylic acid or polar groups to decrease cLogP, strategies that have been used to reduce hERG inhibition,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> are not applicable in this position. Finally, dimethylation provided a highly active compound, <b>15l</b>, but with high hERG inhibition, somehow reduced in the spirocyclopropyl analogue <b>15m</b>.</div><div class="NLM_p">Maintaining a methyl group in position 2, the introduction of substituents in the phenyl ring of position 4 was explored (R<sub>1</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Halogen atoms in <i>ortho</i> (<b>15n</b>,<b>o</b>) provided good affinities, but not the desired improvement in hERG inhibition that could have been achieved by generation of steric bulk through planarity reduction.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> A methoxy group in <i>ortho</i> (<b>15p</b>) reduced MOR affinity, which worsened with a hydroxyl group (<b>15q</b>). Similarly, these groups were not tolerated in the <i>meta</i> or <i>para</i> positions (<b>15r</b>–<b>u</b>). Introduction of other polar groups (CN, NHCOMe, or CONMe<sub>2</sub>) provided also a loss of affinity (results not shown).</div><div class="NLM_p">Introduction of heteroaryl groups in R<sub>1</sub> was also explored (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The three possible pyridyl isomers (<b>15v</b>–<b>x</b>) provided a decrease in MOR affinity in relation to the parent <b>15c</b>. A similar result was obtained with the pyrazinyl derivative <b>15y</b>, which in addition showed a high hERG inhibition. However, substitution by fluoro or trifluoromethyl groups in adequate positions of the 2- and 3-pyridyl derivatives (<b>15z</b>–<b>ag</b>) improved affinities. Particularly interesting were derivatives containing a trifluoromethyl group in <i>ortho</i> (<b>15ab</b>, <b>15ae</b>, <b>15af</b>), which showed better hERG inhibition results, probably due to increase in steric bulk.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Other five- and six-membered heterocycles were also introduced (results not shown), but all of them showed diminished MOR affinity. The only exception was a 2-thiazolyl group that showed acceptable affinities for the primary targets but an exceptionally high hERG inhibition, in spite of its reduced lipophilicity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Exploration of Heteroaryl Substituents in R<sub>1</sub></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0013.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> MOR<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> MOR<a class="ref internalNav" href="#t4fn4" aria-label="b">b</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> MOR<a class="ref internalNav" href="#t4fn5" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>i</sub> σ<sub>1</sub>R<a class="ref internalNav" href="#t4fn6" aria-label="d">d</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t4fn7" aria-label="e">e</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">α<sub>1</sub>AR<a class="ref internalNav" href="#t4fn8" aria-label="f">f</a> % inh (1  μM)</th><th class="colsep0 rowsep0" align="center">M<a class="ref internalNav" href="#t4fn9" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15v</b></td><td class="colsep0 rowsep0" align="center">2-pyridyl</td><td class="colsep0 rowsep0" align="center">930 ± 320</td><td class="colsep0 rowsep0" align="center">1987 ± 193</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 3</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t4fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">63</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15w</b></td><td class="colsep0 rowsep0" align="center">3-pyridyl</td><td class="colsep0 rowsep0" align="center">304 ± 76</td><td class="colsep0 rowsep0" align="center">627 ± 312</td><td class="colsep0 rowsep0" align="center">54</td><td class="colsep0 rowsep0" align="char" char="±">68 ± 17</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t4fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">69</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15x</b></td><td class="colsep0 rowsep0" align="center">4-pyridyl</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t4fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t4fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">88 ± 13</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t4fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">68</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15y</b></td><td class="colsep0 rowsep0" align="center">2-pyrazinyl</td><td class="colsep0 rowsep0" align="center">304 ± 122</td><td class="colsep0 rowsep0" align="center">527 ± 53</td><td class="colsep0 rowsep0" align="center">55</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">64</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15z</b></td><td class="colsep0 rowsep0" align="center">6-trifluoromethyl-2-pyridyl</td><td class="colsep0 rowsep0" align="center">90 ± 36</td><td class="colsep0 rowsep0" align="center">219 ± 156</td><td class="colsep0 rowsep0" align="center">91</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t4fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15aa</b></td><td class="colsep0 rowsep0" align="center">3-fluoro-2-pyridyl</td><td class="colsep0 rowsep0" align="center">93 ± 76</td><td class="colsep0 rowsep0" align="center">199 ± 58</td><td class="colsep0 rowsep0" align="center">90</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="center">77</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ab</b></td><td class="colsep0 rowsep0" align="center">3-trifluoromethyl-2-pyridyl</td><td class="colsep0 rowsep0" align="center">262 ± 47</td><td class="colsep0 rowsep0" align="center">343 ± 29</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="char" char="±">54 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">8.2</td><td class="colsep0 rowsep0" align="center">60</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ac</b></td><td class="colsep0 rowsep0" align="center">5-fluoro-3-pyridyl</td><td class="colsep0 rowsep0" align="center">204 ± 105</td><td class="colsep0 rowsep0" align="center">230 ± 36</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ad</b></td><td class="colsep0 rowsep0" align="center">6-trifluoromethyl-3-pyridyl</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t4fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t4fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">9 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t4fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">66</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ae</b></td><td class="colsep0 rowsep0" align="center">4-trifluoromethyl-3-pyridyl</td><td class="colsep0 rowsep0" align="center">28 ± 19</td><td class="colsep0 rowsep0" align="center">25 ± 6</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="char" char="±">63 ± 8</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">3.3</td><td class="colsep0 rowsep0" align="center">58</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15af</b></td><td class="colsep0 rowsep0" align="center">2-trifluoromethyl-3-pyridyl</td><td class="colsep0 rowsep0" align="center">123 ± 49</td><td class="colsep0 rowsep0" align="center">186 ± 6</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="char" char="±">48 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">3.8</td><td class="colsep0 rowsep0" align="center">55</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ag</b></td><td class="colsep0 rowsep0" align="center">5-trifluoromethyl-3-pyridyl</td><td class="colsep0 rowsep0" align="center">261 ± 115</td><td class="colsep0 rowsep0" align="center">721 ± 63</td><td class="colsep0 rowsep0" align="center">92</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">0.5</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="center">3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) in a MOR binding assay using [3H]-DAMGO as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t4fn4"><sup><sup>b</sup></sup><p class="last">MOR functionality (EC<sub>50</sub>) measuring cyclic AMP (cAMP) on CHO-K1 cells. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t4fn5"><sup><sup>c</sup></sup><p class="last">Efficacy of 100% is defined as the maximum effect induced by stimulation with DAMGO. It is provided for compounds showing EC<sub>50</sub> below 1000 nM in the functional assay.</p></div><div class="footnote" id="t4fn6"><sup><sup>d</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) to human σ<sub>1</sub>R in transfected HEK-293 membranes using [<sup>3</sup>H](+)-pentazocine as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t4fn7"><sup><sup>e</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t4fn8"><sup><sup>f</sup></sup><p class="last">Percentage inhibition of α1A receptor at 1 μM ligand concentration.</p></div><div class="footnote" id="t4fn9"><sup><sup>g</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t4fn2"><sup><sup>h</sup></sup><p class="last">Not tested.</p></div><div class="footnote" id="t4fn3"><sup><sup>i</sup></sup><p class="last">Less than 50% inhibition at 1 μM.</p></div></div></div><div class="NLM_p">Finally, position 9 (R<sub>3</sub>) was modified (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The phenethyl group of <b>15c</b> was substituted with fluorine atoms, which maintained potency but only in the case of the <i>ortho</i> derivative (<b>15ah</b>) a slight improvement in hERG inhibition was observed. Many other small groups were introduced (halogen, alkyl, alkoxy, hydroxyl, results not shown), but only the 3-acetylamino derivative <b>15al</b>, more active than its <i>ortho</i> (<b>15ak</b>) and <i>para</i> (<b>15am</b>) isomers, showed a favorable hERG inhibition result, not reproduced by its cyano analogue, <b>15an</b>. Introduction of five-membered rings provided a loss of MOR affinity, except for the thiophene analogue that showed a similar profile to the parent phenyl derivative <b>15c</b> (results not shown). In the case of six-membered heterocycles, the 3 and 4-pyridyl derivatives (<b>15ap</b>, <b>15aq</b>) showed an impaired MOR agonism, while the 2-pyridyl isomer (<b>15ao</b>), with a more hindered nitrogen atom, was tolerated, providing as well a reduction in hERG and α<sub>1</sub>AR inhibition. Unfortunately, pyridyl substitution of this isomer was detrimental either in terms of affinity or hERG inhibition (results not shown). In addition to the phenethyl type tails, more than 30 different substituents were introduced in R<sub>3</sub>. These went from elongation to phenylpropyl or phenoxyethyl to change to alkyl substituents, such as isopentyl, or introduction of polarity by preparing pyranylethyl, pyranylmethyl, morpholinoethyl, 1-piperidinylcarbonylmethyl, or carboxyethyl derivatives (results not shown). However, these modifications provided an impairment in MOR affinity that precluded any further consideration.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Exploration of Phenethyl Group Variation (R<sub>3′</sub>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0014.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>3′</sub></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> MOR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> MOR<a class="ref internalNav" href="#t5fn5" aria-label="b">b</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> MOR<a class="ref internalNav" href="#t5fn6" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>i</sub> σ<sub>1</sub>R<a class="ref internalNav" href="#t5fn7" aria-label="d">d</a> (<i>h</i>, nM)</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t5fn8" aria-label="e">e</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">α<sub>1</sub>AR<a class="ref internalNav" href="#t5fn9" aria-label="f">f</a> % inh (1 μM)</th><th class="colsep0 rowsep0" align="center">M<a class="ref internalNav" href="#t5fn10" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ah</b></td><td class="colsep0 rowsep0" align="center">2-fluorophenyl</td><td class="colsep0 rowsep0" align="center">6 ± 3</td><td class="colsep0 rowsep0" align="center">4 ± 0.3</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">81</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ai</b></td><td class="colsep0 rowsep0" align="center">3-fluorophenyl</td><td class="colsep0 rowsep0" align="center">10 ± 3</td><td class="colsep0 rowsep0" align="center">13 ± 3</td><td class="colsep0 rowsep0" align="center">94</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="center">0.6</td><td class="colsep0 rowsep0" align="center">74</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15aj</b></td><td class="colsep0 rowsep0" align="center">4-fluorophenyl</td><td class="colsep0 rowsep0" align="center">19 ± 7</td><td class="colsep0 rowsep0" align="center">25 ± 2</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">80</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ak</b></td><td class="colsep0 rowsep0" align="center">2-acetylaminophenyl</td><td class="colsep0 rowsep0" align="center">190 ± 14</td><td class="colsep0 rowsep0" align="center">342 ± 208</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="char" char="±">656 ± 10</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t5fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">68</td><td class="colsep0 rowsep0" align="center">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15al</b></td><td class="colsep0 rowsep0" align="center">3-acetylaminophenyl</td><td class="colsep0 rowsep0" align="center">144 ± 11</td><td class="colsep0 rowsep0" align="center">343 ± 76</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="char" char="±">147 ± 74</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="center">>10<a class="ref internalNav" href="#t5fn3" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="center">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15am</b></td><td class="colsep0 rowsep0" align="center">4-acetylaminophenyl</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t5fn4" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t5fn4" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">237 ± 47</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t5fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">60</td><td class="colsep0 rowsep0" align="center">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15an</b></td><td class="colsep0 rowsep0" align="center">3-cyanophenyl</td><td class="colsep0 rowsep0" align="center">49 ± 14</td><td class="colsep0 rowsep0" align="center">61 ± 15</td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 8</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="center">0.6</td><td class="colsep0 rowsep0" align="center">80</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ao</b></td><td class="colsep0 rowsep0" align="center">2-pyridyl</td><td class="colsep0 rowsep0" align="center">90 ± 16</td><td class="colsep0 rowsep0" align="center">229 ± 89</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="char" char="±">53 ± 14</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">49</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15ap</b></td><td class="colsep0 rowsep0" align="center">3-pyridyl</td><td class="colsep0 rowsep0" align="center">117 ± 120</td><td class="colsep0 rowsep0" align="center">853 ± 132</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="char" char="±">91 ± 28</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t5fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">67</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15aq</b></td><td class="colsep0 rowsep0" align="center">4-pyridyl</td><td class="colsep0 rowsep0" align="center">516 ± 143</td><td class="colsep0 rowsep0" align="center">1424 ± 387</td><td class="colsep0 rowsep0" align="center">81</td><td class="colsep0 rowsep0" align="char" char="±">112 ± 35</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t5fn2" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) in a MOR binding assay using [3H]-DAMGO as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t5fn5"><sup><sup>b</sup></sup><p class="last">MOR functionality (EC<sub>50</sub>) measuring cyclic AMP (cAMP) on CHO-K1 cells. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t5fn6"><sup><sup>c</sup></sup><p class="last">Efficacy of 100% is defined as the maximum effect induced by stimulation with DAMGO. It is provided for compounds showing EC<sub>50</sub> below 1000 nM in the functional assay.</p></div><div class="footnote" id="t5fn7"><sup><sup>d</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) to human σ<sub>1</sub>R in transfected HEK-293 membranes using [<sup>3</sup>H](+)-pentazocine as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t5fn8"><sup><sup>e</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t5fn9"><sup><sup>f</sup></sup><p class="last">Percentage inhibition of α1A receptor at 1 μM ligand concentration.</p></div><div class="footnote" id="t5fn10"><sup><sup>g</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t5fn2"><sup><sup>h</sup></sup><p class="last">Not tested.</p></div><div class="footnote" id="t5fn3"><sup><sup>i</sup></sup><p class="last">Less than 50% inhibition at 10 μM.</p></div><div class="footnote" id="t5fn4"><sup><sup>j</sup></sup><p class="last">Less than 50% inhibition at 1 μM.</p></div></div></div><div class="NLM_p">With the results of the individual modifications in hand, combinations of the best substituents were devised. More than 40 compounds were prepared, but only some of them offered the desired properties. As often happens in medicinal chemistry, assumptions that might seem logical did not work. Particularly, combining polar substituents at both ends of the central scaffold was detrimental for the primary activities. One of such examples is compound <b>15ar</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) that contains some of the best substituents in R<sub>1</sub> (4-trifluoromethyl-3-pyridyl) and R<sub>3</sub> (2-pyridylethyl). We hoped that this combination could improve hERG inhibition because <b>15ae</b> and <b>15ao</b> were among the best individual modifications in this respect, but unfortunately, and probably due to an overly reduction in lipophilicity, compound <b>15ar</b> showed reduced primary affinities.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Selected Derivatives after Combination of Best Substituents in R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0015.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) in a MOR binding assay using [3H]-DAMGO as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t6fn4"><sup><sup>b</sup></sup><p class="last">MOR functionality (EC<sub>50</sub>) measuring cyclic AMP (cAMP) on CHO-K1 cells. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t6fn5"><sup><sup>c</sup></sup><p class="last">Efficacy of 100% is defined as the maximum effect induced by stimulation with DAMGO. It is provided for compounds showing EC<sub>50</sub> below 1000 nM in the functional assay.</p></div><div class="footnote" id="t6fn6"><sup><sup>d</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>) to human σ<sub>1</sub>R in transfected HEK-293 membranes using [<sup>3</sup>H](+)-pentazocine as radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t6fn7"><sup><sup>e</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t6fn8"><sup><sup>f</sup></sup><p class="last">Percentage inhibition of α1A receptor at 1 μM ligand concentration.</p></div><div class="footnote" id="t6fn9"><sup><sup>g</sup></sup><p class="last">Methods used for the synthesis of compounds according to the Schemes described in the <a class="ref internalNav" href="#sec2" aria-label="Chemistry">Chemistry</a> section.</p></div><div class="footnote" id="t6fn2"><sup><sup>h</sup></sup><p class="last">Not tested.</p></div><div class="footnote" id="t6fn3"><sup><sup>i</sup></sup><p class="last">Less than 50% inhibition at 10 μM.</p></div></div><div></div></div><div class="NLM_p">In the end, the four most interesting derivatives identified are depicted in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Compounds <b>15asR</b> and <b>15atR</b> showed a balanced activity for the primary targets and reduced α<sub>1</sub>AR binding but yet retained some hERG inhibition. The <i>R</i>-enantiomer of compound <b>15al</b>, <b>15alR</b>, confirmed the reduced hERG inhibition, but, in addition to retaining α<sub>1</sub>AR binding, the presence of a functionality that could render an aniline moiety was considered as a downside in view of aniline reported link to idiosincratic toxicity.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Overall, <b>15au</b> emerged as the best derivative because it showed a good balance of primary targets affinity, a moderate α<sub>1</sub>AR binding (<i>K</i><sub>i</sub> = 470 nM) and was selective (less than 50% inhibition at 1 μM) in the remaining selectivity panel, except for the 5HT<sub>2B</sub> receptor, where it showed a <i>K</i><sub>i</sub> = 754 nM. Compound <b>15au</b> behaved as a potentially full MOR agonist (<i>E</i><sub>max</sub> = 100%) and was devoid of hERG inhibition. It also showed a good physicochemical profile, heralded by a good solubility (thermodynamic solubility of 2.63 mg/mL at pH 2 and 0.16 mg/mL at pH 7.4) and moderate basicity (p<i>K</i><sub>a</sub> 7.82) and lipophilicity (experimental log <i>P</i> 3.41). In addition, it showed adequate in vitro metabolic stability in human liver microsomes<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> (Cl<sub>int</sub> = 20 μL/min/mg protein) and no potential for drug–drug interactions based on the low inhibition (<50% at 10 μM) of recombinant human cytochrome P450 (rhCYP) isoforms (1A2, 2C9, 2C19, 2D6, 2E1, and 3A4).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Compound <b>15au</b> was tested in vivo in the mouse paw pressure pain test in comparison to oxycodone (<b>2</b>). Mechanical antinociception was measured as the increase in struggle response latency in drug-treated mice with respect to control mice when constant pressure (450 g) was applied to the hindpaw. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B, compound <b>15au</b> exerted a dose-dependent antinociceptive effect with an ED<sub>50</sub> of 15 mg/kg after ip administration (our standard route for in vivo testing of new compounds in order to ensure exposure), a reduced potency versus oxycodone (in this case administered orally, because we have historical data validating this route).</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose–response antinociception curves of compound <b>15au</b> (A) and oxycodone (<b>2</b> (B) in the paw pressure test in mice. Each point and vertical line represents the mean ± SEM percentage of antinociception (<i>n</i> = 8–12 per group). (C) Comparative effect of <b>15au</b> and <b>2</b> on the intestinal transit inhibition in the charcoal test in mice at equianalgesic doses (20 mg/kg ip and 10 mg/kg po, respectively) in the paw pressure test in mice. The bars and vertical lines represent the mean ± SEM percentage of antinociception or intestinal transit inhibition (<i>n</i> = 5–7). (D) Antinociception induced by ipl administration of <b>15au</b> (25 μg, ipl) in the paw pressure test in mice in comparison to the σ<sub>1</sub>R agonist PRE-084 (32 mg/kg, sc) and the concomitant administration of both <b>15au</b> and PRE-084. The bars and vertical lines represent the mean ± SEM struggle response latency during stimulation with 450 g of pressure on the hindpaw of mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The effect of <b>15au</b> on intestinal transit reduction (constipation) in mice was also evaluated as a measure of the potential of the compound in showing a reduced opioid-induced side effect profile. The percentage of distance traveled by charcoal meal versus the total length of the small intestine was measured after drug administration in relation to the control group that received vehicle. Systemic administration of compound <b>15au</b> elicited a reduced intestinal transit inhibition in mice in comparison with oxycodone at equianalgesic doses (20 mg/kg ip and 10 mg/kg po, respectively, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C).</div><div class="NLM_p last">In addition, compound <b>15au</b> locally administered (25 μg ipl) produced a clear antinociceptive effect in the paw pressure test in mice. This is a relevant fact because selective MOR agonists, such as oxycodone, fail to provide local analgesia,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> probably due to the fact that peripheral MOR antinociception in response to mechanical stimulation is limited by σ<sub>1</sub>R tonic inhibitory effect.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Interestingly, the mechanical antinociception induced by the local administration compound <b>15au</b> was abolished by concomitant administration of the σ<sub>1</sub>R agonist PRE-084<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> (32 mg/kg, sc), indicating that <b>15au</b> is recruiting σ<sub>1</sub>R (in addition to MOR) and acting as a σ<sub>1</sub>R antagonist to exert its in vivo antinociceptive effect (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, the synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives, <b>15</b>, as potent dual ligands for σ<sub>1</sub>R and MOR is reported herein. This family, which was designed by using a merging strategy of both target phamacophores, also displayed high hERG inhibition and suboptimal selectivity for the α<sub>1</sub>AR. Attempts to reduce hERG inhibition by increasing polarity were not successful, because both parameters poorly correlated in this case. In addition, marked reduction in lipophilicity led to a loss of potency for the primary targets. Significant improvements in the affinity for σ<sub>1</sub>R and MOR were achieved by substitution in position 2 of the central scaffold with small alkyl groups and the 2<i>R</i> enantiomer was shown to be the eutomer for MOR affinity. Phenethyl derivatives in position 9 and substituted aryl and pyridyl moieties in position 4 were the optimal residues for dual affinity. The best compound identified (<b>15au</b>) showed a balanced dual profile, low hERG inhibition and good ADME properties, as well as a promising in vivo behavior. Thus, compound <b>15au</b> showed analgesic activity in the mice paw pressure test comparable to oxycodone, but less opioid induced constipation at equianalgesic doses. Contrary to oxycodone, <b>15au</b> provided local analgesic activity, reversed by the σ<sub>1</sub>R agonist PRE-084. Altogether these results indicate that dual MOR-agonism/σ<sub>1</sub>R-antagonism could be a useful strategy for obtaining potent analgesics with a safer profile. Compound <b>15au</b> was selected for a lead optimization program that led to the discovery of a clinical candidate, whose identification will be reported soon.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. Reference compounds used in biological assays were obtained from the following vendors: oxycodone hydrochloride (<b>2</b>) from Macfarlan Smith Ltd. (UK), E-52862 (<b>5</b>) was obtained as previously described,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and PRE-084 ([2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate) hydrochloride was acquired from Tocris Cookson Ltd., Bristol, United Kingdom. Flash chromatography was performed on a Teledyne Isco CombiFlash RF system with disposable columns. <sup>1</sup>H spectra were recorded on a Varian Mercury 400 MHz (spectrometer fitted with a 5 mm ATB 1H/19F/X probe) with 2 H lock in deuterated solvents. Chemical shifts (δ) are in parts per million. Commercially available reagents and solvents (HPLC grade) were used without further purification for all the analytical tests. Analytical HPLC–MS for all final compounds and intermediates except <b>15cR</b>, <b>15cS</b>, and <b>15alR</b> were performed on an Agilent HP1200-MS 6110 system. A reverse phase XBridge C18 XP column was used (4.6 mm × 30 mm, 2.5 μm), gradient 5–100% B (A = 10 mM ammonium bicarbonate, B = acetonitrile) over 8 min, injection volume 1 μL, flow 2.0 mL/min, temperature 40 °C. UV spectra were recorded at 210 nm using an Agilent HP1200 VWD detector. Mass spectra were obtained over the range <i>m</i>/<i>z</i> 50–1000 by electron spray ionization (ESI) in positive mode using Agilent MS6110 simple quadrupole. Data were integrated and reported using Agilent ChemStation software. Analytical HPLC–MS for compounds <b>15cR</b>, <b>15cS</b>, and <b>15alR</b> were performed on a Waters Acquity H-Class system. A reverse phase Acquity UPLC BEH C18 column was used (2.1 mm × 50 mm, 1.7 μm), gradient 2–95% B (A = 10 mM ammonium bicarbonate, B = acetonitrile) over 4.75 min, injection volume 2 μL, flow 0.61 mL/min, temperature 35 °C. PDA spectra were recorded at 195–315 nm range using a Waters PDA detector. Mass spectra were obtained over the range <i>m</i>/<i>z</i> 100–1000 by electron spray ionization (ESI) in positive mode using Waters ZQ simple quadrupole. Data were integrated and reported using Waters Masslynx software. All final compounds displayed purity equal or higher than 95% as determined by said methods, with the exception of compounds <b>15m</b> and <b>15w</b>, whose purity was 93% and 94%, respectively. Accurate mass measurements were carried out using an Agilent 6540 UHD accurate-mass QTOF system and obtained by electron spray ionization (ESI) in positive mode. Chiral analytical and preparative HPLC were performed in Agilent 1100 analytical and preparative HPLC systems, respectively. The coated or immobilized polysaccharide columns were acquired from Chiral Technologies Europe; heptane and ethanol or IPA with or without DEA at variable proportions were used as mobile phases. All compounds active in biological assays were electronically filtered for structural attributes common to pan assay interference compounds (PAINS) and were found to be negative.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Determination of Physicochemical Properties</h3><div class="NLM_p last">p<i>K</i><sub>a</sub> was calculated using ACDLABS 9.0.3 and clogP using ChemDraw Ultra 10.0.3. Thermodynamic solubility was measured by HPLC after stirring solid compound for 24 h in phosphate buffer at pH = 7.4. log <i>P</i> and p<i>K</i><sub>a</sub> were determined by using a pHmetric technique<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> in a GlpKa or a Sirius-T3 analytical instrument.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General Procedures for the Synthesis of 4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives <b>15</b></h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> (2<i>R</i>)-2-Methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15cR</b>) (Representative Example of <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div class="NLM_p">Step 1: To a suspension of trimethylsulfoxonium iodide (13.00 g, 59.07 mmol) and NaH (2.36 g, 60 wt % in mineral oil, 59.00 mmol) in dry DMSO (70 mL), a solution of 1-phenethylpiperidin-4-one (<b>16</b>-<b>1</b>, 10.00 g, 49.19 mmol) in dry DMSO (70 mL) was added dropwise. The reaction mixture was stirred at rt for 30 min, then it was heated at 50 °C for 1 h. After cooling to rt, ice was slowly added and the reaction mixture was extracted three times with ethyl acetate. The organic phases were combined, washed with water, dried over MgSO<sub>4</sub>, and concentrated under vacuum to give 6-phenethyl-1-oxa-6-azaspiro[2.5]octane (<b>17</b>-<b>1</b>) as an orange oil (8.24 g, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31–7.25 (m, 2H), 7.23–7.17 (m, 3H), 2.87–2.79 (m, 2H), 2.74–2.58 (m, 8H), 1.88 (ddd, <i>J</i> = 13.2, 9.0, 4.3 Hz, 2H), 1.63–1.53 (m, 2H). HPLC-MS: purity 99%, <i>m</i>/<i>z</i> = 218.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2: To a solution of <b>17</b>-<b>1</b> (2.00 g, 9.20 mmol) in a mixture of EtOH–water 9:1 (40 mL), aniline (0.84 mL, 9.20 mmol) was added. The reaction mixture was heated to 100 °C overnight in an autoclave reactor. The solvent was removed under vacuum, and the residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give 1-phenethyl-4-((phenylamino)methyl)piperidin-4-ol (<b>18</b>-<b>1</b>) as a cream solid (2.18 g, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.24 (m, 2H), 7.23–7.14 (m, 5H), 6.72 (t, <i>J</i> = 7.3 Hz, 1H), 6.68 (d, <i>J</i> = 7.7 Hz, 2H), 3.95 (t, <i>J</i> = 6.3 Hz, 1H), 3.13 (d, <i>J</i> = 6.5 Hz, 2H), 2.85–2.80 (m, 2H), 2.80–2.72 (m, 2H), 2.67–2.59 (m, 2H), 2.48–2.40 (m, 1H), 1.81–1.69 (m, 4H). HPLC-MS: purity 93%, <i>m</i>/<i>z</i> = 311.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 3: To a solution of <b>18</b>-<b>1</b> (578 mg, 1.86 mmol) in DCM (22 mL), TEA (0.62 mL, 4.47 mmol) was added and the mixture was cooled to 0 °C under a nitrogen atmosphere. Then a solution of 2-chloropropionyl chloride (<b>10</b>-<b>1</b>, 0.27 mL, 2.79 mmol) in DCM (22 mL) was added dropwise, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO<sub>3</sub> was then added, and it was extracted with DCM. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give 2-chloro-<i>N</i>-((4-hydroxy-1-phenethylpiperidin-4-yl)methyl)-<i>N</i>-phenylpropanamide (<b>19</b>-<b>1</b>) as an oil used in the next step without further purification (670 mg, 89%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.49–7.36 (m, 4H), 7.30–7.23 (m, 3H), 7.22–7.15 (m, 3H), 4.31 (q, <i>J</i> = 6.6 Hz, 1H), 3.89 (d, <i>J</i> = 14.2 Hz, 1H), 3.77 (d, <i>J</i> = 14.2 Hz, 1H), 2.84–2.77 (m, 2H), 2.77–2.67 (m, 2H), 2.67–2.57 (m, 2H), 2.54–2.40 (m, 2H), 1.76–1.67 (m, 2H), 1.67–1.60 (m, 2H), 1.58 (d, <i>J</i> = 6.6 Hz, 3H).</div><div class="NLM_p">Step 4: To a solution of <b>19</b>-<b>1</b> (670 mg, 1.67 mmol) in THF (28 mL), cooled to −78 °C using a dry ice/acetone bath, and potassium <i>tert</i>-butoxide solution (2.5 mL, 1 M in THF, 2.50 mmol) was added under a nitrogen atmosphere. The reaction mixture was then stirred at −30 °C for 3 h. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15c</b>) as a cream solid (511 mg, 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.44–7.37 (m, 2H), 7.32–7.26 (m, 5H), 7.23–7.17 (m, 3H), 4.38 (q, <i>J</i> = 6.8 Hz, 1H), 3.81 (d, <i>J</i> = 12.2 Hz, 1H), 3.41 (d, <i>J</i> = 12.2 Hz, 1H), 2.89–2.78 (m, 2H), 2.78–2.51 (m, 5H), 2.44 (t, <i>J</i> = 10.3 Hz, 1H), 2.28 (d, <i>J</i> = 14.1 Hz, 1H), 1.82–1.69 (m, 3H), 1.53 (d, <i>J</i> = 6.8 Hz, 3H). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 364.2227 (−0.93).</div><div class="NLM_p last">Starting from racemic <b>15c</b> (241 mg), a chiral preparative HPLC separation (column, Chiralpak IA; temperature, ambient; flow, 12 mL/min; eluent, <i>n</i>-heptane/(IPA + 2% DEA) 95/5 v/v) was carried out to obtain (2<i>R</i>)-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15cR</b>) as a white solid (83 mg, recovery yield 69%) with ee 97% (chiral HPLC) and [α]<sub>D</sub><sup>20</sup> 35 (<i>c</i> 0.09, CHCl<sub>3</sub>) and enantiomer (2<i>S</i>)-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15cS</b>) as a white solid (92 mg, recovery yield 77%) with ee 100% (chiral HPLC) and [α]<sub>D</sub><sup>20</sup> −35 (<i>c</i> 0.15, CHCl<sub>3</sub>). The absolute configuration was established by chiral synthesis of compound <b>15cR</b>: starting from (<i>S</i>)-2-chloropropionyl chloride (<b>10-1S</b>) (ee 95%) and following <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> but using modified acylation conditions (analogous to the ones described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> Step 2, i.e., potassium carbonate as base in a biphasic system of ethyl acetate-water), the corresponding (<i>S</i>)-acyl derivative (<b>19</b>-<b>1S</b>) was obtained, which assuming inversion of configuration in cyclization step, rendered compound <b>15cR</b> with ee 91%, as determined by chiral HPLC.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 2-(Hydroxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15g</b>)</h4><div class="NLM_p last">A mixture of 2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15h</b>, 1.53 g, 3.26 mmol) and palladium hydroxide (306 mg, 20 wt % on charcoal) in a mixture of THF/AcOH 9:1 (15 mL) was heated overnight at 50 °C under 3 bar of hydrogen. After inertizing with nitrogen, the catalyst was filtered off and the solvent was evaporated to dryness. This hydrogenation cycle was repeated 3 times, adding fresh catalyst each time until significant conversion was achieved. Then, the reaction mixture was finally filtered over a pad of Celite to remove the catalyst and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 2-(hydroxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro [5.5]undecan-3-one (<b>15g</b>) as a white solid (0.66 g, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.45–7.39 (m, 2H), 7.33–7.26 (m, 5H), 7.24–7.17 (m, 3H), 4.32 (t, <i>J</i> = 4.4 Hz, 1H), 4.07–3.89 (m, 2H), 3.81 (d, <i>J</i> = 12.3 Hz, 1H), 3.43 (d, <i>J</i> = 12.4 Hz, 1H), 2.93–2.53 (m, 6H), 2.53–2.38 (m, 1H), 2.30 (d, <i>J</i> = 14.9 Hz, 1H), 1.80 (br s, 2H), 1.57 (br s, 2H). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 380.2168 (1.4).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 2-(3-Oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetic Acid Hydrochloride (<b>15j</b>)</h4><div class="NLM_p last">To a solution of methyl 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetate (<b>15i</b>, 250 mg, 0.58 mmol) in a mixture of MeOH/water 7:1 (7 mL), potassium carbonate (317 mg, 2.29 mmol) was added, and the reaction mixture was stirred at rt for 6 days. Water was added, the pH was adjusted to 3–4 by addition of 1 M HCl aqueous solution, and it was extracted with DCM. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetic acid (<b>15j</b> free base) as a white solid (234 mg, quantitative). To a slurry of the previous free base (50 mg, 0.12 mmol) in anhydrous diethyl ether (1 mL), HCl (2 M solution in diethyl ether, 0.06 mL, 0.12 mmol) was added, and the mixture was stirred at rt for 1 h. The solids were filtered and dried in vacuo to give <b>15j</b> HCl salt as a white solid (53 mg, 97%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.51–7.40 (m, 2H), 7.40–7.22 (m, 8H), 4.60 (t, <i>J</i> = 4.7 Hz, 1H), 3.98 (d, <i>J</i> = 12.5 Hz, 1H), 3.73–3.52 (m, 3H), 3.47–3.24 (m, 4H), 3.20–3.08 (m, 2H), 2.97 (qd, <i>J</i> = 17.1, 4.7 Hz, 2H), 2.72 (d, <i>J</i> = 14.2 Hz, 1H), 2.19–1.90 (m, 3H). HPLC-MS: purity 98%. HRMS [M] (diff ppm) 408.2126 (−1).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> <i>N</i>,<i>N</i>-Dimethyl-2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetamide Hydrochloride (<b>15k</b>)</h4><div class="NLM_p last">To a solution of 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetic acid (<b>15j</b>, 50 mg, 0.12 mmol) in DCM (4 mL), dimethylamine solution (0.18 mL, 2 M in THF, 0.36 mmol), 1-hydroxybenzotriazole (18 mg, 0.13 mmol), <i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (24 mg, 0.12 mmol), and TEA (0.06 mL, 0.40 mmol) were added under a nitrogen atmosphere, and the reaction mixture was stirred at rt overnight. Water was added, and it was extracted with DCM. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give <i>N</i>,<i>N</i>-dimethyl-2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetamide (<b>15k</b> free base) as an oil (17 mg, 32%). To a solution of the previous free base (17 mg, 0.04 mmol) in anhydrous diethyl ether (1 mL), HCl (2 M solution in diethyl ether, 0.02 mL, 0.04 mmol) was added and the mixture was stirred at rt for 2 h. Then it was evaporated to dryness and dried in vacuo to give <b>15k</b> HCl salt as a white solid (14 mg, 76%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.48–7.41 (m, 2H), 7.40–7.24 (m, 8H), 4.63 (t, <i>J</i> = 4.7 Hz, 1H), 4.04 (d, <i>J</i> = 12.4 Hz, 1H), 3.70–3.56 (m, 2H), 3.53 (d, <i>J</i> = 12.4 Hz, 1H), 3.51–3.33 (m, 4H), 3.15–3.09 (m, 2H), 3.08 (s, 3H), 3.06 (d, <i>J</i> = 4.6 Hz, 2H), 2.98 (s, 3H), 2.77 (d, <i>J</i> = 15.4 Hz, 1H), 2.07–1.91 (m, 3H). HPLC-MS: purity 97%. HRMS [M] (diff ppm) 435.2605 (−2.1).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 8-Phenethyl-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one (<b>15m</b>) (Representative Example of <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> Using Copper Catalyst in Final Step)</h4><div class="NLM_p">Step 1: To a suspension of trimethylsulfoxonium iodide (24.30 g, 110.42 mmol) and NaH (4.40 g, 60 wt % in mineral oil, 110.00 mmol) in DMSO (140 mL), a solution of <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (<b>6</b>, 20.00 g, 100.38 mmol) in DMSO (140 mL) was added dropwise. The reaction mixture was stirred at rt for 30 min, then it was heated at 50 °C for 1 h. After cooling to rt, ice was slowly added, and the reaction mixture was extracted with ethyl acetate. The organic phases were combined, washed with water, dried over MgSO<sub>4</sub>, and concentrated under vacuum to give <i>tert</i>-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (<b>7</b>) as a white solid (17.60 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.77–3.63 (m, 2H), 3.42 (ddd, <i>J</i> = 13.3, 9.5, 3.7 Hz, 2H), 2.68 (s, 2H), 1.79 (ddd, <i>J</i> = 13.7, 9.5, 4.4 Hz, 2H), 1.46 (s, 9H), 1.44–1.40 (m, 2H). HPLC-MS: purity 95%, <i>m</i>/<i>z</i> = 158.1 [M + H-56]<sup>+</sup> (−tBu, Boc fragmentation).</div><div class="NLM_p">Step 2: To a solution of <b>7</b> (10.00 g, 46.89 mmol) in a mixture of EtOH–water 9:1 (200 mL), 4-methoxybenzylamine (6.43 g, 46.90 mmol) was added. The reaction mixture was heated at 100 °C overnight in a sealed vessel. The solvent was removed under vacuum, and the residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give <i>tert</i>-butyl 4-hydroxy-4-(((4-methoxybenzyl)amino)methyl) piperidine-1-carboxylate (<b>30</b>) as a yellow oil (13.55 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.25–7.20 (m, 2H), 6.89–6.84 (m, 2H), 3.80 (s, 3H), 3.89–3.70 (br s, 2H), 3.78 (s, 2H), 3.15 (t, <i>J</i> = 11.7 Hz, 2H), 2.55 (s, 2H), 1.54–1.47 (m, 2H), 1.45 (s, <i>J</i> = 9.5 Hz, 9H), 1.43–1.35 (m, 2H). HPLC-MS: purity 98%, <i>m</i>/<i>z</i> = 351.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 3: To a solution of compound <b>30</b> (9.94 g, 28.36 mmol) and TEA (9.5 mL, 68.16 mmol) in DCM (500 mL), a solution of 2-bromo-4-chlorobutanoyl chloride (<b>31</b>)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (9.35 g, 42.53 mmol) in DCM (200 mL) was added dropwise at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO<sub>3</sub> was added, and it was extracted with DCM. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give crude <i>tert</i>-butyl 4-((2-bromo-4-chloro-<i>N</i>-(4-methoxybenzyl)butanamido)methyl)-4-hydroxypiperidine-1-carboxylate (<b>32</b>) as an orange oil (15.10 g, quantitative). To a solution of crude <b>32</b> (14.80 g, 27.72 mmol) in THF (185 mL), cooled to 0 °C under a nitrogen atmosphere, potassium <i>tert</i>-butoxide solution (111 mL, 1 M in THF, 111.00 mmol) was slowly added, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NH<sub>4</sub>Cl was then added, and it was extracted with ethyl acetate. The organic phases were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give <i>tert</i>-butyl 12-(4-methoxybenzyl)-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate (<b>33</b>) as a yellow oil (5.51 g, 48%). <sup>1</sup>H NMR (400 MHz,CDCl<sub>3</sub>) δ 7.18 (d, <i>J</i> = 8.6 Hz, 2H), 6.87 (d, <i>J</i> = 8.7 Hz, 2H), 4.54 (s, 2H), 3.81 (s, 3H), 3.63 (br s, 2H), 3.18 (s, 2H), 3.06 (t, <i>J</i> = 11.4 Hz, 2H), 1.86 (d, <i>J</i> = 13.5 Hz, 2H), 1.43 (s, 9H), 1.48–1.34 (m, 4H), 0.98 (q, <i>J</i> = 4.5 Hz, 2H). HPLC-MS: purity 95%, <i>m</i>/<i>z</i> = 417.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 4: To a solution of <b>33</b> (1.50 g, 3.60 mmol) in DCM (36 mL), trifluoroacetic acid (2.8 mL, 36.34 mmol) was added, and the reaction mixture was stirred at rt for 4 h. The solvent was evaporated to dryness to give 12-(4-methoxybenzyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one trifluoroacetate (<b>34·TFA salt</b>) as a viscous yellow oil (2.30 g, 67 wt %, quantitative). The crude product was used in the following step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.31 (br s, 1H), 8.94 (br s, 1H), 7.20–7.16 (m, 2H), 6.92–6.84 (m, 2H), 4.54 (s, 2H), 3.80 (s, 3H), 3.24 (s, 2H), 3.20 (d, <i>J</i> = 12.1 Hz, 2H), 3.11–2.97 (m, 2H), 2.09 (d, <i>J</i> = 14.4 Hz, 2H), 1.75 (td, <i>J</i> = 14.5, 4.3 Hz, 2H), 1.46 (q, <i>J</i> = 4.7 Hz, 2H), 0.97 (q, <i>J</i> = 4.7 Hz, 2H).</div><div class="NLM_p">Step 5: A mixture of <b>34·TFA salt</b> (1.50 g, 67 wt %, 3.60 mmol), (2-bromoethyl)benzene (0.59 mL, 4.33 mmol), sodium iodide (0.32 g, 2.17 mmol), and K<sub>2</sub>CO<sub>3</sub> (2.49 g, 18.05 mmol) in acetonitrile (36 mL) was heated at 80 °C in a sealed tube overnight. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 12-(4-methoxybenzyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one (<b>36</b>-<b>1</b>) as an oil (1.17 g, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30–7.25 (m, 2H), 7.23–7.17 (m, 5H), 6.88–6.84 (m, 2H), 4.55 (s, 2H), 3.80 (s, 3H), 3.19 (s, 2H), 2.80–2.68 (m, 2H), 2.58–2.47 (m, 4H), 2.31 (td, <i>J</i> = 11.4, 2.7 Hz, 2H), 1.97–1.87 (m, 2H), 1.66–1.48 (m, 2H), 1.42 (dd, <i>J</i> = 7.9, 4.5 Hz, 2H), 0.99 (dd, <i>J</i> = 7.9, 4.5 Hz, 2H). HPLC-MS: purity 92%, <i>m</i>/<i>z</i> = 421.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 6: A mixture of <b>36</b>-<b>1</b> (0.17 g, 0.40 mmol) and CAN (0.57 g, 1.21 mmol) in a mixture of acetonitrile–water 1:1 (4 mL) was stirred at rt for 7 h. Saturated aqueous Na<sub>2</sub>CO<sub>3</sub> was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by eluting through an acidic ion-exchange resin cartridge (SCX) to give 8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one (<b>37</b>-<b>1</b>) as a pale-brown oil (106 mg, 88%). The crude product was used in the following step without further purification. <sup>1</sup>H NMR (400 MHz,) δ 7.32–7.27 (m, 2H), 7.23–7.17 (m, 3H), 5.83 (br s, 1H, NH), 3.37 (d, <i>J</i> = 2.7 Hz, 2H), 2.84–2.77 (m, 2H), 2.71–2.57 (m, 4H), 2.39 (t, <i>J</i> = 10.2 Hz, 2H), 2.08–2.00 (m, 2H), 1.79–1.70 (m, 2H), 1.37 (dd, <i>J</i> = 8.0, 4.6 Hz, 2H), 1.02 (q, <i>J</i> = 4.6 Hz, 2H).</div><div class="NLM_p last">Step 7: A mixture of <b>37</b>–<b>1</b> (50 mg, 0.17 mmol), K<sub>3</sub>PO<sub>4</sub> (72 mg, 0.34 mmol), CuI (4 mg, 0.02 mmol), <i>trans</i>-1,2-cyclohexanediamine (5 mg, 0.04 mmol), and iodobenzene (0.12 mL, 1.04 mmol) in dry 1,4-dioxane (1 mL) was heated in a sealed tube at 110 °C overnight under an argon atmosphere. The reaction mixture was allowed to cool to rt, and ethyl acetate and 1 M NaOH aqueous solution were added. The phases were separated, and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 8-phenethyl-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one (<b>15m</b>) as an oil (33 mg, 52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43–7.36 (m, 2H), 7.33–7.27 (m, 5H), 7.24–7.18 (m, 3H), 3.74 (s, 2H), 2.90–2.79 (m, 2H), 2.79–2.56 (m, 4H), 2.56–2.40 (m, 2H), 2.15 (br d, <i>J</i> = 13.6 Hz, 2H), 1.95–1.76 (m, 2H), 1.46 (dd, <i>J</i> = 8.0, 4.0 Hz, 2H), 1.07 (dd, <i>J</i> = 8.0, 4.0 Hz, 2H). HPLC-MS: purity 93%. HRMS [M] (diff ppm) 376.2228 (−1.3).</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-(2-Fluorophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one Hydrochloride (<b>15o</b>) (Representative Example of <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>)</h4><div class="NLM_p">Step 1: A mixture of 6-phenethyl-1-oxa-6-azaspiro[2.5]octane (<b>17</b>-<b>1</b>, 4.00 g, 18.41 mmol) and ammonia solution (79 mL, 7 M solution in MeOH, 0.55 mol) was stirred at rt overnight. The solvent was removed under vacuum to give 4-(aminomethyl)-1-phenethylpiperidin-4-ol (<b>22</b>-<b>1</b>) as a yellow oil (4.31 g, quantitative). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30–7.25 (m, 2H), 7.22–7.15 (m, 3H), 2.85–2.79 (m, 2H), 2.76 (dt, <i>J</i> = 7.0, 3.2 Hz, 2H), 2.66–2.59 (m, 4H), 2.44 (td, <i>J</i> = 10.8, 4.7 Hz, 2H), 1.66–1.54 (m, 4H). HPLC-MS: purity 90%, <i>m</i>/<i>z</i> = 235.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2: To a solution of <b>22</b>-<b>1</b> (4.95 g, 21.12 mmol) in ethyl acetate (45 mL), a solution of K<sub>2</sub>CO<sub>3</sub> (7.33 g, 53.03 mmol) in water (35 mL) was added. After cooling to 0 °C, 2-chloropropionyl chloride (<b>10</b>-<b>1</b>, 2.5 mL, 25.75 mmol) was added dropwise, and the reaction mixture was stirred at 0 °C for 30 min. The layers were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give 2-chloro-<i>N</i>-((4-hydroxy-1-phenethylpiperidin-4-yl)methyl)propanamide (<b>24</b>-<b>1</b>) as an orange oil (6.00 g, 88%), which was used in the following step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31–7.25 (m, 2H), 7.22–7.16 (m, 3H), 6.98 (s, 1H, NH), 4.45 (q, <i>J</i> = 7.0 Hz, 1H), 3.34 (d, <i>J</i> = 6.0 Hz, 2H), 2.84–2.76 (m, 2H), 2.75–2.67 (m, 2H), 2.67–2.58 (m, 2H), 2.50–2.41 (m, 2H), 1.75 (d, <i>J</i> = 7.1 Hz, 3H), 1.70–1.61 (m, 4H).</div><div class="NLM_p">Step 3: To a solution of potassium <i>tert</i>-butoxide (31.3 mL, 1 M in THF, 31.30 mmol) in THF (35 mL), a solution of <b>24</b>-<b>1</b> (6.00 g, 18.47 mmol) in THF (100 mL) was added dropwise over 3 h. The reaction mixture was stirred at rt overnight. The solvent was removed under vacuum, water was added to the residue, and it was extracted with ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give 2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>26</b>-<b>1</b>) as a beige solid (2.30 g, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.26 (m, 2H), 7.23–7.17 (m, 3H), 6.10 (br s, 1H, NH), 4.21 (q, <i>J</i> = 6.8 Hz, 1H), 3.37 (d, <i>J</i> = 11.9 Hz, 1H), 3.12 (dd, <i>J</i> = 11.9, 4.8 Hz, 1H), 2.85–2.78 (m, 2H), 2.74–2.67 (m, 1H), 2.67–2.60 (m, 2H), 2.59–2.48 (m, 1H), 2.35 (td, <i>J</i> = 11.2, 2.1 Hz, 1H), 2.20 (d, <i>J</i> = 14.0 Hz, 1H), 1.77–1.61 (m, 4H), 1.46 (d, <i>J</i> = 6.8 Hz, 3H). HPLC-MS: purity 100%, <i>m</i>/<i>z</i> = 289.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 4: A mixture of <b>26</b>-<b>1</b> (250 mg, 0.87 mmol), K<sub>3</sub>PO<sub>4</sub> (368 mg, 1.73 mmol), CuI (17 mg, 0.09 mmol), <i>trans</i>-1,2-cyclohexanediamine (0.02 mL, 0.17 mmol), and 1-fluoro-2-iodobenzene (0.12 mL, 1.04 mmol) in dry 1,4-dioxane (2 mL) was heated in a sealed tube at 110 °C overnight under an argon atmosphere. The reaction mixture was allowed to cool to rt, and ethyl acetate and 1 N NaOH aqueous solution were added. The phases were separated, and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 4-(2-fluorophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15o</b> free base) as an oil (213 mg, 64%). To a solution of the previous free base (213 mg, 0.56 mmol) in anhydrous diethyl ether (3 mL), HCl (2 M solution in diethyl ether, 0.28 mL, 0.56 mmol) was added and the mixture was stirred at rt for 1 h. The solids were filtered and dried in vacuo to give <b>15o</b> HCl salt as a white solid (188 mg, 81%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45–7.21 (m, 9H), 4.48 (q, <i>J</i> = 6.7 Hz, 1H), 3.89 (d, <i>J</i> = 12.7 Hz, 1H), 3.58 (br s, 2H), 3.45–3.35 (m, 3H), 3.30 (br s, 2H), 3.15–3.07 (m, 2H), 2.62 (br s, 1H), 2.04 (s, 3H), 1.51 (d, <i>J</i> = 6.7 Hz, 3H). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 382.2131 (−0.6).</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-(2-Hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15q</b>)</h4><div class="NLM_p last">To a solution of 4-(2-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15p</b>, 116 mg, 0.29 mmol) in DCM (6 mL), cooled to −78 °C under a nitrogen atmosphere, boron tribromide solution (1.5 mL, 1 M in DCM, 1.50 mmol) was added dropwise. The reaction mixture was allowed to warm to −20 °C for 2 h. Then, 6 N NaOH aqueous solution was added until pH 9–10, and it was extracted with DCM. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 4-(2-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15q</b>) as a white solid (42 mg, 35%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33–7.17 (m, 6H), 7.12 (d, <i>J</i> = 8.1 Hz, 1H), 7.04 (d, <i>J</i> = 8.1 Hz, 1H), 6.97 (t, <i>J</i> = 7.6 Hz, 1H), 4.41 (q, <i>J</i> = 6.6 Hz, 1H), 3.91 (d, <i>J</i> = 12.0 Hz, 1H), 3.46 (d, <i>J</i> = 12.0 Hz, 1H), 2.92–2.59 (m, 7H), 2.46 (t, <i>J</i> = 9.0 Hz, 1H), 2.24 (d, <i>J</i> = 15.4 Hz, 1H), 1.81 (br s, 3H), 1.56 (d, <i>J</i> = 6.6 Hz, 3H). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 380.219 (−4.6).</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 9-(2-Fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one Hydrochloride (<b>15ah</b>) (Representative Example of <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p">Step 1: To a solution of <i>tert</i>-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (<b>7</b>, 5.00 g, 23.44 mmol) in a mixture of EtOH–water 9:1 (103 mL), aniline (2.14 mL, 23.48 mmol) was added. The reaction mixture was heated to 100 °C overnight in an autoclave reactor. The solvent was removed under vacuum, and the residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give <i>tert</i>-butyl 4-hydroxy-4-((phenylamino)methyl)piperidine-1-carboxylate (<b>9</b>-<b>1</b>) as a white solid (4.90 g, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.18 (t, <i>J</i> = 7.9 Hz, 2H), 6.74 (t, <i>J</i> = 7.3 Hz, 1H), 6.68 (d, <i>J</i> = 8.3 Hz, 2H), 3.96–3.80 (m, 2H), 3.18 (t, <i>J</i> = 11.7 Hz, 2H), 3.12 (s, 2H), 1.89 (br s, 1H), 1.69–1.51 (m, 3H), 1.46 (s, 9H). HPLC-MS: purity 94%, <i>m</i>/<i>z</i> = 251.1 [M + H-56]<sup>+</sup> (−tBu, Boc fragmentation).</div><div class="NLM_p">Step 2: To a solution of <b>9</b>-<b>1</b> (4.90 g, 15.99 mmol)) in DCM (180 mL), TEA (5.3 mL, 38.03 mmol) was added and the mixture was cooled to 0 °C under a nitrogen atmosphere. Then 2-chloropropionyl chloride (<b>10</b>-<b>1</b>, 2.3 mL, 23.69 mmol) was added dropwise, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO<sub>3</sub> was added, the phases were separated, and the aqueous phase was extracted with DCM. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give <i>tert</i>-butyl 4-((2-chloro-<i>N</i>-phenylpropanamido)methyl)-4-hydroxypiperidine-1-carboxylate (<b>11</b>-<b>1</b>) as a cream solid used in the next step without purification (6.40 g, quantitative). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.50–7.37 (m, 3H), 7.35–7.23 (br s, 2H), 4.28 (q, <i>J</i> = 6.6 Hz, 1H), 3.81 (m, 4H), 3.15 (br s, 2H), 1.66–1.59 (m, 2H), 1.58 (d, <i>J</i> = 6.6 Hz, 3H), 1.42 (s, 9H), 1.41–1.35 (m, 2H).</div><div class="NLM_p">Step 3: To a solution of <b>11</b>-<b>1</b> (6.40 g, 16.12 mmol) in THF (280 mL), cooled to −78 °C using a dry ice/acetone bath, potassium <i>tert</i>-butoxide solution (25 mL, 1 M in THF, 25.00 mmol) was added under a nitrogen atmosphere. The reaction mixture was stirred at −78 °C for 30 min and then at −30 °C for 4 h. Saturated aqueous NaHCO<sub>3</sub> was added, and it was extracted with DCM. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give <i>tert</i>-butyl 2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5] undecane-9-carboxylate (<b>12</b>-<b>1</b>) as a white solid (4.56 g, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.44–7.35 (m, 2H), 7.29–7.24 (m, 3H), 4.36 (q, <i>J</i> = 6.8 Hz, 1H), 3.87 (br s, 2H), 3.80 (d, <i>J</i> = 12.3 Hz, 1H), 3.41 (d, <i>J</i> = 12.3 Hz, 1H), 3.28 (t, <i>J</i> = 12.2 Hz, 1H), 3.13 (t, <i>J</i> = 12.0 Hz, 1H), 2.22 (ddd, <i>J</i> = 13.8, 5.7, 2.8 Hz, 1H), 1.71 (ddd, <i>J</i> = 13.5, 5.8, 3.4 Hz, 1H), 1.63–1.55 (m, 2H), 1.53 (d, <i>J</i> = 6.8 Hz, 3H), 1.46 (s, 9H). HPLC-MS: purity 94%, <i>m</i>/<i>z</i> = 361.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 4: To a solution of <b>12</b>-<b>1</b> (3.24 g, 8.99 mmol) in DCM (31 mL), trifluoroacetic acid (6.2 mL, 80.97 mmol) was added, and the reaction mixture was refluxed for 5 h. The solvent was evaporated to dryness to give 2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one trifluoroacetate (<b>13</b>-<b>1·TFA</b> salt) as a viscous oil (5.49 g, 61 wt %, quantitative). The crude product was used in the following step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.30 (br s, 2H), 7.43 (t, <i>J</i> = 7.6 Hz, 2H), 7.34 (t, <i>J</i> = 7.4 Hz, 1H), 7.22 (d, <i>J</i> = 7.3 Hz, 2H), 4.39 (q, <i>J</i> = 6.7 Hz, 1H), 3.85 (d, <i>J</i> = 12.9 Hz, 1H), 3.53 (d, <i>J</i> = 12.9 Hz, 1H), 3.49–3.34 (m, 3H), 3.29–3.19 (m, 1H), 2.49 (d, <i>J</i> = 14.6 Hz, 1H), 2.03–1.88 (m, 3H), 1.56 (d, <i>J</i> = 6.8 Hz, 3H).</div><div class="NLM_p last">Step 5: A mixture of <b>13</b>-<b>1·TFA</b> salt (0.33 g, 61 wt %, 0.53 mmol), 1-(2-bromoethyl)-2-fluorobenzene (0.07 mL, 0.53 mmol), sodium iodide (0.05 g, 0.32 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.37 g, 2.67 mmol) in acetonitrile (4 mL) was heated at 80 °C in a sealed tube overnight. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 9-(2-fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15ah</b> free base) as an oil (148 mg, 72%). To a solution of the previous free base (148 mg, 0.39 mmol) in anhydrous diethyl ether (1.5 mL), HCl (2 M solution in diethyl ether, 0.19 mL, 0.39 mmol) was added and the mixture was stirred at rt for 3 h. The solids were filtered and dried in vacuo to give <b>15ah</b> HCl salt as a white solid (117 mg, 72%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.48–7.42 (m, 2H), 7.41–7.36 (m, 1H), 7.36–7.30 (m, 4H), 7.22–7.11 (m, 2H), 4.47 (q, <i>J</i> = 6.7 Hz, 1H), 3.94 (d, <i>J</i> = 12.9 Hz, 1H), 3.72–3.49 (m, 3H), 3.46–3.34 (m, 4H), 3.23–3.14 (m, 2H), 2.58 (br s, 1H), 2.13–1.93 (m, 3H), 1.51 (d, <i>J</i> = 6.7 Hz, 3H). HPLC-MS: purity 98%. HRMS [M] (diff ppm) 382.2142 (−3.4).</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2<i>R</i>-<i>N</i>-(3-(2-(2-Methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide (<b>15alR</b>) (Representative Example of <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>)</h4><div class="NLM_p">Step 1: A mixture of 2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one trifluoroacetate (<b>13</b>-<b>1·TFA</b> salt) (3.90 g, 53 wt %, 5.50 mmol), 1-(2-bromoethyl)-3-nitrobenzene (1.52 g, 6.60 mmol), sodium iodide (0.49 g, 3.30 mmol), and K<sub>2</sub>CO<sub>3</sub> (6.08 g, 43.99 mmol) in acetonitrile (46 mL) was heated at 80 °C in a sealed vessel overnight. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 2-methyl-9-(3-nitrophenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>39</b>-<b>1</b>) as a yellow oil (2.05 g, 91%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.12–8.04 (m, 2H), 7.56–7.51 (m, 1H), 7.48–7.37 (m, 4H), 7.31–7.27 (m, 2H), 4.37 (q, <i>J</i> = 6.8 Hz, 1H), 3.80 (d, <i>J</i> = 12.2 Hz, 1H), 3.41 (d, <i>J</i> = 12.2 Hz, 1H), 2.94–2.88 (m, 2H), 2.75–2.63 (m, 4H), 2.58 (td, <i>J</i> = 10.8, 3.5 Hz, 1H), 2.44 (td, <i>J</i> = 11.1, 2.5 Hz, 1H), 2.31–2.23 (m, 1H), 1.80–1.67 (m, 3H), 1.53 (d, <i>J</i> = 6.8 Hz, 3H). HPLC-MS: purity 96%, <i>m</i>/<i>z</i> = 410.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2: A mixture of <b>39</b>-<b>1</b> (2.05 g, 5.01 mmol) and palladium (205 mg, 10 wt % on charcoal, wet) in MeOH (39 mL) was stirred at rt under 4 bar of hydrogen overnight. Then, after inertizing with nitrogen, the reaction mixture was filtered over a pad of Celite to remove the catalyst. The filtrate was concentrated to dryness to give 9-(3-aminophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>40</b>-<b>1</b>) (1.42 g, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43–7.38 (m, 2H), 7.30–7.27 (m, 2H), 7.07 (t, <i>J</i> = 8.0 Hz, 1H), 6.61 (d, <i>J</i> = 7.4 Hz, 1H), 6.56–6.50 (m, 2H), 4.38 (q, <i>J</i> = 6.7 Hz, 1H), 3.81 (d, <i>J</i> = 12.2 Hz, 1H), 3.62 (br s, 2H), 3.42 (d, <i>J</i> = 12.1 Hz, 1H), 2.82–2.53 (m, 6H), 2.45 (t, <i>J</i> = 11.6 Hz, 1H), 2.28 (d, <i>J</i> = 13.9 Hz, 1H), 1.78 (br s, 2H), 1.53 (d, <i>J</i> = 6.8 Hz, 3H). HPLC-MS: purity 95%, <i>m</i>/<i>z</i> = 380.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 3: To a solution of <b>40</b>-<b>1</b> (0.63 g, 1.66 mmol) and TEA (0.35 mL, 2.51 mmol) in DCM (17 mL), cooled to 0 °C under a nitrogen atmosphere, acetyl chloride (0.13 mL, 1.83 mmol) was added dropwise. The reaction mixture was allowed to warm, and it was stirred at rt overnight. Saturated aqueous NaHCO<sub>3</sub> was added, and it was extracted with DCM. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give <i>N</i>-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide (<b>15al</b>) as a white solid (505 mg, 72% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.47 (s, 1H), 7.43–7.38 (m, 2H), 7.32–7.22 (m, 4H), 7.18 (s, 1H), 6.97 (d, <i>J</i> = 7.4 Hz, 1H), 4.36 (q, <i>J</i> = 6.7 Hz, 1H), 3.81 (d, <i>J</i> = 12.4 Hz, 1H), 3.46 (d, <i>J</i> = 12.5 Hz, 1H), 3.00–2.48 (m, 8H), 2.30 (d, <i>J</i> = 14.6 Hz, 1H), 2.17 (s, 3H), 2.04–1.79 (m, 3H), 1.53 (d, <i>J</i> = 6.8 Hz, 3H). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 421.2457 (−3).</div><div class="NLM_p last">Starting from racemic <b>15al</b>, a chiral preparative HPLC separation (column, Chiralpak ASH; temperature, ambient; flow: 9 mL/min; eluent, <i>n</i>-heptane/EtOH 80/20 v/v) was carried out to give 2<i>R</i>-<i>N</i>-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide (<b>15alR</b>) as a white solid (92 mg, recovery yield 41%) with ee 99% (chiral HPLC) and [α]<sub>D</sub><sup>20</sup> 43 (<i>c</i> 0.07, CHCl<sub>3</sub>). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 421.2453 (−3.5). Its enantiomer (<b>15alS</b>) was recovered as a white solid (123 mg, recovery yield 54%) with ee 95% (chiral HPLC).</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Methyl-9-(2-(pyridin-2-yl)ethyl)-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one Hydrochloride (<b>15ar</b>) (Representative Example of <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> Using Variation from Compound <b>12</b>)</h4><div class="NLM_p">Step 1: A mixture of <i>tert</i>-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (<b>7</b>, 16.67 g, 78.16 mmol) and ammonia solution (39 mL, 7 M solution in MeOH, 2.34 mol) was stirred at rt overnight. The solvent was removed under vacuum, and the residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give <i>tert</i>-butyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate (<b>23</b>) as a yellow oil (13.39 g, 74%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 3.86 (br s, <i>J</i> = 21.2 Hz, 2H), 3.17 (t, <i>J</i> = 12.0 Hz, 2H), 2.60 (s, 2H), 1.51 (d, <i>J</i> = 12.4 Hz, 2H), 1.46 (s, 9H), 1.43–1.32 (m, 2H). HPLC-MS: purity 97%, <i>m</i>/<i>z</i> = 175.1 [M + H-56]<sup>+</sup> (−tBu, Boc fragmentation).</div><div class="NLM_p">Step 2: To a solution of <b>23</b> (9.50 g, 41.25 mmol) in ethyl acetate (85 mL), a solution of K<sub>2</sub>CO<sub>3</sub> (15.90 g, 115.04 mmol) in water (66 mL) was added. After cooling to 0 °C, 2-chloropropionyl chloride (<b>10</b>–<b>1</b>, 5.4 mL, 56.09 mmol) was added dropwise and the reaction mixture was stirred at 0 °C for further 30 min. The layers were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give <i>tert</i>-butyl 4-((2-chloropropanamido)methyl)-4-hydroxypiperidine-1-carboxylate (<b>25</b>) as a yellow oil (12.20 g, 92%), which was used in the following step without purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.95 (t, <i>J</i> = 4.9 Hz, 1H, NH), 4.46 (q, <i>J</i> = 7.1 Hz, 1H), 3.80 (m, 2H), 3.33 (m, 2H), 3.27–3.13 (m, 2H), 1.75 (d, <i>J</i> = 7.1 Hz, 3H), 1.61–1.48 (m, 4H), 1.45 (s, 9H). HPLC-MS: purity 98%, <i>m</i>/<i>z</i> = 221.1 [M + H-100]<sup>+</sup> (−Boc, Boc fragmentation).</div><div class="NLM_p">Step 3: To a solution of potassium <i>tert</i>-butoxide (62.7 mL, 1 M in THF, 62.70 mmol) in a mixture of THF (164 mL) and <i>tert</i>-butanol (82 mL), warmed at 80 °C, a solution of <b>25</b> (12.20 g, 38.03 mmol) in THF (205 mL) was added dropwise over 3 h. The reaction mixture was stirred at rt overnight. The solvent was removed under vacuum, water was added to the residue, and it was extracted with ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give <i>tert</i>-butyl 2-methyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate (<b>27</b>) as a white solid (9.29 g, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.75 (br s, 1H, NH), 4.20 (q, <i>J</i> = 6.8 Hz, 1H), 3.82 (br s, 2H), 3.38 (d, <i>J</i> = 12.0 Hz, 1H), 3.26 (t, <i>J</i> = 11.9 Hz, 1H), 3.10 (dd, <i>J</i> = 11.9, 4.8 Hz, 1H), 3.05 (t, <i>J</i> = 11.0 Hz, 1H), 2.16 (d, <i>J</i> = 15.2 Hz, 1H), 1.67–1.49 (m, 3H), 1.46 (s, 9H), 1.46 (d, <i>J</i> = 6.8 Hz, 3H). HPLC-MS: purity 94%, <i>m</i>/<i>z</i> = 229.1 [M + H-56]<sup>+</sup> (−tBu, Boc fragmentation).</div><div class="NLM_p">Step 4: In a Schlenk tube, a mixture of <b>27</b> (1.00 g, 3.52 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.49 g, 7.74 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.16 g, 0.18 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.17 g, 0.29 mmol), and 3-bromo-4-(trifluoromethyl)pyridine (0.95 g, 4.22 mmol) in dry 1,4-dioxane (28 mL, previously degassed by bubbling N<sub>2</sub> gas) was heated at 110 °C overnight under a nitrogen atmosphere. The reaction mixture was allowed to cool to rt, and it was filtered over a pad of Celite and concentrated to dryness. The residue was submitted to a second reaction cycle with the same amount of reagents and catalyst, and it was stirred at 110 °C for 2 days. Then the reaction mixture was allowed to cool to rt, and it was filtered over a pad of Celite and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give <i>tert</i>-butyl 2-methyl-3-oxo-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate (<b>12</b>-<b>2</b>) as a cream solid (627 mg, 41%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 8.80 (d, <i>J</i> = 5.0 Hz, 1H), 8.63 (s, 0.6H), 8.54 (s, 0.4H), 7.66–7.61 (m, 1H), 4.39 (dq, <i>J</i> = 13.7, 6.8 Hz, 1H), 4.00–3.80 (m, 2H), 3.84 (d, <i>J</i> = 12.0 Hz, 0.4H), 3.71 (d, <i>J</i> = 11.6 Hz, 0.6H), 3.36–3.18 (m, 2H), 3.17–3.02 (m, 1H), 2.42–2.31 (m, 1H), 1.68 (t, <i>J</i> = 14.7 Hz, 1H), 1.56–1.49 (m, 5H), 1.47 (s, 9H). HPLC-MS: purity 95%, <i>m</i>/<i>z</i> = 374.1 [M + H-56]<sup>+</sup> (−tBu, Boc fragmentation).</div><div class="NLM_p">Step 5: To a solution of <b>12</b>-<b>2</b> (107 mg, 0.25 mmol) in DCM (2.5 mL), trifluoroacetic acid (0.2 mL, 2.50 mmol) was added, and the reaction mixture was refluxed for 5 h. The solvent was evaporated to dryness to give 2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one trifluoroacetate (<b>13</b>-<b>2·TFA</b> salt) as a crude product that was used in the following step without purification.</div><div class="NLM_p last">Step 6: A mixture of crude <b>13</b>-<b>2·TFA</b> salt (0.25 mmol), 2-(2-bromoethyl)pyridine hydrobromide (80 mg, 0.30 mmol), sodium iodide (22 mg, 0.15 mmol), and K<sub>2</sub>CO<sub>3</sub> (172 mg, 1.24 mmol) in acetonitrile (2.5 mL) was heated at 80 °C in a sealed tube overnight. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give 2-methyl-9-(2-(pyridin-2-yl)ethyl)-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15ar</b> free base) as a yellow oil (65 mg, 60%). To a solution of the previous free base (65 mg, 0.15 mmol) in anhydrous diethyl ether (0.6 mL), HCl (2 M solution in diethyl ether, 0.08 mL, 0.16 mmol) was added and the mixture was stirred at rt for 1 h. The solids were filtered and dried in vacuo to give <b>15ar</b> HCl salt as a white solid (49 mg, 71%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.86 (d, <i>J</i> = 5.1 Hz, 1H), 8.79 (s, 0.5H), 8.70 (s, 0.5 H), 8.57 (d, <i>J</i> = 4.9 Hz, 1H), 7.92–7.82 (m, 2H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (t, <i>J</i> = 5.9 Hz, 1H), 4.55 (q, <i>J</i> = 6.6 Hz, 0.5H), 4.51 (q, <i>J</i> = 6.8 Hz, 0.5H), 4.00 (d, <i>J</i> = 12.2 Hz, 0.5H), 3.89 (d, <i>J</i> = 12.5 Hz, 0.5H), 3.74–3.59 (m, 5H), 3.57–3.32 (m, 4H), 2.75 (t, <i>J</i> = 16.6 Hz, 1H), 2.23–1.98 (m, 3H), 1.55 (d, <i>J</i> = 6.7 Hz, 1.5H), 1.52 (d, <i>J</i> = 6.8 Hz, 1.5H). HPLC-MS: purity 98%. HRMS [M] (diff ppm) 434.2016 (−3.2).</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>R</i>)-9-(2-Fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one Hydrochloride (<b>15asR</b>) (Representative Example of <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> Using Variation from Compound <b>27</b>)</h4><div class="NLM_p">Step 1: To a solution of <i>tert</i>-butyl 2-methyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate (<b>27</b>, 3.22 g, 11.34 mmol) in DCM (32 mL), trifluoroacetic acid (8.7 mL, 113.40 mmol) was added, and the reaction mixture was stirred at rt for 5 h. The solvent was evaporated to dryness to give 2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one trifluoroacetate (<b>41</b>) as a crude product that was used in the following step without purification.</div><div class="NLM_p">Step 2: A mixture of <b>41</b> (11.34 mmol), 2-fluorophenethylmethanesulfonate (3.93 g, 18.01 mmol), and K<sub>2</sub>CO<sub>3</sub> (7.77 g, 56.20 mmol) in acetonitrile (94 mL) was heated at 80 °C in a sealed vessel overnight. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give 9-(2-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>26</b>-<b>2</b>) as a cream solid (2.65 g, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24–7.14 (m, 2H), 7.10–6.96 (m, 2H), 6.21 (br s, 1H, NH), 4.21 (q, <i>J</i> = 6.9 Hz, 1H), 3.37 (d, <i>J</i> = 11.9 Hz, 1H), 3.12 (dd, <i>J</i> = 11.9, 4.8 Hz, 1H), 2.89–2.80 (m, 2H), 2.76–2.52 (m, 5H), 2.37 (t, <i>J</i> = 10.1 Hz, 1H), 2.19 (d, <i>J</i> = 14.1 Hz, 1H), 1.74–1.60 (m, 3H), 1.46 (d, <i>J</i> = 6.8 Hz, 3H). HPLC-MS: purity 99%, <i>m</i>/<i>z</i> = 307.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 3: In a Schlenk tube, a mixture of <b>26</b>-<b>2</b> (2.06 g, 6.73 mmol), Cs<sub>2</sub>CO<sub>3</sub> (3.07 g, 9.42 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.31 g, 0.34 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.39 g, 0.67 mmol), and 3-bromo-4-(trifluoromethyl)pyridine (1.82 g, 8.07 mmol) in dry 1,4-dioxane (52 mL, previously degassed by bubbling N<sub>2</sub> gas) was heated at 110 °C overnight under a nitrogen atmosphere. The reaction mixture was allowed to cool to rt, and it was filtered over a pad of Celite and concentrated to dryness. The residue was submitted to a second reaction cycle with the same amount of reagents and catalyst, and it was stirred at 110 °C for 2 days. Then the reaction mixture was allowed to cool to rt, and it was filtered over a pad of Celite and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15as</b>) as a pale-brown solid (1.53 g, 50%). Starting from racemic <b>15as</b> (796 mg), a chiral preparative HPLC separation (column, Chiralpak ASH; temperature, ambient; flow, 12 mL/min; eluent, <i>n</i>-heptane/(EtOH + 0.33% DEA) 90/10 v/v) was carried out to give (<i>R</i>)-9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (<b>15asR</b>) as a white solid (315 mg) with ee 98.6% (chiral HPLC) and (<i>S</i>)-enantiomer <b>15asS</b> as a white solid (300 mg) with ee 98% (chiral HPLC). To a solution of compound <b>15asR</b> free base (315 mg, 0.70 mmol) in anhydrous diethyl ether (5 mL), HCl (2 M solution in diethyl ether, 0.38 mL, 0.76 mmol) was added and the mixture was stirred at rt for 1 h. The solids were filtered and dried in vacuo to give <b>15asR</b> HCl salt as a white solid (311 mg, 91%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.88 (d, <i>J</i> = 5.1 Hz, 1H), 8.82 (s, 0.5H), 8.73 (s, 0.5H), 7.88 (t, <i>J</i> = 5.9 Hz, 1H), 7.45–7.28 (m, 2H), 7.25–7.09 (m, 2H), 4.57–4.46 (m, 1H), 4.00 (d, <i>J</i> = 12.2 Hz, 0.5H), 3.89 (d, <i>J</i> = 12.5 Hz, 0.5H), 3.74–3.60 (m, 2H), 3.54–3.26 (m, 5H), 3.24–3.12 (m, 2H), 2.87–2.72 (m, 1H), 2.17–1.92 (m, 3H), 1.54 (d, <i>J</i> = 6.7 Hz, 1.5H), 1.51 (d, <i>J</i> = 6.8 Hz, 1.5H). HPLC-MS: purity 97%. HRMS [M] (diff ppm) 451.197 (−3.3). [α]<sub>D</sub><sup>20</sup> 21 (<i>c</i> 0.13, CHCl<sub>3</sub>).</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 8-(2-Fluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one Dihydrochloride (<b>15au</b>) (Representative Example of <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> Using Palladium Catalyst in Final Step)</h4><div class="NLM_p">Step 1: A mixture of 12-(4-methoxybenzyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one trifluoroacetate (<b>34·TFA</b> salt, 1.02 g, 2.37 mmol), 1-(2-bromoethyl)-2-fluorobenzene (0.63 mL, 3.11 mmol), sodium iodide (0.213 g, 1.42 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.64 g, 11.87 mmol) in acetonitrile (20 mL) was heated at 80 °C in a sealed tube overnight. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness to give 8-(2-fluorophenethyl)-12-(4-methoxybenzyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one (<b>36</b>-<b>2</b>) as an oil (1.04 g, quantitative). The crude product was used in the following step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.21–7.13 (m, 4H), 7.07–6.95 (m, 2H), 6.89–6.84 (m, 2H), 4.54 (s, 2H), 3.80 (s, 3H), 3.18 (s, 2H), 2.78 (dd, <i>J</i> = 9.7, 6.4 Hz, 2H), 2.57–2.50 (m, 4H), 2.33 (td, <i>J</i> = 11.2, 2.4 Hz, 2H), 1.92 (d, <i>J</i> = 13.7 Hz, 2H), 1.59–1.50 (m, 2H), 1.41 (q, <i>J</i> = 4.5 Hz, 2H), 0.98 (q, <i>J</i> = 4.5 Hz, 2H).</div><div class="NLM_p">Step 2: A mixture of <b>36</b>-<b>2</b> (1.04 g, 2.37 mmol) and CAN (3.33 g, 7.11 mmol) in a mixture of acetonitrile–water 1:1 (24 mL) was stirred at rt for 16 h. Saturated aqueous NaHCO<sub>3</sub> was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give 8-(2-fluorophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one (<b>37</b>–<b>2</b>) as a pale-brown oil (462 mg, 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24–7.15 (m, 2H), 7.08–7.04 (m, 1H), 7.04–6.98 (m, 1H), 6.19 (s, 1H, NH), 3.37 (d, <i>J</i> = 2.7 Hz, 2H), 2.91–2.83 (m, 2H), 2.79–2.68 (m, 2H), 2.68–2.61 (m, 2H), 2.44 (t, <i>J</i> = 11.2 Hz, 2H), 2.04 (d, <i>J</i> = 13.7 Hz, 2H), 1.82–1.75 (m, 2H), 1.40–1.33 (m, 2H), 1.01 (q, <i>J</i> = 4.6 Hz, 2H). HPLC-MS: purity 98%, <i>m</i>/<i>z</i> = 319.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 3: In a Schlenk tube, a mixture of <b>37</b>-<b>2</b> (100 mg, 0.31 mmol), Cs<sub>2</sub>CO<sub>3</sub> (133 mg, 0.41 mmol), tris(dibenzylideneacetone)dipalladium(0) (15 mg, 0.02 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (154 mg, 0.26 mmol), and 3-bromo-2-(trifluoromethyl)pyridine (85 mg, 0.38 mmol) in dry 1,4-dioxane (2.5 mL, previously degassed by bubbling N<sub>2</sub> gas) was heated at 110 °C overnight under a nitrogen atmosphere. The reaction mixture was allowed to cool to rt, and it was filtered over a pad of Celite and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 8-(2-fluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one (<b>15au</b> free base) as a cream solid (99 mg, 68%). To a solution of the previous free base (71 mg, 0.15 mmol) in MeOH (1.4 mL), HCl (2 M solution in diethyl ether, 0.17 mL, 0.34 mmol) was added and the mixture was stirred at rt for 1 h and then concentrated to dryness. To the residue, Et<sub>2</sub>O (1 mL) was added, and the suspension was stirred at rt for 15 min. The solids were filtered and dried in vacuo to give <b>15au</b> di-HCl salt as a white solid (60 mg, 79%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.73 (d, <i>J</i> = 4.0 Hz, 1H), 8.04 (d, <i>J</i> = 8.1 Hz, 1H), 7.81 (dd, <i>J</i> = 8.1, 4.7 Hz, 1H), 7.42–7.30 (m, 2H), 7.22–7.10 (m, 2H), 3.96 (d, <i>J</i> = 12.2 Hz, 1H), 3.70 (d, <i>J</i> = 12.2 Hz, 1H), 3.68–3.61 (m, 2H), 3.45–3.39 (m, 2H), 3.30–3.23 (m, 2H), 3.22–3.15 (m, 2H), 2.64 (d, <i>J</i> = 15.4 Hz, 1H), 2.37 (d, <i>J</i> = 15.2 Hz, 1H), 2.16–2.01 (m, 2H), 1.48–1.41 (m, 1H), 1.37–1.20 (m, 3H). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 463.1974 (−3.8).</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 8-Phenethyl-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (<b>20</b>)</h4><div class="NLM_p last">To a solution of 1-phenethyl-4-((phenylamino)methyl)piperidin-4-ol (<b>18</b>-<b>1</b>, 150 mg, 0.48 mmol) in THF (2 mL), 1,1′-carbonyldiimidazole (110 mg, 0.68 mmol) was added. The reaction mixture was heated to reflux overnight, and then it was concentrated to dryness. HPLC-MS analysis showed 65% conversion only, but workup was performed. The residue was diluted with brine, and it was extracted with Et<sub>2</sub>O. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 10%) to give 8-phenethyl-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (<b>20</b>) as a white solid (50 mg, 31%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.55 (d, <i>J</i> = 7.9 Hz, 2H), 7.41–7.35 (m, 2H), 7.33–7.27 (m, 2H), 7.24–7.18 (m, 3H), 7.14 (t, <i>J</i> = 7.4 Hz, 1H), 3.77 (s, 2H), 2.83 (dd, <i>J</i> = 10.0, 6.1 Hz, 2H), 2.76–2.59 (m, 6H), 2.12–2.02 (m, 2H), 1.97–1.85 (m, 2H). HPLC-MS: purity 97%. HRMS [M] (diff ppm) 336.1927 (−5.1).</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Phenethyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one Hydrochloride (<b>21</b>)</h4><div class="NLM_p">Step 1: A mixture of 2-benzyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one (<b>42</b>, prepared following the procedure described for compound <b>15c</b>, but starting from <i>N</i>-benzyl-pyrrolidin-3-one and 2-chloroacetyl chloride; 124 mg, 0.38 mmol) and palladium (12 mg, 10 wt % on charcoal) in MeOH (10 mL) was stirred at rt under 3 bar of hydrogen for 3 days. Then after inertizing with nitrogen, the reaction mixture was filtered over a pad of Celite to remove the catalyst and the filtrate was submitted to a second hydrogenation cycle, using fresh catalyst and a drop of AcOH. The mixture was stirred at rt under 3 bar of hydrogen overnight. Again, after inertizing with nitrogen, the reaction mixture was filtered over a pad of Celite, and the filtrate was concentrated to dryness to give 9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one (<b>43</b>) as an oil (96 mg, overweight, quantitative). The crude product was used in the following step without purification.</div><div class="NLM_p last">Step 2: A mixture of crude <b>43</b> (95 mg, 0.38 mmol), (2-bromoethyl)benzene (0.06 mL, 0.41 mmol) and DIPEA (0.18 mL, 1.06 mmol) in 1,4-dioxane (3 mL) was heated at 95 °C in a sealed tube overnight. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH up to 20%) to give 2-phenethyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one (<b>21</b> free base) as a an oil (23 mg, 18%). To a solution of the previous free base (23 mg, 0.07 mmol) in diethyl ether (2 mL), HCl (2 M solution in diethyl ether, 0.04 mL, 0.08 mmol) was added and the mixture was stirred at rt for 1 h. The solids were filtered and dried in vacuo to give <b>21</b> HCl salt as a white solid (19 mg, 75%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm: 7.50–7.43 (m, 2H), 7.40–7.26 (m, 8H), 4.45 (s, 2H), 4.18–3.37 (m, 8H), 3.12–3.02 (m, 2H), 2.64–2.24 (m, 2H). HPLC-MS: purity 100%. HRMS [M] (diff ppm) 336.1925 (−4.5).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Human Sigma-1 Receptor Radioligand Assay.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></h3><div class="NLM_p last">The binding properties of the test compounds to human σ<sub>1</sub>R were studied in transfected HEK-293 membranes using [<sup>3</sup>H](+)-pentazocine (PerkinElmer, NET-1056) as the radioligand. The assay was carried out with 7 μg of membrane suspension, [<sup>3</sup>H]-(+)-pentazocine (5 nM, 100 μL) in either absence or presence of either buffer or 10 μM haloperidol for total and nonspecific binding, respectively. Binding buffer contained Tris-HCl (50 mM, at pH 8). Plates were incubated at 37 °C for 120 min. After the incubation period, the reaction mix was transferred to MultiScreen HTS, FC plates (Millipore) presoaked in 100 μL of 0.1% polyethylenimine and filtered. Then, plates were washed (3 times) with ice-cold Tris-HCl (10 mM, pH 7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (PerkinElmer) using EcoScint liquid scintillation cocktail.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Human μ-Opioid Receptor Radioligand Assay.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></h3><div class="NLM_p last">Transfected CHO-K1 cell membranes (20 μg) were incubated with [<sup>3</sup>H]-DAMGO (1 nM,) in 250 μL of assay buffer containing 50 mM Tris-HCl and 5 mM MgCl<sub>2</sub> at pH 7.4. NBS (nonspecific binding) was measured by adding 10 μM naloxone. The binding of the test compound was measured at five different concentrations. Plates were incubated at 27 °C for 60 min. After the incubation period, the reaction mixture was then transferred to MultiScreen HTS, FC plates (Millipore) presoaked in 100 μL of 0.5% polyethylenimine and filtered. Then, plates were washed 3 times with ice-cold 10 mM Tris–HCl (pH 7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (PerkinElmer) using EcoScint liquid scintillation cocktail.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Human μ-Opioid Receptor Functionality.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></h3><div class="NLM_p last">cAMP measurements on CHO-K1 cells stably expressing human μ-opioid receptor (PerkinElmer, ES-542-C) were performed by using homogeneous time resolved fluorescence (HTRF). The 2500 cells/well were seeded the day before the experiment in Opti-Mem (10 μL) in 384 well plates. The compounds were prepared in Opti-Mem with 0.5 mM IBMX and 7.5 μM forskolin, and 10 μL added to the cells. After 45 min at 37 °C, the reaction was stopped by lysing the cells with a mixture of 10 μL of each HTRF detection reagents (Cisbio, 62AM4PEJ). Plates were incubated for an additional h at room temperature and read at 665 nm/620 nm using a RubyStar plate reader (BMG LabTech). DAMGO was included in each assay, and its maximum effect was considered as <i>E</i><sub>max</sub> = 100%.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Human α<sub>1A</sub> Adrenoreceptor Radioligand Assay.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></h3><div class="NLM_p last">Human α<sub>1A</sub> adrenoreceptor enriched membranes (10 μg) were incubated with 0.2 nM of radiolabeled [<sup>3</sup>H]-prazosin in 250 μL of assay buffer containing 50 mM Hepes, 5 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, and 0.2% BSA, pH 7.4. NSB (nonspecific binding) was measured by adding 1 μM prazosin in 25 μL volume. Final DMSO concentration was 0.1% (v/v). After 90 min incubation at 25 °C, binding reaction was terminated by filtering 200 μL through Multiscreen GF/C (Millipore) presoaked in 150 μL of 0.5% polyethylenimine in a vacuum manifold station, followed by three washes with 200 μL/well of ice-cold filtration buffer containing 50 mM Hepes, 500 mM NaCl, and BSA 0.1%, pH 7.4.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> hERG Assay.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></h3><div class="NLM_p last">CHO cells stably expressing hERG channels (Millipore) were cultured in F12 HAM medium supplemented with 10% FBS and 400 μg/L geneticin. The extracellular Ringer’s solution consisted of (in mM): 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 4 KCl, 145 NaCl, and 10 glucose, pH 7.4, 305 mOsm. The intracellular Ringer’s solution consisted of (in mM): 5.37 CaCl<sub>2</sub>, 1.75 MgCl<sub>2</sub>, 31.25/10 KOH/EGTA, 10 HEPES, and 210 KCl, pH 7.2, 295 mOsm. Then 4 mM Na<sub>2</sub>-ATP was added to intracellular Ringer’s solution shortly before use. Whole-cell currents were measured with a QPatch system (Sophion) in response to continuously executed voltage protocols as per manufacturer’s recommendations. Upon onset of the voltage protocol, cells were maintained at a holding potential (Vh) of −80 mV, then clamped briefly to −50 mV (20 ms), subsequently depolarized to 20 mV for 4800 ms, and finally repolarized to −50 mV for 5000 ms, at which potential the peak outward tail current was measured. Finally, the voltage returned to Vh for 3100 ms. Thus, voltage protocols were repeated each 15 s. For each cell, extracellular solution was applied previous to increasing concentrations of the tested compound.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> In Vivo Studies: Animals</h3><div class="NLM_p last">Six- to eight-week-old male CD1 mice were used. Animals had free access to food and water and were kept in controlled laboratory conditions with temperature at 21 ± 1 °C and a light–dark cycle of 12 h (lights on at 7:00 a.m.). Behavioral testing was conducted in a soundproof and air-regulated experimental room during the light phase and was carried out without knowledge of treatment. All animal husbandry and experimental procedures complied with European guidelines regarding the protection of animals used for experimental and other scientific purposes international standards (European Communities Council directive 2010/63) and were approved by the local ethics committee.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Drug Administration</h3><div class="NLM_p last">For systemic administration, compound <b>15au</b> and oxycodone (<b>2</b>) were dissolved in 0.5% hydroxypropyl methyl cellulose (HPMC) and administered ip or po, respectively, at a volume of 10 mL/kg. PRE-084 was dissolved in sterile physiologic saline (0.9% NaCl) and was administered sc at a volume of 5 mL/kg. To test for local effects of treatments, compound <b>15au</b> or its solvent were administered ipl in a volume of 20 μL.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Evaluation of Mechanical Nociception (Paw Pressure Test)</h3><div class="NLM_p last">The effects of the drugs on mechanical nociception were evaluated with an analgesimeter (model 37215; Ugo-Basile, Varese, Italy) according to previously described methods.<a onclick="showRef(event, 'ref50 ref51 ref55'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref55">(50,51,55)</a> In brief, the hindpaw of the mice was stimulated with a constant pressure of 450 g using a cone-shaped paw-presser with a rounded tip until the animal showed a struggle reaction. Immediately thereafter, the stimulus was stopped and the response latency (in seconds) was recorded. The test was done twice alternately to each hindpaw at intervals of 1 min between each stimulation, with a 50 s cutoff for each determination. The antinociceptive effect was evaluated 30 min after systemic administration of <b>15au</b> or <b>2</b>. When drugs were administered systemically, the struggle response latency was calculated as the mean of the two averaged times in each hindpaw because no differences between sides were seen in the response of each hindpaw. To study the local effects of <b>15au</b> or its solvent, the animals were evaluated 5 min after the injection to minimize possible systemic effects induced by the drug. The average of the two values from the injected (ipsi) and noninjected (contra) hindpaws was independently calculated.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Intestinal Transit Inhibition (Constipation)</h3><div class="NLM_p last">Intestinal transit was evaluated by identifying the leading front of an intragastrically administered marker located in the small intestine. A fresh 5% charcoal suspension in distilled water was prepared. Animals were fasted for 3–4 h and then given vehicle (HPMC 0.5%), oxycodone (10 mg/kg, po), or <b>15au</b> (20 mg/kg, ip). Then 30 min later, 0.3 mL of the charcoal suspension was administered by oral route using an intragastric probe, mice were sacrificed 30 min later under CO<sub>2</sub> atmosphere saturation, and the entire length of the small intestine was dissected free and removed from pylorus to ileocecal valve. The distance traveled by the charcoal meal, and the total length of the intestine were measured in cm. The percentage of the distance traveled by the charcoal meal in relation to the total length of the intestine was calculated. The percentage of intestinal transit versus the total intestine length of each animal, and the percentage of intestinal transit inhibition versus the vehicle-treated group were calculated as % of inhibition = (((% of intestinal transit of each mouse × 100)/mean % of intestinal transit of control group) – 100) × (−1).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Data and Statistical Analysis</h3><div class="NLM_p last">Data were expressed as means ± SEM. ED<sub>50</sub> values were determined using a four-parameter logistic equation (sigmoidal dose–response curve, variable slope). The effect of systemic treatments was expressed as percentage of antinociception: % antinociception = ((individual test latency – vehicle mean latency)/(cut-off latency – vehicle mean latency)) × 100. ED<sub>50</sub> was defined as the dose that produced 50% of the maximum possible effect. ED<sub>50</sub> values with 95% confidence intervals (CI) were calculated with GraphPad Prism version 5 software (San Diego, CA, USA) by using nonlinear regression methods.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01256" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04707" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04707" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01256?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01256</a>. <ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical data for all the final compounds and intermediates; chiral preparative HPLC separation data and optical purity of enantiopure compounds; HPLC traces for final compounds of formula <b>15</b>; interfeature distances and tolerance radii for the generated MOR and σ<sub>1</sub>R pharmacophores; experimental methods for affinity measurement in selectivity panel targets (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_001.pdf">jm9b01256_si_001.pdf (2.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_002.csv">jm9b01256_si_002.csv (5.34 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01256" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmen Almansa</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5665-4685" title="Orcid link">http://orcid.org/0000-0001-5665-4685</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e182808d8c808f9280a1849295849784cf828e8c"><span class="__cf_email__" data-cfemail="c7a4a6abaaa6a9b4a687a2b4b3a2b1a2e9a4a8aa">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mónica García</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Virgili</span> - <span class="hlFld-Affiliation affiliation">Carrer
Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mònica Alonso</span> - <span class="hlFld-Affiliation affiliation">Carrer
Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carles Alegret</span> - <span class="hlFld-Affiliation affiliation">Carrer
Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Begoña Fernández</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adriana Port</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1881-6449" title="Orcid link">http://orcid.org/0000-0003-1881-6449</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rosalía Pascual</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2535-0272" title="Orcid link">http://orcid.org/0000-0002-2535-0272</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xavier Monroy</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alba Vidal-Torres</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María-Teresa Serafini</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José Miguel Vela</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6776-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank M<sup>a</sup> Magdalena Bordas, Raquel Enrech, Joan Andreu Morató, Mónica Carro, Edmundo Ortega, Inés Álvarez, Pilar Pérez, Javier Burgueño, Marta Pujol, Enrique Hernández, Javier Farré, Eva Ayet, Raquel Fernández-Reinoso, Sandra Yeste, Georgia Gris, Carmen Segalés, Bertrand Aubel, Alicia Pardo, and Daniel Zamanillo for their expert contribution to analytical, in vitro and in vivo studies, and Carlos Pérez and Eduardo Villarroel for their contribution to compound management. This work was a part of activities in R&D projects IDI20130943 and IDI20150915, supported by the Spanish Ministerio de Economía y Competitividad (MINECO), through the Centro para el Desarrollo Tecnológico Industrial (CDTI), cofinanced by the European Union through the European Regional Development Fund (ERDF; Fondo Europeo de Desarrollo Regional, FEDER).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term">α1AR</td><td class="NLM_def"><p class="first last">adrenergic 1A receptor</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">aromatic group</p></td></tr><tr><td class="NLM_term">CAN</td><td class="NLM_def"><p class="first last">cerium ammonium nitrate</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GPB-MOR</td><td class="NLM_def"><p class="first last">G protein biased (versus β-arrestin pathway) μ-opioid receptor agonist</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen bond acceptor feature</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor feature</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HYD</td><td class="NLM_def"><p class="first last">hydrophobic feature</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">μ-opioid receptor</p></td></tr><tr><td class="NLM_term">NSAIDs</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">positive ionizable feature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">σ<sub>1</sub>R</td><td class="NLM_def"><p class="first last">sigma-1 receptor</p></td></tr><tr><td class="NLM_term">σ<sub>1</sub>R-KO</td><td class="NLM_def"><p class="first last">sigma-1 receptor knockout mice</p></td></tr><tr><td class="NLM_term">TMSOI</td><td class="NLM_def"><p class="first last">trimethylsulfoxonium iodide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahana, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic non-cancer pain</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2235</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60402-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2FS0140-6736%2811%2960402-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=21704872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=2226-2235&author=D.+C.+Turkauthor=H.+D.+Wilsonauthor=A.+Cahana&title=Treatment+of+chronic+non-cancer+pain&doi=10.1016%2FS0140-6736%2811%2960402-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic non-cancer pain</span></div><div class="casAuthors">Turk, Dennis C.; Wilson, Hilary D.; Cahana, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9784</span>),
    <span class="NLM_cas:pages">2226-2235</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Chronic pain is a pervasive problem that affects the patient, their significant others, and society in many ways.  The past decade has seen advances in our understanding of the mechanisms underlying pain and in the availability of tech. advanced diagnostic procedures; however, the most notable therapeutic changes have not been the development of novel evidenced-based methods, but rather changing trends in applications and practices within the available clin. armamentarium.  We provide a general overview of empirical evidence for the most commonly used interventions in the management of chronic non-cancer pain, including pharmacol., interventional, phys., psychol., rehabilitative, and alternative modalities.  Overall, currently available treatments provide modest improvements in pain and min. improvements in phys. and emotional functioning.  The quality of evidence is mediocre and has not improved substantially during the past decade.  There is a crucial need for assessment of combination treatments, identification of indicators of treatment response, and assessment of the benefit of matching of treatments to patient characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxyG7QutTErVg90H21EOLACvtfcHk0ljFogbJx5vH_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D&md5=55b3b3e920ec253406736fcee3337754</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960402-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960402-9%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DD.%2BC.%26aulast%3DWilson%26aufirst%3DH.%2BD.%26aulast%3DCahana%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520chronic%2520non-cancer%2520pain%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D2226%26epage%3D2235%26doi%3D10.1016%2FS0140-6736%2811%2960402-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, S. J.</span></span> <span> </span><span class="NLM_article-title">Pain as a global public health priority</span>. <i>BMC Public Health</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">770</span>, <span class="refDoi"> DOI: 10.1186/1471-2458-11-770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1186%2F1471-2458-11-770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=21978149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A280%3ADC%252BC3MbjvFChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=770&author=D.+S.+Goldbergauthor=S.+J.+McGee&title=Pain+as+a+global+public+health+priority&doi=10.1186%2F1471-2458-11-770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pain as a global public health priority</span></div><div class="casAuthors">Goldberg Daniel S; McGee Summer J</div><div class="citationInfo"><span class="NLM_cas:title">BMC public health</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">770</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pain is an enormous problem globally.  Estimates suggest that 20% of adults suffer from pain globally and 10% are newly diagnosed with chronic pain each year.  Nevertheless, the problem of pain has primarily been regarded as a medical problem, and has been little addressed by the field of public health.  DISCUSSION:  Despite the ubiquity of pain, whether acute, chronic or intermittent, public health scholars and practitioners have not addressed this issue as a public health problem.  The importance of viewing pain through a public health lens allows one to understand pain as a multifaceted, interdisciplinary problem for which many of the causes are the social determinants of health.  Addressing pain as a global public health issue will also aid in priority setting and formulating public health policy to address this problem, which, like most other chronic non-communicable diseases, is growing both in absolute numbers and in its inequitable distribution across the globe.  SUMMARY:  The prevalence, incidence, and vast social and health consequences of global pain requires that the public health community give due attention to this issue.  Doing so will mean that health care providers and public health professionals will have a more comprehensive understanding of pain and the appropriate public health and social policy responses to this problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3b5yAa6dhG-IHSmpohpd0fW6udTcc2eaAO9OdYeDfZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbjvFChtQ%253D%253D&md5=ef3530eca2039dd5bb7073816b0127c6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2F1471-2458-11-770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2458-11-770%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BS.%26aulast%3DMcGee%26aufirst%3DS.%2BJ.%26atitle%3DPain%2520as%2520a%2520global%2520public%2520health%2520priority%26jtitle%3DBMC%2520Public%2520Health%26date%3D2011%26volume%3D11%26spage%3D770%26doi%3D10.1186%2F1471-2458-11-770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meldrum, M. L.</span></span>, Ed. <span> </span><span class="NLM_article-title">Opioids and Pain Relief: A Historical Perspective</span>. In  <i>Progress in Pain Research and Management</i>; <span class="NLM_publisher-name">IASP Press</span>: <span class="NLM_publisher-loc">Seattle, WA</span>, <span class="NLM_year">2003</span>; Vol.  <span class="NLM_volume">25</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+L.+Meldrum&title=Progress+in+Pain+Research+and+Management"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeldrum%26aufirst%3DM.%2BL.%26atitle%3DOpioids%2520and%2520Pain%2520Relief%253A%2520A%2520Historical%2520Perspective%26btitle%3DProgress%2520in%2520Pain%2520Research%2520and%2520Management%26pub%3DIASP%2520Press%26date%3D2003%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickenson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span> <span> </span><span class="NLM_article-title">Opioids in neuropathic pain: Clues from animal studies</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.ejpain.2004.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejpain.2004.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15737797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslWrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=113-116&author=A.+H.+Dickensonauthor=R.+Suzuki&title=Opioids+in+neuropathic+pain%3A+Clues+from+animal+studies&doi=10.1016%2Fj.ejpain.2004.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids in neuropathic pain: clues from animal studies</span></div><div class="casAuthors">Dickenson, Anthony H.; Suzuki, Rie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-116</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1090-3801</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  For many years the clin. consensus was that opioids were ineffective in neuropathic pain.  However this view is changing and here we discuss the mechanisms of opioid analgesia in terms of the changes that can occur in preclin. models of nerve injury.  We argue that opioid mechanisms can be perturbed by neuropathy but in most cases these neg. influences can be overcome by dose-escalation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcGfiK-MHKLLVg90H21EOLACvtfcHk0lgRLMawtqXfDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslWrsro%253D&md5=edcad0356537b8256e5cb6152a06126e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpain.2004.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpain.2004.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DDickenson%26aufirst%3DA.%2BH.%26aulast%3DSuzuki%26aufirst%3DR.%26atitle%3DOpioids%2520in%2520neuropathic%2520pain%253A%2520Clues%2520from%2520animal%2520studies%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2005%26volume%3D9%26spage%3D113%26epage%3D116%26doi%3D10.1016%2Fj.ejpain.2004.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanath, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simopoulos, T. T.</span></span> <span> </span><span class="NLM_article-title">A Brief history of the opioid epidemic and strategies for pain medicine</span>. <i>Pain Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/s40122-018-0097-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1007%2Fs40122-018-0097-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=29691801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmtlekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=13-21&author=M.+R.+Jonesauthor=O.+Viswanathauthor=J.+Peckauthor=A.+D.+Kayeauthor=J.+S.+Gillauthor=T.+T.+Simopoulos&title=A+Brief+history+of+the+opioid+epidemic+and+strategies+for+pain+medicine&doi=10.1007%2Fs40122-018-0097-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A Brief History of the Opioid Epidemic and Strategies for Pain Medicine</span></div><div class="casAuthors">Jones Mark R; Viswanath Omar; Gill Jatinder S; Simopoulos Thomas T; Peck Jacquelin; Kaye Alan D</div><div class="citationInfo"><span class="NLM_cas:title">Pain and therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-21</span>
        ISSN:<span class="NLM_cas:issn">2193-8237</span>.
    </div><div class="casAbstract">The opioid epidemic has resulted from myriad causes and will not be solved by any simple solution.  Consequent to a staggering increase in opioid-related deaths in the USA, various governmental inputs and stakeholder strategies have been proposed and implemented with varying success.  This article summarizes the history of opioid use and explores the causes for the present day epidemic.  Recent trends in opioid-related data demonstrate an almost fourfold increase in overdose deaths from 1999 to 2008.  Tragically, opioids claimed over 64,000 lives just last year.  Some solutions have undergone legislation, including the limitation of numbers of opioids postsurgery, as well as growing national prevalence of enhanced recovery after surgery protocols which focus on reduced postoperative opioid consumption and shortened hospital stays.  Stricter prescribing practices and prescription monitoring programs have been instituted in the recent past.  Improvement in abuse deterrent strategies which is a major focus of the Food and Drug Administration (FDA) for all opioid preparations will likely play an important role by increasing the safety of these medications.  Future potential strategies such as additional legislative policies, public awareness, and physician education are also detailed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUyZ-LWOyWCEbxh97K6Vt6fW6udTcc2eY11pWOsHIuPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmtlekuw%253D%253D&md5=386633388006687ea4c304927a1625bb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs40122-018-0097-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40122-018-0097-6%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DM.%2BR.%26aulast%3DViswanath%26aufirst%3DO.%26aulast%3DPeck%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DA.%2BD.%26aulast%3DGill%26aufirst%3DJ.%2BS.%26aulast%3DSimopoulos%26aufirst%3DT.%2BT.%26atitle%3DA%2520Brief%2520history%2520of%2520the%2520opioid%2520epidemic%2520and%2520strategies%2520for%2520pain%2520medicine%26jtitle%3DPain%2520Ther.%26date%3D2018%26volume%3D7%26spage%3D13%26epage%3D21%26doi%3D10.1007%2Fs40122-018-0097-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burford, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">10830</span>– <span class="NLM_lpage">10835</span>, <span class="refDoi"> DOI: 10.1073/pnas.1300393110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1073%2Fpnas.1300393110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23754417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=10830-10835&author=N.+T.+Burfordauthor=M.+J.+Clarkauthor=T.+S.+Wehrmanauthor=S.+W.+Gerritzauthor=M.+Banksauthor=J.+O%E2%80%99Connellauthor=J.+R.+Traynorauthor=A.+Alt&title=Discovery+of+positive+allosteric+modulators+and+silent+allosteric+modulators+of+the+%CE%BC-opioid+receptor&doi=10.1073%2Fpnas.1300393110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor</span></div><div class="casAuthors">Burford, Neil T.; Clark, Mary J.; Wehrman, Tom S.; Gerritz, Samuel W.; Banks, Martyn; O'Connell, Jonathan; Traynor, John R.; Alt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">10830-10835,S10830/1-S10830/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">μ-Opioid receptors are among the most studied G protein-coupled receptors because of the therapeutic value of agonists, such as morphine, that are used to treat chronic pain.  However, these drugs have significant side effects, such as respiratory suppression, constipation, allodynia, tolerance, and dependence, as well as abuse potential.  Efforts to fine tune pain control while alleviating the side effects of drugs, both physiol. and psychol., have led to the development of a wide variety of structurally diverse agonist ligands for the μ-opioid receptor, as well as compds. that target κ- and δ-opioid receptors.  In recent years, the identification of allosteric ligands for some G protein-coupled receptors has provided breakthroughs in obtaining receptor subtype-selectivity that can reduce the overall side effect profiles of a potential drug.  However, pos. allosteric modulators (PAMs) can also have the specific advantage of only modulating the activity of the receptor when the orthosteric agonist occupies the receptor, thus maintaining spatial and temporal control of receptor signaling in vivo.  This second advantage of allosteric modulators may yield breakthroughs in opioid receptor research and could lead to drugs with improved side-effect profiles or fewer tolerance and dependence issues compared with orthosteric opioid receptor agonists.  Here, the authors describe the discovery and characterization of μ-opioid receptor PAMs and silent allosteric modulators, identified from high-throughput screening using a β-arrestin-recruitment assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdiTL5ko3pr7Vg90H21EOLACvtfcHk0lg6AgMzhw7lsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7nJ&md5=5fd64e5ae56607fa2396fdd3f32caf54</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1300393110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1300393110%26sid%3Dliteratum%253Aachs%26aulast%3DBurford%26aufirst%3DN.%2BT.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DWehrman%26aufirst%3DT.%2BS.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DBanks%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DAlt%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520positive%2520allosteric%2520modulators%2520and%2520silent%2520allosteric%2520modulators%2520of%2520the%2520%25CE%25BC-opioid%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D10830%26epage%3D10835%26doi%3D10.1073%2Fpnas.1300393110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeomans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobczyk-Kojiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span> <span> </span><span class="NLM_article-title">Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3148</span>– <span class="NLM_lpage">3153</span>, <span class="refDoi"> DOI: 10.1021/jm5002088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2it7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3148-3153&author=H.+I.+Mosbergauthor=L.+Yeomansauthor=J.+P.+Anandauthor=V.+Porterauthor=K.+Sobczyk-Kojiroauthor=J.+R.+Traynorauthor=E.+M.+Jutkiewicz&title=Development+of+a+bioavailable+%CE%BC+opioid+receptor+%28MOPr%29+agonist%2C+%CE%B4+opioid+receptor+%28DOPr%29+antagonist+peptide+that+evokes+antinociception+without+development+of+acute+tolerance&doi=10.1021%2Fjm5002088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance</span></div><div class="casAuthors">Mosberg, Henry I.; Yeomans, Larisa; Anand, Jessica P.; Porter, Vanessa; Sobczyk-Kojiro, Katarzyna; Traynor, John R.; Jutkiewicz, Emily M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3148-3153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors have previously described a cyclic tetrapeptide, KSK-103, that displays μ opioid receptor (MOPr) agonist and δ opioid receptor (DOPr) antagonist activity, a profile assocd. with a reduced incidence of opioid tolerance and dependence.  Like many peptides KSK-103 has poor bioavailability.  The authors describe here an analog of KSK-103 with an added C-terminal β-glucosylserine residue, Ser(β-Glc)NH2, a modification that has previously been shown to improve bioavailability of opioid peptides.  The resulting peptide exhibits full antinociceptive efficacy in the mouse warm water tail withdrawal assay after i.p. administration with potency similar to that of morphine.  Further, the peptide analog does not give rise to acute tolerance and thus represents a promising lead for the development of opioid analgesics with reduced side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe9qN8vLm1lrVg90H21EOLACvtfcHk0lh36liDv8xKug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2it7Y%253D&md5=02801871402feaa30e4268cd137dbbe9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm5002088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002088%26sid%3Dliteratum%253Aachs%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DYeomans%26aufirst%3DL.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DPorter%26aufirst%3DV.%26aulast%3DSobczyk-Kojiro%26aufirst%3DK.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520bioavailable%2520%25CE%25BC%2520opioid%2520receptor%2520%2528MOPr%2529%2520agonist%252C%2520%25CE%25B4%2520opioid%2520receptor%2520%2528DOPr%2529%2520antagonist%2520peptide%2520that%2520evokes%2520antinociception%2520without%2520development%2520of%2520acute%2520tolerance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3148%26epage%3D3153%26doi%3D10.1021%2Fjm5002088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rouzic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polikar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagakura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocampo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6352</span>– <span class="NLM_lpage">6362</span>, <span class="refDoi"> DOI: 10.1021/jm300305c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300305c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2nsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6352-6362&author=S.+Majumdarauthor=J.+Subrathauthor=V.+Le+Rouzicauthor=L.+Polikarauthor=M.+Burgmanauthor=K.+Nagakuraauthor=J.+Ocampoauthor=N.+Haseltonauthor=A.+R.+Pasternakauthor=S.+Grinnellauthor=Y.+X.+Panauthor=G.+W.+Pasternak&title=Synthesis+and+evaluation+of+aryl-naloxamide+opiate+analgesics+targeting+truncated+exon+11-associated+%CE%BC+opioid+receptor+%28MOR-1%29+splice+variants&doi=10.1021%2Fjm300305c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Aryl-Naloxamide Opiate Analgesics Targeting Truncated Exon 11-Associated μ Opioid Receptor (MOR-1) Splice Variants</span></div><div class="casAuthors">Majumdar, Susruta; Subrath, Joan; Le Rouzic, Valerie; Polikar, Lisa; Burgman, Maxim; Nagakura, Kuni; Ocampo, Julie; Haselton, Nathan; Pasternak, Anna R.; Grinnell, Steven; Pan, Ying-Xian; Pasternak, Gavril W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6352-6362</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Iodobenzoylnaltrexamide (IBNtxA) is a potent analgesic acting through a novel receptor target that lack many side-effects of traditional opiates composed, in part, of exon 11-assocd. truncated six transmembrane domain MOR-1 (6TM/E11) splice variants.  To better understand the SAR of this drug target, a no. of 4,5-epoxymorphinan analogs were synthesized.  Results show the importance of a free 3-phenolic group, a Ph ring at the 6 position, an iodine at the 3' or 4' position of the Ph ring, and an N-allyl or c-propylmethyl group to maintain high 6TM/E11 affinity and activity.  3-Iodobenzoylnaloxamide (I; IBNalA) with a N-allyl group displayed lower δ opioid receptor affinity than its naltrexamine analog, was 10-fold more potent an analgesic than morphine, elicited no respiratory depression or phys. dependence, and only limited inhibition of gastrointestinal transit.  Thus, the aryl-naloxamide scaffold can generate a potent analgesic acting through the 6TM/E11 sites with advantageous side-effect profile and greater selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdeU2T8NJ1bVg90H21EOLACvtfcHk0lgsEACJLSwwXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2nsbw%253D&md5=bc0d7f9897b58833cec1ef633e89a8ec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm300305c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300305c%26sid%3Dliteratum%253Aachs%26aulast%3DMajumdar%26aufirst%3DS.%26aulast%3DSubrath%26aufirst%3DJ.%26aulast%3DLe%2BRouzic%26aufirst%3DV.%26aulast%3DPolikar%26aufirst%3DL.%26aulast%3DBurgman%26aufirst%3DM.%26aulast%3DNagakura%26aufirst%3DK.%26aulast%3DOcampo%26aufirst%3DJ.%26aulast%3DHaselton%26aufirst%3DN.%26aulast%3DPasternak%26aufirst%3DA.%2BR.%26aulast%3DGrinnell%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DY.%2BX.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520aryl-naloxamide%2520opiate%2520analgesics%2520targeting%2520truncated%2520exon%252011-associated%2520%25CE%25BC%2520opioid%2520receptor%2520%2528MOR-1%2529%2520splice%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6352%26epage%3D6362%26doi%3D10.1021%2Fjm300305c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbotham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agaiby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimbel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doberstein, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagliaferri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddhanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, M.</span></span> <span> </span><span class="NLM_article-title">SUMMIT-07, a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000001517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1097%2Fj.pain.0000000000001517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=30747908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVOqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2019&pages=1374-1382&author=J.+Markmanauthor=J.+Gudinauthor=R.+Rauckauthor=C.+Argoffauthor=M.+Rowbothamauthor=E.+Agaibyauthor=J.+Gimbelauthor=N.+Katzauthor=S.+K.+Dobersteinauthor=M.+Tagliaferriauthor=L.+Luauthor=S.+Siddhantiauthor=M.+Hale&title=SUMMIT-07%2C+a+randomized+trial+of+NKTR-181%2C+a+new+molecular+entity%2C+full+mu-opioid+receptor+agonist+for+chronic+low-back+pain&doi=10.1097%2Fj.pain.0000000000001517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain</span></div><div class="casAuthors">Markman, John; Gudin, Jeffrey; Rauck, Richard; Argoff, Charles; Rowbotham, Michael; Agaiby, Eva; Gimbel, Joseph; Katz, Nathaniel; Doberstein, Stephen K.; Tagliaferri, Mary; Lu, Lin; Siddhanti, Suresh; Hale, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1374-1382</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">NKTR-181, a new mol. entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide analgesia while reducing abuse potential.  This phase 3, enriched-enrollment, randomized-withdrawal trial evaluated the analgesic efficacy, safety, and tolerability of NKTR-181 in patients with chronic low-back pain (CLBP).  Adults with moderate-to-severe CLBP refractory to nonopioid analgesics achieving an analgesic NKTR-181 dosage (100-400 mg twice daily) during the open-label titrn. period were randomized to continued NKTR-181 treatment, double-blind, or switched to placebo.  The study was conducted at 55 sites in the United States.  Of 1189 patients exposed to NKTR-181 during the titrn. period, 610 were randomized to NKTR-181 100 to 400 mg every 12 h or placebo for 12 wk.  The primary outcome measure was change in weekly pain score (scale, 0-10) at 12 wk from randomization baseline.  Secondary outcome measures included responder rates defined by ≥30% and ≥50% improvement in pain score from screening to 12 wk.  Among 610 randomized patients, the mean pain score decreased from 6.73 to 2.32 during open-label titrn.  After randomization, the least-squares mean change in pain score was +0.92 for NKTR-181 vs +1.46 for placebo (P = 0.002).  The ≥30%-improvement responder rate of NKTR-181 vs placebo was 71.2% vs 57.1% (P < 0.001), and the ≥50%-improvement responder rate was 51.1% vs 37.9% (P = 0.001).  NKTR-181 was well tolerated with a low incidence (<3%) of CNS-related adverse events during the randomized treatment phase.  In patients with moderate-to-severe CLBP, NKTR-181 demonstrated significant analgesic efficacy and a favorable safety/tolerability profile, with a low incidence of CNS adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9IZqMh58nibVg90H21EOLACvtfcHk0ljFaMJSe7d-9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVOqurk%253D&md5=8a0a5d976021ac32036ee644e355e851</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000001517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000001517%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DJ.%26aulast%3DGudin%26aufirst%3DJ.%26aulast%3DRauck%26aufirst%3DR.%26aulast%3DArgoff%26aufirst%3DC.%26aulast%3DRowbotham%26aufirst%3DM.%26aulast%3DAgaiby%26aufirst%3DE.%26aulast%3DGimbel%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DN.%26aulast%3DDoberstein%26aufirst%3DS.%2BK.%26aulast%3DTagliaferri%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DSiddhanti%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DM.%26atitle%3DSUMMIT-07%252C%2520a%2520randomized%2520trial%2520of%2520NKTR-181%252C%2520a%2520new%2520molecular%2520entity%252C%2520full%2520mu-opioid%2520receptor%2520agonist%2520for%2520chronic%2520low-back%2520pain%26jtitle%3DPain%26date%3D2019%26volume%3D160%26spage%3D1374%26epage%3D1382%26doi%3D10.1097%2Fj.pain.0000000000001517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&author=X.+T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+DeWireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure%E2%80%93activity+relationships+and+discovery+of+a+G+protein+biased+%CE%BC+opioid+receptor+ligand%2C+%5B%283-methoxythiophen-2-yl%29methyl%5D%28%7B2-%5B%289R%29-9-%28pyridin-2-yl%29-6-oxaspiro-%5B4.5%5Ddecan-9-yl%5Dethyl%7D%29amine+%28TRV130%29%2C+for+the+treatment+of+acute+severe+pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain</span></div><div class="casAuthors">Chen, Xiao-Tao; Pitis, Philip; Liu, Guodong; Yuan, Catherine; Gotchev, Dimitar; Cowan, Conrad L.; Rominger, David H.; Koblish, Michael; DeWire, Scott M.; Crombie, Aimee L.; Violin, Jonathan D.; Yamashita, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8019-8031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another.  There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs.  The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events.  Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 (I).  This novel mol. demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clin. development.  It is currently being evaluated in human clin. trials for the treatment of acute severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rI0Et_vFqrVg90H21EOLACvtfcHk0lgQG-C7o2vJHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK&md5=c80bd62062f31418f18392f97c880bea</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520and%2520discovery%2520of%2520a%2520G%2520protein%2520biased%2520%25CE%25BC%2520opioid%2520receptor%2520ligand%252C%2520%255B%25283-methoxythiophen-2-yl%2529methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528pyridin-2-yl%2529-6-oxaspiro-%255B4.5%255Ddecan-9-yl%255Dethyl%257D%2529amine%2520%2528TRV130%2529%252C%2520for%2520the%2520treatment%2520of%2520acute%2520severe%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graczyk, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">A G Protein-biased ligand at the m-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1124%2Fjpet.112.201616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23300227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=708-717&author=S.+W.+DeWireauthor=D.+S.+Yamashitaauthor=D.+H.+Romingerauthor=G.+Liuauthor=C.+L.+Cowanauthor=T.+M.+Graczykauthor=X.+T.+Chenauthor=P.+M.+Pitisauthor=D.+Gotchevauthor=C.+Yuanauthor=M.+Koblishauthor=M.+W.+Larkauthor=J.+D.+Violin&title=A+G+Protein-biased+ligand+at+the+m-opioid+receptor+is+potently+analgesic+with+reduced+gastrointestinal+and+respiratory+dysfunction+compared+with+morphine&doi=10.1124%2Fjpet.112.201616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span></div><div class="casAuthors">DeWire, Scott M.; Yamashita, Dennis S.; Rominger, David H.; Liu, Guodong; Cowan, Conrad L.; Graczyk, Thomas M.; Chen, Xiao-Tao; Pitis, Philip M.; Gotchev, Dimitar; Yuan, Catherine; Koblish, Michael; Lark, Michael W.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics.  Morphine pharmacol. in β-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the μ-opioid receptor (MOR) to G proteins, but not β-arrestins, would result in higher analgesic efficacy, less gastrointestinal dysfunction, and less respiratory suppression than morphine.  Here we report the discovery of TRV130 ([(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine), a novel MOR G protein-biased ligand.  In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization.  In mice and rats, TRV130 is potently analgesic while causing less gastrointestinal dysfunction and respiratory suppression than morphine at equianalgesic doses.  TRV130 successfully translates evidence that analgesic and adverse MOR signaling pathways are distinct into a biased ligand with differentiated pharmacol.  These preclin. data suggest that TRV130 may be a safer and more tolerable therapeutic for treating severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3tTP2BOOKrVg90H21EOLACvtfcHk0li1h1pan4kpVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D&md5=33a685cd1952dd9cb1fb82afe78452af</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201616%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DGraczyk%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%2BM.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520G%2520Protein-biased%2520ligand%2520at%2520the%2520m-opioid%2520receptor%2520is%2520potently%2520analgesic%2520with%2520reduced%2520gastrointestinal%2520and%2520respiratory%2520dysfunction%2520compared%2520with%2520morphine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D708%26epage%3D717%26doi%3D10.1124%2Fjpet.112.201616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span> <span> </span><span class="NLM_article-title">Abuse potential of biased mu opioid receptor agonists</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2018.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.tips.2018.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=30343727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=916-919&author=S.+S.+Negusauthor=K.+B.+Freeman&title=Abuse+potential+of+biased+mu+opioid+receptor+agonists&doi=10.1016%2Fj.tips.2018.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Abuse Potential of Biased Mu Opioid Receptor Agonists</span></div><div class="casAuthors">Negus, S. Stevens; Freeman, Kevin B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">916-919</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-biased mu opioid receptor (GPB-MOR) agonists constitute an emerging class of opioid analgesics.  The first-in-class GPB-MOR agonist TRV130 (oliceridine) produces typical opioid-like abuse-related effects in rodents and humans.  Although GPB-MOR agonists may be safer than conventional opioids on some endpoints, prevailing evidence suggests that they will retain opioid-like abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg0Xf3TNu4LrVg90H21EOLACvtfcHk0ljAsy6aCSkiKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF&md5=b33e27478c5d58a4232fffad6de7412f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2018.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2018.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26atitle%3DAbuse%2520potential%2520of%2520biased%2520mu%2520opioid%2520receptor%2520agonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2018%26volume%3D39%26spage%3D916%26epage%3D919%26doi%3D10.1016%2Fj.tips.2018.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span> <i>Anesthetic
and Analgesic Drug Products Advisory Committee (AADPAC)</i>; <span class="NLM_series">FDA Briefing Document</span>; <span class="NLM_publisher-name">U.S. Food and Drug
Administration</span>, October 11, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/media/121233/download" class="extLink">https://www.fda.gov/media/121233/download</a> (accessed July, 4, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Anesthetic%0Aand+Analgesic+Drug+Products+Advisory+Committee+%28AADPAC%29%3B+FDA+Briefing+Document%3B+U.S.+Food+and+Drug%0AAdministration%2C+October+11%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F121233%2Fdownload+%28accessed+July%2C+4%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs%26jtitle%3DAnesthetic%250Aand%2520Analgesic%2520Drug%2520Products%2520Advisory%2520Committee%2520%2528AADPAC%2529%26pub%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schunk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frormann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberbörsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundermann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemolka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kless, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenschein, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent analgesic NOP and opioid receptor agonist: cebranopadol</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1021/ml500117c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500117c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=857-862&author=S.+Schunkauthor=K.+Linzauthor=C.+Hinzeauthor=S.+Frormannauthor=S.+Oberb%C3%B6rschauthor=B.+Sundermannauthor=S.+Zemolkaauthor=W.+Englbergerauthor=T.+Germannauthor=T.+Christophauthor=B.+K%C3%B6gelauthor=W.+Schr%C3%B6derauthor=S.+Harlfingerauthor=D.+Saundersauthor=A.+Klessauthor=H.+Schickauthor=H.+Sonnenschein&title=Discovery+of+a+potent+analgesic+NOP+and+opioid+receptor+agonist%3A+cebranopadol&doi=10.1021%2Fml500117c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol</span></div><div class="casAuthors">Schunk, Stefan; Linz, Klaus; Hinze, Claudia; Frormann, Sven; Oberboersch, Stefan; Sundermann, Bernd; Zemolka, Saskia; Englberger, Werner; Germann, Tieno; Christoph, Thomas; Koegel, Babette-Y.; Schroeder, Wolfgang; Harlfinger, Stephanie; Saunders, Derek; Kless, Achim; Schick, Hans; Sonnenschein, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">857-862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous communication, our efforts leading from 1 to the identification of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amine 2a as analgesic NOP and opioid receptor agonist were disclosed and their favorable in vitro and in vivo pharmacol. properties revealed.  We herein report our efforts to further optimize lead 2a, toward trans-6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine (cebranopadol, 3a), which is currently in clin. development for the treatment of severe chronic nociceptive and neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_oo_6lpPHoLVg90H21EOLACvtfcHk0ljz1d11v4O6hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL&md5=270b1eef8252dcae7ce2e84c17d78b81</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fml500117c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500117c%26sid%3Dliteratum%253Aachs%26aulast%3DSchunk%26aufirst%3DS.%26aulast%3DLinz%26aufirst%3DK.%26aulast%3DHinze%26aufirst%3DC.%26aulast%3DFrormann%26aufirst%3DS.%26aulast%3DOberb%25C3%25B6rsch%26aufirst%3DS.%26aulast%3DSundermann%26aufirst%3DB.%26aulast%3DZemolka%26aufirst%3DS.%26aulast%3DEnglberger%26aufirst%3DW.%26aulast%3DGermann%26aufirst%3DT.%26aulast%3DChristoph%26aufirst%3DT.%26aulast%3DK%25C3%25B6gel%26aufirst%3DB.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DW.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DSaunders%26aufirst%3DD.%26aulast%3DKless%26aufirst%3DA.%26aulast%3DSchick%26aufirst%3DH.%26aulast%3DSonnenschein%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520analgesic%2520NOP%2520and%2520opioid%2520receptor%2520agonist%253A%2520cebranopadol%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D857%26epage%3D862%26doi%3D10.1021%2Fml500117c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Sigma 1 receptor: A new therapeutic target for pain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>716</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.01.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejphar.2013.01.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23500210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt12ju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=716&publication_year=2013&pages=78-93&author=D.+Zamanilloauthor=L.+Romeroauthor=M.+Merlosauthor=J.+M.+Vela&title=Sigma+1+receptor%3A+A+new+therapeutic+target+for+pain&doi=10.1016%2Fj.ejphar.2013.01.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma 1 receptor: A new therapeutic target for pain</span></div><div class="casAuthors">Zamanillo, Daniel; Romero, Luz; Merlos, Manuel; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">716</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">78-93</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sigma 1 receptor (σ1 receptor) is a unique ligand-regulated mol. chaperone located mainly in the endoplasmic reticulum and the plasma membrane. σ1 receptor is activated under stress or pathol. conditions and interacts with several neurotransmitter receptors and ion channels to modulate their function.  The effects reported preclinically with σ1 receptor ligands are consistent with a role for σ1 receptor in central sensitization and pain hypersensitivity and suggest a potential therapeutic use of σ1 receptor antagonists for the management of neuropathic pain as monotherapy.  Moreover, data support their use in opioid adjuvant therapy: combination of σ1 receptor antagonists and opioids results in potentiation of opioid analgesia, without significant increases in opioid-related unwanted effects.  Results from clin. trials using selective σ1 receptor antagonists in several pain conditions are eagerly awaited to ascertain the potential of σ1 receptor modulation in pain therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZl3UX9-U94rVg90H21EOLACvtfcHk0ljuQ9s06J0AvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt12ju70%253D&md5=7eba2c57ef558fbc50fb90d7067ab2e8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.068%26sid%3Dliteratum%253Aachs%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSigma%25201%2520receptor%253A%2520A%2520new%2520therapeutic%2520target%2520for%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D716%26spage%3D78%26epage%3D93%26doi%3D10.1016%2Fj.ejphar.2013.01.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocasalbas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touriño, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bura, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>711</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejphar.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23632394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=711&publication_year=2013&pages=63-72&author=A.+Vidal-Torresauthor=B.+de+la+Puenteauthor=M.+Rocasalbasauthor=C.+Touri%C3%B1oauthor=S.+A.+Buraauthor=B.+Fern%C3%A1ndez-Pastorauthor=L.+Romeroauthor=X.+Codonyauthor=D.+Zamanilloauthor=H.+Buschmannauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=R.+Maldonadoauthor=J.+M.+Vela&title=Sigma-1+receptor+antagonism+as+opioid+adjuvant+strategy%3A+Enhancement+of+opioid+antinociception+without+increasing+adverse+effects&doi=10.1016%2Fj.ejphar.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects</span></div><div class="casAuthors">Vidal-Torres, Alba; de la Puente, Beatriz; Rocasalbas, Maria; Tourino, Clara; Andreea Bura, Simona; Fernandez-Pastor, Begona; Romero, Luz; Codony, Xavier; Zamanillo, Daniel; Buschmann, Helmut; Merlos, Manuel; Manuel Baeyens, Jose; Maldonado, Rafael; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">711</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">While opioids are potent analgesics widely used in the management of pain, a no. of well-known adverse effects limit their use.  The sigma-1 receptor is a ligand-regulated mol. chaperone involved in pain processing, including modulation of opioid antinociception.  However, data supporting the potential use of sigma-1 receptor ligands as suitable opioid adjuvants are based on studies that use non selective ligands.  Also, safety issues derived from combination therapy are poorly addressed.  In this study we used the new selective sigma-1 receptor antagonist S1RA (E-52862) to characterize the effect of selective sigma-1 receptor blockade on opioid-induced efficacy- and safety-related outcomes in mice.  S1RA (40 mg/kg) had no effect in the tail-flick test but did enhance the antinociceptive potency of several opioids by a factor between 2 and 3.3.  The potentiating effect of S1RA on morphine antinociception did not occur in sigma-1 receptor knockout mice, which supports the selective involvement of the sigma-1 receptor.  Interestingly, S1RA co-administration restored morphine antinociception in tolerant mice and reverted the reward effects of morphine in the conditioned place preference paradigm.  In addn., enhancement of antinociception was not accompanied by potentiation of other opioid-induced effects, such as the development of morphine analgesic tolerance, phys. dependence, inhibition of gastrointestinal transit, or mydriasis.  The use of sigma-1 receptor antagonists as opioid adjuvants could represent a promising pharmacol. strategy to enhance opioid potency and, most importantly, to increase the safety margin of opioids.  S1RA is currently in phase II clin. trials for the treatment of several pain conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVTGE08MufobVg90H21EOLACvtfcHk0lhOH_tKN3UbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D&md5=c2cd0eb6fe5a9232bff11fe1539f74d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DB.%26aulast%3DRocasalbas%26aufirst%3DM.%26aulast%3DTouri%25C3%25B1o%26aufirst%3DC.%26aulast%3DBura%26aufirst%3DS.%2BA.%26aulast%3DFern%25C3%25A1ndez-Pastor%26aufirst%3DB.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSigma-1%2520receptor%2520antagonism%2520as%2520opioid%2520adjuvant%2520strategy%253A%2520Enhancement%2520of%2520opioid%2520antinociception%2520without%2520increasing%2520adverse%2520effects%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D711%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.ejphar.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backonja, M.</span></span> <span> </span><span class="NLM_article-title">Combination drug therapy for chronic pain: a call for more clinical studies</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.jpain.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=20851058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=157-166&author=J.+Maoauthor=M.+S.+Goldauthor=M.+Backonja&title=Combination+drug+therapy+for+chronic+pain%3A+a+call+for+more+clinical+studies&doi=10.1016%2Fj.jpain.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Therapy for Chronic Pain: A Call for More Clinical Studies</span></div><div class="casAuthors">Mao, Jianren; Gold, Michael S.; Backonja, Miroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic pain is a debilitating clin. condition assocd. with a variety of disease entities including diabetic neuropathy, postherpetic neuralgia, low back pathol., fibromyalgia, and neurol. disorders.  For many general practitioners and specialists, managing chronic pain has become a daunting challenge.  As a modality of multidisciplinary chronic pain management, medications are often prescribed in combinations, an approach referred to as combination drug therapy (CDT).  However, many medications for pain therapy, including antidepressants and opioid analgesics, have significant side effects that can compd. when used in combination and impact the effectiveness of CDT.  To date, clin. practice of CDT for chronic pain has been based largely on clin. experiences.  In this article, we will focus on (1) the scientific basis and rationales for CDT, (2) current clin. data on CDT, and (3) the need for more clin. studies to establish a framework for the use of CDT.  Perspective: More preclin., clin., and translational studies are needed to improve the efficacy of combination drug therapy that is an integral part of a comprehensive approach to the management of chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDPNs-xJvEbVg90H21EOLACvtfcHk0lg-EKLiBCTEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D&md5=955711ac2946dd44adc0e8b96b6ee423</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DGold%26aufirst%3DM.%2BS.%26aulast%3DBackonja%26aufirst%3DM.%26atitle%3DCombination%2520drug%2520therapy%2520for%2520chronic%2520pain%253A%2520a%2520call%2520for%2520more%2520clinical%2520studies%26jtitle%3DJ.%2520Pain%26date%3D2011%26volume%3D12%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.jpain.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljcFxSGcwuGsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of sigma-1 receptors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.pharmthera.2009.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=19619582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2009&pages=195-206&author=T.+Mauriceauthor=T.+P.+Su&title=The+pharmacology+of+sigma-1+receptors&doi=10.1016%2Fj.pharmthera.2009.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of sigma-1 receptors</span></div><div class="casAuthors">Maurice, Tangui; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Originally considered an enigmatic protein, the sigma-1 receptor has recently been identified as a unique ligand-regulated mol. chaperone in the endoplasmic reticulum of cells.  This discovery causes us to look back at the many proposed roles of this receptor, even before its mol. function was identified, in many diseases such as methamphetamine or cocaine addiction, amnesia, pain, depression, Alzheimer's disease, stroke, retinal neuroprotection, HIV infection, and cancer.  In this review, we examine the reports that have clearly shown an agonist-antagonist relationship regarding sigma-1 receptors in models of those diseases and also review the relatively known mechanisms of action of sigma-1 receptors in an attempt to spur the speculation of readers on how the sigma-1 receptor at the endoplasmic reticulum might relate to so many diseases.  We found that the most prominent action of sigma-1 receptors in biol. systems including cell lines, primary cultures, and animals is the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca2+-, K+-, Na+, Cl-, and SK channels, and NMDA and IP3 receptors.  We found that the final output of the action of sigma-1 receptor agonists is to inhibit all above-mentioned voltage-gated ion channels, while they potentiate ligand-gated channels.  The inhibition or potentiation induced by agonists is blocked by sigma-1 receptor antagonists.  Other mechanisms of action of sigma-1 receptors, and to some extent those of sigma-2 receptors, were also considered.  We conclude that the sigma-1 and sigma-2 receptors represent potential fruitful targets for therapeutic developments in combating many human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4d_UAy6J4KbVg90H21EOLACvtfcHk0lhff3K-U6_Dkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM&md5=7b5e251decc29edef42ffef1d65dd487</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DThe%2520pharmacology%2520of%2520sigma-1%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D124%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.pharmthera.2009.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span> <span> </span><span class="NLM_article-title">Sigma antagonists potentiate opioid analgesia in rats</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(95)11504-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2F0304-3940%2895%2911504-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=7644123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaK2MXls12nsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=1995&pages=137-139&author=C.+C.+Chienauthor=G.+W.+Pasternak&title=Sigma+antagonists+potentiate+opioid+analgesia+in+rats&doi=10.1016%2F0304-3940%2895%2911504-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma antagonists potentiate opioid analgesia in rats</span></div><div class="casAuthors">Chien, Chih-Cheng; Pasternak, Gavril W.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-9</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In mice, activation of sigma1 receptors antagonizes opioid analgesia.  Sigma antagonists potentiate opioid analgesia, implying that the anti-opioid sigma system is tonically active.  Co-administration of haloperidol with the mu opioid morphine, the kappa1 analgesic U 50488H or the kappa3 agonist naloxone benzoylhydrazone enhances the analgesic activity of all agents.  The effect results from sigma receptor blockade since (-)sulpiride, a selective D2 antagonist which does not block sigma receptors, is inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7Y-iEDEl3bVg90H21EOLACvtfcHk0lgDS4InUF2kGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls12nsr8%253D&md5=66ace8f372aca6d388626a9d9ba09728</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2895%2911504-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252895%252911504-P%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DC.%2BC.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26atitle%3DSigma%2520antagonists%2520potentiate%2520opioid%2520analgesia%2520in%2520rats%26jtitle%3DNeurosci.%2520Lett.%26date%3D1995%26volume%3D190%26spage%3D137%26epage%3D139%26doi%3D10.1016%2F0304-3940%2895%2911504-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cendán, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujalte, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montoliu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Formalin-induced pain is reduced in sigma(1) receptor knockout mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>511</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2005.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejphar.2005.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15777781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2005&pages=73-74&author=C.+M.+Cend%C3%A1nauthor=J.+M.+Pujalteauthor=E.+Portillo-Salidoauthor=L.+Montoliuauthor=J.+M.+Baeyens&title=Formalin-induced+pain+is+reduced+in+sigma%281%29+receptor+knockout+mice&doi=10.1016%2Fj.ejphar.2005.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Formalin-induced pain is reduced in σ1 receptor knockout mice</span></div><div class="casAuthors">Cendan, Cruz Miguel; Pujalte, Jose Miguel; Portillo-Salido, Enrique; Montoliu, Lluis; Baeyens, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-74</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The role of σ1 receptors in non-acute pain has not been explored.  In this study we show that both phases of formalin-induced pain were reduced by approx. 55% in σ1 receptor knockout mice in comparison to wild-type animals.  These results suggest that the tonic pain induced by formalin is altered in mice lacking σ1 receptors, and highlight the potential usefulness of further studies of the role of σ1 receptors in models of non-acute pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLfs5SOcqYY7Vg90H21EOLACvtfcHk0lj32qFi2ZQvWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCjsLs%253D&md5=71d93bc7957c3f85824ab4a63d174a6b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DCend%25C3%25A1n%26aufirst%3DC.%2BM.%26aulast%3DPujalte%26aufirst%3DJ.%2BM.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DMontoliu%26aufirst%3DL.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DFormalin-induced%2520pain%2520is%2520reduced%2520in%2520sigma%25281%2529%2520receptor%2520knockout%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D511%26spage%3D73%26epage%3D74%26doi%3D10.1016%2Fj.ejphar.2005.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuberes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrocal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contijoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueño, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the 1-arylpyrazole class of σ<sub>1</sub> receptor antagonists: Identification of 4-{2-[5-methyl-1-(naphtalen-2-yl)-1<i>H</i>-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8211</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1021/jm3007323</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3007323" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8211-8224&author=J.+L.+D%C3%ADazauthor=R.+Cuberesauthor=J.+Berrocalauthor=M.+Contijochauthor=U.+Christmannauthor=A.+Fern%C3%A1ndezauthor=A.+Portauthor=J.+Holenzauthor=H.+Buschmannauthor=C.+Laggnerauthor=M.+T.+Serafiniauthor=J.+Burgue%C3%B1oauthor=D.+Zamanilloauthor=M.+Merlosauthor=J.+M.+Velaauthor=C.+Almansa&title=Synthesis+and+biological+evaluation+of+the+1-arylpyrazole+class+of+%CF%831+receptor+antagonists%3A+Identification+of+4-%7B2-%5B5-methyl-1-%28naphtalen-2-yl%29-1H-pyrazol-3-yloxy%5Dethyl%7Dmorpholine+%28S1RA%2C+E-52862%29&doi=10.1021%2Fjm3007323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of σ1 Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span></div><div class="casAuthors">Diaz, Jose Luis; Cuberes, Rosa; Berrocal, Joana; Contijoch, Montserrat; Christmann, Ute; Fernandez, Ariadna; Port, Adriana; Holenz, Jorg; Buschmann, Helmut; Laggner, Christian; Serafini, Maria Teresa; Burgueno, Javier; Zamanillo, Daniel; Merlos, Manuel; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8211-8224</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-arylpyrazoles as potent σ1 receptor (σ1R) antagonists are reported.  The new compds. were evaluated in vitro in human σ1R and guinea pig σ2 receptor (σ2R) binding assays.  The nature of the pyrazole substituents was crucial for activity, and a basic amine was shown to be necessary, in accordance with known receptor pharmacophores.  A wide variety of amines and spacer lengths between the amino and pyrazole groups was tolerated, but only the ethylenoxy spacer and small cyclic amines provided compds. with sufficient selectivity for σ1R vs σ2R.  The most selective compds. were further profiled, and 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862, I), which showed high activity in the mouse capsaicin model of neurogenic pain, emerged as the most interesting candidate.  In addn., compd. I exerted dose-dependent antinociceptive effects in several neuropathic pain models.  This, together with its good physicochem., safety, and ADME properties, led compd. I to be selected as clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQxd7-vnvc7Vg90H21EOLACvtfcHk0liiaUVEbG6zZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI&md5=0d6a5c8008d27635117c3901ec1db3c4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm3007323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3007323%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BL.%26aulast%3DCuberes%26aufirst%3DR.%26aulast%3DBerrocal%26aufirst%3DJ.%26aulast%3DContijoch%26aufirst%3DM.%26aulast%3DChristmann%26aufirst%3DU.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSerafini%26aufirst%3DM.%2BT.%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%25201-arylpyrazole%2520class%2520of%2520%25CF%25831%2520receptor%2520antagonists%253A%2520Identification%2520of%25204-%257B2-%255B5-methyl-1-%2528naphtalen-2-yl%2529-1H-pyrazol-3-yloxy%255Dethyl%257Dmorpholine%2520%2528S1RA%252C%2520E-52862%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8211%26epage%3D8224%26doi%3D10.1021%2Fjm3007323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyriou, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalofonos, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaqué, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: A randomized, double-blind, placebo-controlled phase IIa clinical trial</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s13311-017-0572-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1007%2Fs13311-017-0572-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=28924870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=178-189&author=J.+Brunaauthor=S.+Videlaauthor=A.+A.+Argyriouauthor=R.+Velascoauthor=J.+Villoriaauthor=C.+Santosauthor=C.+Nadalauthor=G.+Cavalettiauthor=P.+Albertiauthor=C.+Brianiauthor=H.+P.+Kalofonosauthor=D.+Cortinovisauthor=M.+Sustauthor=A.+Vaqu%C3%A9author=T.+Kleinauthor=C.+Plata-Salam%C3%A1n&title=Efficacy+of+a+novel+sigma-1+receptor+antagonist+for+oxaliplatin-induced+neuropathy%3A+A+randomized%2C+double-blind%2C+placebo-controlled+phase+IIa+clinical+trial&doi=10.1007%2Fs13311-017-0572-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span></div><div class="casAuthors">Bruna, Jordi; Videla, Sebastian; Argyriou, Andreas A.; Velasco, Roser; Villoria, Jesus; Santos, Cristina; Nadal, Cristina; Cavaletti, Guido; Alberti, Paola; Briani, Chiara; Kalofonos, Haralabos P.; Cortinovis, Diego; Sust, Mariano; Vaque, Anna; Klein, Thomas; Plata-Salaman, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn).  A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer receiving FOLFOX in a phase II, randomized, double-blind, placebo-controlled, multicenter clin. trial.  Outcome measures included changes in 24-wk quant. measures of thermal sensitivity and total neuropathy score.  In total, 124 patients were randomized (1:1) to MR309 or placebo.  Sixty-three (50.8%) patients withdrew prematurely before completing 12 planned oxaliplatin cycles.  Premature withdrawal because of cancer progression was less frequent in the MR309 group (7.4% vs 25.0% with placebo; p = 0.054).  MR309 significantly reduced cold pain threshold temp. [mean treatment effect difference (SE) vs placebo: 5.29 (1.60)°C; p = 0.001] and suprathreshold cold stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032].  Total neuropathy score, health-related quality-of-life measures, and nerve-conduction parameters changed similarly in both arms, whereas the proportion of patients with severe chronic neuropathy (National Cancer Institute Common Terminol. Criteria for Adverse Events ≥ 3) was significantly lower in the MR309 group (3.0% vs 18.2% with placebo; p = 0.046).  The total amt. of oxaliplatin delivered was greater in the active arm (1618.9 mg vs 1453.8 mg with placebo; p = 0.049).  Overall, 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, resp.).  Intermittent treatment with MR309 was assocd. with reduced acute oxaipn and higher oxaliplatin exposure, and showed a potential neuroprotective role for chronic cumulative oxaipn.  Furthermore, MR309 showed an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkVyo1fPRe7Vg90H21EOLACvtfcHk0lg20qjuTETPHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E&md5=78eac14b1175a004af19c4c9a53af1be</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs13311-017-0572-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-017-0572-5%26sid%3Dliteratum%253Aachs%26aulast%3DBruna%26aufirst%3DJ.%26aulast%3DVidela%26aufirst%3DS.%26aulast%3DArgyriou%26aufirst%3DA.%2BA.%26aulast%3DVelasco%26aufirst%3DR.%26aulast%3DVilloria%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DNadal%26aufirst%3DC.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DAlberti%26aufirst%3DP.%26aulast%3DBriani%26aufirst%3DC.%26aulast%3DKalofonos%26aufirst%3DH.%2BP.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DVaqu%25C3%25A9%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520for%2520oxaliplatin-induced%2520neuropathy%253A%2520A%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520clinical%2520trial%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs13311-017-0572-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span> <span> </span><span class="NLM_article-title">S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freund’s adjuvant models in mice</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1097/FBP.0000000000000038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1097%2FFBP.0000000000000038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=24776490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlGitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=226-235&author=G.+Grisauthor=M.+Merlosauthor=J.+M.+Velaauthor=D.+Zamanilloauthor=E.+Portillo-Salido&title=S1RA%2C+a+selective+sigma-1+receptor+antagonist%2C+inhibits+inflammatory+pain+in+the+carrageenan+and+complete+Freund%E2%80%99s+adjuvant+models+in+mice&doi=10.1097%2FFBP.0000000000000038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freund's adjuvant models in mice</span></div><div class="casAuthors">Gris, Georgia; Merlos, Manuel; Vela, Jose M.; Zamanillo, Daniel; Portillo-Salido, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The therapeutic potential of S1RA (E-52862), a selective sigma-1 receptor (σ1R) antagonist, has been explored in exptl. neuropathic pain, but not in inflammatory pain models.  The present study investigated the effect of the i.p. administration of S1RA on the hind paw withdrawal response to thermal and mech. stimulation following an intraplantar injection of carrageenan (CARR) and complete Freund's adjuvant (CFA), which are two well-characterized models of acute and chronic inflammatory pain, resp.  S1RA fully reversed both mech. [dose of drug that produced half of its maximal response (ED50)=35.9 and 42.1 mg/kg for CARR-induced and CFA-induced pain, resp.] and thermal (ED50=27.9 mg/kg, CARR) hypersensitivity, whereas ibuprofen (CARR, mech. allodynia) and celecoxib (CARR, thermal hyperalgesia; CFA, mech. allodynia) failed to reach max. efficacy.  Morphine also showed max. efficacy in all tests.  Unlike celecoxib and ibuprofen, which decreased paw vol. significantly, CARR-induced paw edema was not reduced by S1RA and morphine, thus suggesting that the antinociceptive effect of S1RA does not involve a major anti-inflammatory (antioedema) action.  S1RA was devoid of efficacy when administered to σ1R knockout mice, thus suggesting the involvement of σ1R in the antinociceptive effects exerted by S1RA.  We conclude that S1RA represents a promising novel analgesic therapy for inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVw_rDFuxlmrVg90H21EOLACvtfcHk0lhRus72FD0DeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlGitbc%253D&md5=4582585803d7d15b7e9b6aae886c3793</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000038%26sid%3Dliteratum%253Aachs%26aulast%3DGris%26aufirst%3DG.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26atitle%3DS1RA%252C%2520a%2520selective%2520sigma-1%2520receptor%2520antagonist%252C%2520inhibits%2520inflammatory%2520pain%2520in%2520the%2520carrageenan%2520and%2520complete%2520Freund%25E2%2580%2599s%2520adjuvant%2520models%2520in%2520mice%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2014%26volume%3D25%26spage%3D226%26epage%3D235%26doi%3D10.1097%2FFBP.0000000000000038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1007/s00213-014-3524-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1007%2Fs00213-014-3524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=24639046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=3855-3869&author=M.+A.+Tejadaauthor=A.+Montilla-Garc%C3%ADaauthor=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=J.+M.+Entrenaauthor=G.+Perazzoliauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptor+inhibition+reverses+acute+inflammatory+hyperalgesia+in+mice%3A+role+of+peripheral+sigma-1+receptors&doi=10.1007%2Fs00213-014-3524-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span></div><div class="casAuthors">Tejada, M. A.; Montilla-Garcia, A.; Sanchez-Fernandez, C.; Entrena, J. M.; Perazzoli, G.; Baeyens, J. M.; Cobos, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Sigma-1 (σ1) receptor inhibition ameliorates neuropathic pain by inhibiting central sensitization.  However, it is unknown whether σ1 receptor inhibition also decreases inflammatory hyperalgesia, or whether peripheral σ1 receptors are involved in this process.  Objective: The purpose of this study was to det. the role of σ1 receptors in carrageenan-induced inflammatory hyperalgesia, particularly at the inflammation site.  Results: The s.c. (s.c.) administration of the selective σ1 antagonists BD-1063 and S1RA to wild-type mice dose-dependently and fully reversed inflammatory mech. (paw pressure) and thermal (radiant heat) hyperalgesia.  These antihyperalgesic effects were abolished by the s.c. administration of the σ1 agonist PRE-084 and also by the intraplantar (i.pl.) administration of this compd. in the inflamed paw, suggesting that blockade of peripheral σ1 receptors in the inflamed site is involved in the antihyperalgesic effects induced by σ1 antagonists.  In fact, the i.pl. administration of σ1 antagonists in the inflamed paw (but not in the contralateral paw) was sufficient to completely reverse inflammatory hyperalgesia. σ1 knockout (σ1-KO) mice did not develop mech. hyperalgesia but developed thermal hypersensitivity; however, the s.c. administration of BD-1063 or S1RA had no effect on thermal hyperalgesia in σ1-KO mice, supporting on-target mechanisms for the effects of both drugs.  The antiedematous effects of σ1 inhibition do not account for the decreased hyperalgesia, since carrageenan-induced edema was unaffected by σ1 knockout or systemic σ1 pharmacol. antagonism.  Conclusions: σ1 receptors play a major role in inflammatory hyperalgesia.  Targeting σ1 receptors in the inflamed tissue may be useful for the treatment of inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvS0b6PcEhLVg90H21EOLACvtfcHk0ljUnQivvFrC6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D&md5=b62ff92aeee8ae0fbc9a4c1c4d272c82</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3524-3%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptor%2520inhibition%2520reverses%2520acute%2520inflammatory%2520hyperalgesia%2520in%2520mice%253A%2520role%2520of%2520peripheral%2520sigma-1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D3855%26epage%3D3869%26doi%3D10.1007%2Fs00213-014-3524-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span> <i>EU Clinical Trials</i>; <span class="NLM_publisher-name">European
Medicines Agency</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2019</span>; <a href="http://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003302-24/results" class="extLink">www.clinicaltrialsregister.eu/ctr-search/trial/2011-003302-24/results</a> (accessed Nov, 14, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+EU+Clinical+Trials%3B+European%0AMedicines+Agency%3A+Amsterdam%2C+2019%3B+www.clinicaltrialsregister.eu%2Fctr-search%2Ftrial%2F2011-003302-24%2Fresults+%28accessed+Nov%2C+14%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEU%2520Clinical%2520Trials%26pub%3DEuropean%250AMedicines%2520Agency%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0liisg_jHdbEtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Selective sigma-1 receptor antagonists for the treatment of pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.4155%2Ffmc.14.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=25078137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1179-1199&author=C.+Almansaauthor=J.+M.+Vela&title=Selective+sigma-1+receptor+antagonists+for+the+treatment+of+pain&doi=10.4155%2Ffmc.14.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Selective sigma-1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Almansa, Carmen; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1179-1199</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The sigma-1 receptor (σ1R) is located in areas of the CNS key for pain control and belongs to a unique target class with chaperoning functions over different mol. targets involved in transmission and amplification of nociceptive messages.  Preclin. evidence supports a role for σ1R antagonists in the treatment of pain states where hypersensitivity develops as hyperalgesia and allodynia, two common symptoms encountered in neuropathic and other chronic pain conditions.  Addnl., σ1R antagonists increase opioid analgesia without increasing opioid-related unwanted effects, which point to their potential use as opioid adjuvant therapy.  This review summarizes the structure and function of the σ1R as well as the medicinal chem. and pharmacol. studies directed to the identification of σ1R antagonists for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ0qGYS21i37Vg90H21EOLACvtfcHk0liisg_jHdbEtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK&md5=3ced452012e44f478a377f0fa52995d4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.54%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSelective%2520sigma-1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1179%26epage%3D1199%26doi%3D10.4155%2Ffmc.14.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dvoracsko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, A.</span></span> <span> </span><span class="NLM_article-title">The design of multitarget ligands for chronic and neuropathic pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.4155%2Ffmc.15.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=26652942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2469-2483&author=S.+Dvoracskoauthor=A.+Stefanucciauthor=E.+Novellinoauthor=A.+Mollica&title=The+design+of+multitarget+ligands+for+chronic+and+neuropathic+pain&doi=10.4155%2Ffmc.15.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The design of multitarget ligands for chronic and neuropathic pain</span></div><div class="casAuthors">Dvoracsko, Szabolcs; Stefanucci, Azzurra; Novellino, Ettore; Mollica, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2469-2483</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Monodrug therapy has been used with success to fight various pathologies.  When one medicine fails, co-administration of two or more drugs at the same time may be successfully applied in the treatment of infections, hypertension, HIV and in many other fields.  Discussion: This approach has some weakness related to the pharmacokinetic of the two different substances administered, side effects, possible drug-drug interaction.  Bivalent ligand approach would maintain the strength of the multidrug therapy (synergistic effect, lower doses, and little side effects) and overcome the weakness of a co-administration.  Conclusion: In this review we have described the state-of-the-art of the multitarget approach for the control of pain.  Several approaches adopted by different research groups and future perspectives have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEdmKaU-Blf7Vg90H21EOLACvtfcHk0lhhF_EwAH4XGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K&md5=04d64c3fd3e5f442094cbd40ebf25303</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.156%26sid%3Dliteratum%253Aachs%26aulast%3DDvoracsko%26aufirst%3DS.%26aulast%3DStefanucci%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMollica%26aufirst%3DA.%26atitle%3DThe%2520design%2520of%2520multitarget%2520ligands%2520for%2520chronic%2520and%2520neuropathic%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2469%26epage%3D2483%26doi%3D10.4155%2Ffmc.15.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhosle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharambe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gairola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaneshwar, S. S.</span></span> <span> </span><span class="NLM_article-title">Mutual prodrug concept: fundamentals and applications</span>. <i>Indian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.4103/0250-474X.26654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.4103%2F0250-474X.26654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2006&pages=286-294&author=D.+Bhosleauthor=S.+Bharambeauthor=N.+Gairolaauthor=S.+S.+Dhaneshwar&title=Mutual+prodrug+concept%3A+fundamentals+and+applications&doi=10.4103%2F0250-474X.26654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mutual prodrug concept: fundamentals and applications</span></div><div class="casAuthors">Bhosle, D.; Bharambe, S.; Gairola, Neha; Dhaneshwar, Suneela S.</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-294</span>CODEN:
                <span class="NLM_cas:coden">IJSIDW</span>;
        ISSN:<span class="NLM_cas:issn">0250-474X</span>.
    
            (<span class="NLM_cas:orgname">Indian Pharmaceutical Association</span>)
        </div><div class="casAbstract">A review.  A therapeutically significant drug may have limited utilization in clin. practice because of poor organoleptic properties, poor bioavailability, short duration of action, nonspecificity, incomplete absorption, poor aq. soly., high first-pass metab. or other adverse effects.  There is a great emphasis on research to discover methods aimed at improving their therapeutic efficacy by minimizing or eliminating these undesirable properties.  Sometimes, an adequate pharmaceutical formulation can overcome these drawbacks, but often the galenic formulation is inoperant and a chem. modification of active mol. is necessary to correct its pharmacokinetic insufficiencies.  This chem. formulation process, whose objective is to convert an interesting active mol. into a clin. acceptable drug, often involves the so-called 'Prodrug design.'.  Mutual prodrug is a type of carrier-linked prodrug, where the carrier used is another biol. active drug instead of some inert mol.  A mutual prodrug consists of two pharmacol. active agents coupled together so that each acts as a promoiety for the other agent and vice versa.  Mutual prodrug design is really no different from the general drug discovery process, in which a unique substance is obsd. to have desirable pharmacol. effects, and studies of its properties lead to the design of better drugs.  It is a very fruitful area of research, and its introduction in human therapy has given successful results in improving the clin. and therapeutic effectiveness of drugs suffering from some undesirable properties that otherwise hinder their clin. usefulness.  The present article takes a review of various applications of mutual prodrugs and the developments in this field during the last few decades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH3cW1cvTkVLVg90H21EOLACvtfcHk0lhhF_EwAH4XGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D&md5=3dcaac61d251a1027fe9d212d0aef51c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4103%2F0250-474X.26654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0250-474X.26654%26sid%3Dliteratum%253Aachs%26aulast%3DBhosle%26aufirst%3DD.%26aulast%3DBharambe%26aufirst%3DS.%26aulast%3DGairola%26aufirst%3DN.%26aulast%3DDhaneshwar%26aufirst%3DS.%2BS.%26atitle%3DMutual%2520prodrug%2520concept%253A%2520fundamentals%2520and%2520applications%26jtitle%3DIndian%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D68%26spage%3D286%26epage%3D294%26doi%3D10.4103%2F0250-474X.26654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Design strategies for bivalent ligands targeting GPCRs</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1002%2Fcmdc.201100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=21520422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=963-974&author=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Design+strategies+for+bivalent+ligands+targeting+GPCRs&doi=10.1002%2Fcmdc.201100101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design Strategies for Bivalent Ligands Targeting GPCRs</span></div><div class="casAuthors">Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Specifically designed bivalent ligands targeting G protein-coupled receptor (GPCR) dimeric structures have become increasingly popular in recent literature.  The advantages of the bivalent approach are numerous, including enhanced potency and receptor subtype specificity.  However, the use of bivalent ligands as potential pharmacotherapeutics is limited by problematic mol. properties, such as high mol. wt. and lipophilicity.  This Minireview focuses on the design of bivalent ligands recently described in the literature; discussing the choice of lead pharmacophore, the position and nature of the attachment point for linking the two pharmacophore units, and the length and compn. of the spacer group.  Furthermore, this Minireview distills the mol. descriptors of the bivalent ligands that exhibit in vivo activity, as well as highlights their ability to access the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7uDrMXq0sprVg90H21EOLACvtfcHk0lhhF_EwAH4XGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D&md5=569a8a988cdd9d2daf8f492211303934</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100101%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DDesign%2520strategies%2520for%2520bivalent%2520ligands%2520targeting%2520GPCRs%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D963%26epage%3D974%26doi%3D10.1002%2Fcmdc.201100101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2259</span>– <span class="NLM_lpage">2269</span>, <span class="refDoi"> DOI: 10.1021/jm010158+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010158%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Oit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2259-2269&author=P.+S.+Portoghese&title=From+models+to+molecules%3A+opioid+receptor+dimers%2C+bivalent+ligands%2C+and+selective+opioid+receptor+probes&doi=10.1021%2Fjm010158%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">From Models to Molecules: Opioid Receptor Dimers, Bivalent Ligands, and Selective Opioid Receptor Probes</span></div><div class="casAuthors">Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2259-2269</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opiates have been the most widely investigated class of natural products.  The development of totally synthetic analgesics subsequently led to the development of diverse structural classes of ligands that mimic the actions of the opiates.  Compds. with mixed agonist-antagonist activity during that period represented a new approach to reducing the abuse potential and some of the side effects assocd. with the classical opiates, and several of the analgesics in this group are presently employed clin.  In this presentation I will draw on selected examples from my research to illustrate how key conceptual models have led to the design of selective ligands, some of which are widely employed as pharmacol. tools for the investigation of opioid receptors.  I will also illustrate how site-directed mutagenesis, when combined with the classical structure-activity relationship (SAR) approach, has led to the identification of amino acid residues on opioid receptors and groups on ligands that participate in mol. recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJApX5SmJarVg90H21EOLACvtfcHk0lhhF_EwAH4XGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Oit7s%253D&md5=95afe28e1417088a0a934aafa689bb83</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm010158%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010158%252B%26sid%3Dliteratum%253Aachs%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DFrom%2520models%2520to%2520molecules%253A%2520opioid%2520receptor%2520dimers%252C%2520bivalent%2520ligands%252C%2520and%2520selective%2520opioid%2520receptor%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2259%26epage%3D2269%26doi%3D10.1021%2Fjm010158%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Naour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akgün, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yekkirala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunzer, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyuzhny, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5513</span>, <span class="refDoi"> DOI: 10.1021/jm4005219</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4005219" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5505-5513&author=M.+Le%0ANaourauthor=E.+Akg%C3%BCnauthor=A.+Yekkiralaauthor=M.+M.+Lunzerauthor=M.+D.+Powersauthor=A.+E.+Kalyuzhnyauthor=P.+S.+Portoghese&title=Bivalent+ligands+that+target+%CE%BC+opioid+%28MOP%29+and+cannabinoid1+%28CB1%29+receptors+are+potent+analgesics+devoid+of+tolerance&doi=10.1021%2Fjm4005219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid 1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance</span></div><div class="casAuthors">Le Naour, Morgan; Akgun, Eyup; Yekkirala, Ajay; Lunzer, Mary M.; Powers, Mike D.; Kalyuzhny, Alexander E.; Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5505-5513</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given that μ opioid (MOP) and cannabinoid (CB1) receptors are colocalized in various regions of the central nervous system and have been reported to assoc. as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP-CB1 in nociception and other pharmacol. effects has been raised.  As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo.  Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer.  Antinociceptive testing in mice revealed 5 to be the most potent member of the series.  As neither a mixt. of monovalent ligands 9+10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdqGOG4RA1RLVg90H21EOLACvtfcHk0lgOiPyXtCcjxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D&md5=b3df3237bfebc84448056724c3cfca4d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm4005219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005219%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BNaour%26aufirst%3DM.%26aulast%3DAkg%25C3%25BCn%26aufirst%3DE.%26aulast%3DYekkirala%26aufirst%3DA.%26aulast%3DLunzer%26aufirst%3DM.%2BM.%26aulast%3DPowers%26aufirst%3DM.%2BD.%26aulast%3DKalyuzhny%26aufirst%3DA.%2BE.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DBivalent%2520ligands%2520that%2520target%2520%25CE%25BC%2520opioid%2520%2528MOP%2529%2520and%2520cannabinoid1%2520%2528CB1%2529%2520receptors%2520are%2520potent%2520analgesics%2520devoid%2520of%2520tolerance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5505%26epage%3D5513%26doi%3D10.1021%2Fjm4005219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Virgili-Bernardo, M.</span>; <span class="NLM_string-name">Alonso-Xalma, M.</span>; <span class="NLM_string-name">Alegret-Molina, C.</span>; <span class="NLM_string-name">Almansa_Rosales, C.</span>; <span class="NLM_string-name">García Lopez, M.</span></span> <span> </span><span class="NLM_article-title">Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain</span>. PCT Int. Appl. <span class="NLM_patent">WO2015185207A1</span> 20151012, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Virgili-Bernardo&author=M.+Alonso-Xalma&author=C.+Alegret-Molina&author=C.+Almansa_Rosales&author=M.+Garc%C3%ADa+Lopez&title=Alkyl+and+aryl+derivatives+of+1-oxa-4%2C9-diazaspiro+undecane+compounds+having+multimodal+activity+against+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVirgili-Bernardo%26aufirst%3DM.%26atitle%3DAlkyl%2520and%2520aryl%2520derivatives%2520of%25201-oxa-4%252C9-diazaspiro%2520undecane%2520compounds%2520having%2520multimodal%2520activity%2520against%2520pain%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caroon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repke, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strosberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, R. L.</span></span> <span> </span><span class="NLM_article-title">Antihypertensive 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1021/jm00360a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00360a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaL3sXhvFWhurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1983&pages=855-861&author=R.+D.+Clarkauthor=J.+M.+Caroonauthor=D.+B.+Repkeauthor=A.+M.+Strosbergauthor=S.+M.+Bitterauthor=M.+D.+Okadaauthor=A.+D.+Michelauthor=R.+L.+Whiting&title=Antihypertensive+9-substituted+1-oxa-4%2C9-diazaspiro%5B5.5%5Dundecan-3-ones&doi=10.1021%2Fjm00360a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Antihypertensive 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones</span></div><div class="casAuthors">Clark, Robin D.; Caroon, Joan M.; Repke, David B.; Strosberg, Arthur M.; Bitter, Susan M.; Okada, Marlys D.; Michel, Anton D.; Whiting, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title compds. I (R = H, Me, Et, Ph; R1 = H, C1-3 alkyl, Ph, substituted Ph, or benzyl; R2 = H, Me, or Et; R3 = indolylethyl, benzodioxanylmethyl, substituted phenethyl, etc.) prepd. by stepwise reactions from the substituted 6-carbobenzoxy-1-oxa-6-azaspiro[2.5]octane and I ring-opened analogs II (R = Me, Et, MeOCH2, or Ph; R1 = H or MeO) prepd. either by acylation of 3-[2-[4-(aminomethyl)piperidino]ethyl]indole  [85151-25-3] or from benzyl 4-(azidomethyl)-4-hydroxy-1-piperidinecarboxylate  [85151-24-2], as HCl salts were evaluated as antihypertensives in spontaneously hypertensive rats.  9-(2-indol-3-ylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one-HCl  [85151-27-5] Was the most effective antihypertensive, its activity apparently due to peripheral α1-adrenoceptor blockade.  Structure activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCtn48e407MbVg90H21EOLACvtfcHk0lgOiPyXtCcjxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhvFWhurk%253D&md5=91b65ec71c690bb9765b7ad7e306ae51</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00360a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00360a013%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DCaroon%26aufirst%3DJ.%2BM.%26aulast%3DRepke%26aufirst%3DD.%2BB.%26aulast%3DStrosberg%26aufirst%3DA.%2BM.%26aulast%3DBitter%26aufirst%3DS.%2BM.%26aulast%3DOkada%26aufirst%3DM.%2BD.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DWhiting%26aufirst%3DR.%2BL.%26atitle%3DAntihypertensive%25209-substituted%25201-oxa-4%252C9-diazaspiro%255B5.5%255Dundecan-3-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1983%26volume%3D26%26spage%3D855%26epage%3D861%26doi%3D10.1021%2Fjm00360a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyloxosulfonium methylide ((CH<sub>3</sub>)<sub>2</sub>SOCH<sub>2</sub>) and dimethylsulfonium methylide ((CH<sub>3</sub>)<sub>2</sub>SCH<sub>2</sub>). Formation and application to organic synthesis</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/ja01084a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01084a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1965&pages=1353-1364&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethyloxosulfonium+methylide+%28%28CH3%292SOCH2%29+and+dimethylsulfonium+methylide+%28%28CH3%292SCH2%29.+Formation+and+application+to+organic+synthesis&doi=10.1021%2Fja01084a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyloxosulfonium methylide and dimethylsulfonium methylide. Formation and application to organic synthesis</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-64</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The generation of dimethyloxosulfonium methylide (Me2SOCH2) and dimethylsulfonium methylide (Me2SCH2) as reactive intermediates is described.  Both ylides are nucleophiles and both function to transfer methylene to certain electrophilic unsatd. linkages, including C:O, C:N, C:S, and in certain cases, C:C.  The less reactive oxosulfonium ylide interacts with the carbonyl function of aromatic and nonconjugated aldehydes and ketones to form oxiranes and with α,β-unsatd. ketones which are Michael receptors to form cyclopropyl ketones.  The sulfonium ylide reacts with the same substrates to give oxiranes exclusively even with the α,β-unsatd. carbonyl systems.  These reactions are quite general and, therefore, of considerable practical value.  The stereochemistry of carbonyl addn. to cyclohexanones varies depending on the ylide; the oxosulfonium ylide reacts by equatorial addn. (i.e., of methylene) and the sulfonium ylide shows a preference for axial addn.  A no. of other reactions of these ylides are described including "over-all methylene insertion," and a differential comparison of their chem. properties is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt0xfN-tNfFLVg90H21EOLACvtfcHk0lgegxXCO4sy-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D&md5=ae22573e36db50409c7832e5950df7f1</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fja01084a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01084a034%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethyloxosulfonium%2520methylide%2520%2528%2528CH3%25292SOCH2%2529%2520and%2520dimethylsulfonium%2520methylide%2520%2528%2528CH3%25292SCH2%2529.%2520Formation%2520and%2520application%2520to%2520organic%2520synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1965%26volume%3D87%26spage%3D1353%26epage%3D1364%26doi%3D10.1021%2Fja01084a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. S.</span></span> <span> </span><span class="NLM_article-title">Concise and versatile syntheses of <i>N</i>-arylalkylpiperidines as potential intermediates for 4-anilidopiperidine analgesics</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.3987/COM-97-8056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.3987%2FCOM-97-8056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaK1cXitVemu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1998&pages=239-242&author=Y.+G.+Suhauthor=D.+Y.+Shinauthor=K.+H.+Choauthor=J.+S.+Ryu&title=Concise+and+versatile+syntheses+of+N-arylalkylpiperidines+as+potential+intermediates+for+4-anilidopiperidine+analgesics&doi=10.3987%2FCOM-97-8056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Concise and versatile syntheses of N-arylalkylpiperidines as potential intermediates for 4-anilidopiperidine analgesics</span></div><div class="casAuthors">Suh, Young-Ger; Shin, Dong-Yun; Cho, Kyung-Ho; Ryu, Jae-Sang</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    
            (<span class="NLM_cas:orgname">Japan Institute of Heterocyclic Chemistry</span>)
        </div><div class="casAbstract">N-(Arylalkyl)piperidones I (R = Ph, 2-thienyl) and the (arylalkyl)spiroepoxypiperidine II, potential intermediates for 4-anilidopiperidine analgesics and their structural analogs, were efficiently synthesized from arylalkylamines by two- and three-step sequences, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm0W0FqhD7yrVg90H21EOLACvtfcHk0lgegxXCO4sy-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVemu7Y%253D&md5=420100137985a2849e29e94e122db544</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3987%2FCOM-97-8056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-97-8056%26sid%3Dliteratum%253Aachs%26aulast%3DSuh%26aufirst%3DY.%2BG.%26aulast%3DShin%26aufirst%3DD.%2BY.%26aulast%3DCho%26aufirst%3DK.%2BH.%26aulast%3DRyu%26aufirst%3DJ.%2BS.%26atitle%3DConcise%2520and%2520versatile%2520syntheses%2520of%2520N-arylalkylpiperidines%2520as%2520potential%2520intermediates%2520for%25204-anilidopiperidine%2520analgesics%26jtitle%3DHeterocycles%26date%3D1998%26volume%3D48%26spage%3D239%26epage%3D242%26doi%3D10.3987%2FCOM-97-8056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caroon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strosberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, R. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1320</span>– <span class="NLM_lpage">1328</span>, <span class="refDoi"> DOI: 10.1021/jm00143a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00143a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaL3MXls1WktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1320-1328&author=J.+M.+Caroonauthor=R.+D.+Clarkauthor=A.+F.+Klugeauthor=J.+T.+Nelsonauthor=A.+M.+Strosbergauthor=S.+H.+Ungerauthor=A.+D.+Michelauthor=R.+L.+Whiting&title=Synthesis+and+antihypertensive+activity+of+a+series+of+8-substituted+1-oxa-3%2C8-diazaspiro%5B4.5%5Ddecan-2-ones&doi=10.1021%2Fjm00143a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones</span></div><div class="casAuthors">Caroon, Joan M.; Clark, Robin D.; Kluge, Arthur F.; Nelson, Janis T.; Strosberg, Arthur M.; Unger, Stefan H.; Michel, Anton D.; Whiting, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1320-8</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Forty-three title compds. I, II, and III (R and R1 = H, Me, CH2Ph, etc.; R2 = H, Et, or Pr) were synthesized and tested as antihypertensive agents in the spontaneous hypertensive rat.  I substituted in the 4 position were the most active I.  III were less active than their corresponding II.  II (R = R2 = H, R1 = Et)  [79053-05-7] and III (R = Me, R1 = R2 = H)  [79053-04-6], designed as mixed α- and β-adrenergic receptor blockers, lowered blood pressure but gave no evidence of working as β-adrenergic blockers.  I (R = R1 = R2 = H)  [78741-66-9] and II (R = Me, R1 = R2 = H)  [79101-49-8] were α-adrenergic blockers in dogs, and in tilt-response studies for evaluating the potential for producing orthostatic hypotension both compds. had little potential for avoiding orthostatic hypotension at therapeutically EDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzT_RyPEUqSbVg90H21EOLACvtfcHk0lgegxXCO4sy-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXls1WktLs%253D&md5=5f55f46d792fcf59bccd3fb0101cc65a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm00143a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00143a012%26sid%3Dliteratum%253Aachs%26aulast%3DCaroon%26aufirst%3DJ.%2BM.%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26aulast%3DNelson%26aufirst%3DJ.%2BT.%26aulast%3DStrosberg%26aufirst%3DA.%2BM.%26aulast%3DUnger%26aufirst%3DS.%2BH.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DWhiting%26aufirst%3DR.%2BL.%26atitle%3DSynthesis%2520and%2520antihypertensive%2520activity%2520of%2520a%2520series%2520of%25208-substituted%25201-oxa-3%252C8-diazaspiro%255B4.5%255Ddecan-2-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D1320%26epage%3D1328%26doi%3D10.1021%2Fjm00143a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrecht, S.</span></span> <span> </span><span class="NLM_article-title">Method for the preparation of alpha-bromo-lactam derivatives</span>. U.S. Patent <span class="NLM_patent">US6,114,541</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=S.+Abrecht&title=Method+for+the+preparation+of+alpha-bromo-lactam+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbrecht%26aufirst%3DS.%26atitle%3DMethod%2520for%2520the%2520preparation%2520of%2520alpha-bromo-lactam%2520derivatives%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span> <i>Discovery Studio
16</i>; <span class="NLM_publisher-name">Dassault Systèmes
BIOVIA</span>: <span class="NLM_publisher-loc">San Diego, CA</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Discovery+Studio%0A16%3B+Dassault+Syst%C3%A8mes%0ABIOVIA%3A+San+Diego%2C+CA%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDiscovery%2520Studio%250A16%26pub%3DDassault%2520Syst%25C3%25A8mes%250ABIOVIA%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieferer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiechtner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, F. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of high-affinity ligands of sigma-1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4754</span>– <span class="NLM_lpage">4764</span>, <span class="refDoi"> DOI: 10.1021/jm049073+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049073%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4754-4764&author=C.+Laggnerauthor=C.+Schiefererauthor=B.+Fiechtnerauthor=G.+Polesauthor=R.+D.+Hoffmannauthor=H.+Glossmannauthor=T.+Langerauthor=F.+F.+Moebius&title=Discovery+of+high-affinity+ligands+of+sigma-1+receptor%2C+ERG2%2C+and+emopamil+binding+protein+by+pharmacophore+modeling+and+virtual+screening&doi=10.1021%2Fjm049073%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of High-Affinity Ligands of σ1 Receptor, ERG2, and Emopamil Binding Protein by Pharmacophore Modeling and Virtual Screening</span></div><div class="casAuthors">Laggner, Christian; Schieferer, Claudia; Fiechtner, Birgit; Poles, Gloria; Hoffmann, Remy D.; Glossmann, Hartmut; Langer, Thierry; Moebius, Fabian F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4754-4764</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ERG2, emopamil binding protein (EBP), and sigma-1 receptor (σ1) are enzymes of sterol metab. and an enzyme-related protein, resp., that share high affinity for various structurally diverse compds.  To discover novel high-affinity ligands, pharmacophore models were built with Catalyst based upon a series of 23 structurally diverse chems. exhibiting Ki values from 10 pM to 100 μM for all three proteins.  In virtual screening expts., we retrieved drugs that were previously reported to bind to one or several of these proteins and also tested 11 new hits exptl., of which three, among them raloxifene, had affinities for σ1 or EBP of <60 nM.  When used to search a database of 3525 biochems. of intermediary metab., a slightly modified ERG2 pharmacophore model successfully retrieved 10 substrate candidates among the top 28 hits.  Our results indicate that inhibitor-based pharmacophore models for σ1, ERG2, and EBP can be used to screen drug and metabolite databases for chem. diverse compds. and putative endogenous ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYGPlSy4wI8rVg90H21EOLACvtfcHk0ljiEoKhgyxz4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb8%253D&md5=f96d318b2e3d5575dfe6bbe98e0f5ef0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm049073%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049073%252B%26sid%3Dliteratum%253Aachs%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSchieferer%26aufirst%3DC.%26aulast%3DFiechtner%26aufirst%3DB.%26aulast%3DPoles%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DR.%2BD.%26aulast%3DGlossmann%26aufirst%3DH.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DMoebius%26aufirst%3DF.%2BF.%26atitle%3DDiscovery%2520of%2520high-affinity%2520ligands%2520of%2520sigma-1%2520receptor%252C%2520ERG2%252C%2520and%2520emopamil%2520binding%2520protein%2520by%2520pharmacophore%2520modeling%2520and%2520virtual%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4754%26epage%3D4764%26doi%3D10.1021%2Fjm049073%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span> <span> </span><span class="NLM_article-title">A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">519</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.3389%2Ffphar.2019.00519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=31214020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=519&author=R.+Pascualauthor=C.+Almansaauthor=J.+M.+Velaauthor=C.+Plata-Salam%C3%A1n&title=A+new+pharmacophore+model+for+the+design+of+sigma-1+ligands+validated+on+a+large+experimental+dataset&doi=10.3389%2Ffphar.2019.00519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset</span></div><div class="casAuthors">Pascual, Rosalia; Almansa, Carmen; Plata-Salaman, Carlos; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The recent publication of the σ1R crystal structure is an important cornerstone for the derivation of more accurate activity prediction models.  We report here a comparative study involving a set of more than 25,000 structures from our internal database that had been screened for σ1R affinity.  Using the recently published crystal structure, 5HK1, two new pharmacophore models were generated.  The first one, 5HK1-Ph.A, was obtained by an algorithm that identifies the most important receptor-ligand interactions including vol. restrictions enforced by the at. structure of the recognition site.  The second, 5HK1-Ph.B, resulted from a manual edition of the first one by the fusion of two hydrophobic (HYD) features.  Finally, we also docked the database using a high throughput docking technique and scored the resulting poses with seven different scoring functions.  Statistical performance measures were obtained for the two models, comparing them with previously published σ1R pharmacophores (Hit Rate, sensitivity, specificity, and Receiver Operator Characteristic) and 5HK1-Ph.B emerged as the best one in discriminating between active and inactive compds., with a ROC-AUC value above 0.8 and enrichment values above 3 at different fractions of screened samples. 5HK1-Ph.B also showed better results than the direct docking, which may be due to the rigidity of the crystal structure in the docking process (i.e., feature tolerances in the pharmacophore model).  Addnl., the impact of the HYD interactions and the penalty for desolvating ligands with polar atoms may be not adequately captured by scoring functions, whereas HYD groups filling up such regions of the binding site are entailed in the pharmacophore model.  Altogether, using annotated data from a large and diverse compd. collection together with crystal structure information provides a sound basis for the generation and validation of predictive models to design new mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGommlNCghqBXrVg90H21EOLACvtfcHk0ljiEoKhgyxz4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D&md5=156ec236d1cf03779cae199e0716b497</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00519%26sid%3Dliteratum%253Aachs%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26atitle%3DA%2520new%2520pharmacophore%2520model%2520for%2520the%2520design%2520of%2520sigma-1%2520ligands%2520validated%2520on%2520a%2520large%2520experimental%2520dataset%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D519%26doi%3D10.3389%2Ffphar.2019.00519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejmech.2019.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=31129453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2019&pages=47-62&author=S.+Thumauthor=D.+Schepmannauthor=E.+Ayetauthor=M.+Pujolauthor=F.+R.+Nietoauthor=S.+M.+Ametameyauthor=B.+W%C3%BCnsch&title=Tetrahydro-3-benzazepines+with+fluorinated+side+chains+as+NMDA+and+%CF%831+receptor+antagonists%3A+Synthesis%2C+receptor+affinity%2C+selectivity+and+antiallodynic+activity&doi=10.1016%2Fj.ejmech.2019.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity</span></div><div class="casAuthors">Thum, Simone; Schepmann, Dirk; Ayet, Eva; Pujol, Marta; Nieto, Francisco R.; Ametamey, Simon M.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-62</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The class of tetrahydro-1H-3-benzazepines was systematically modified in 1-, 3- and 7-position.  In particular, a F-atom was introduced in β- or γ-position of the 4-phenylbutyl side chain in 3-position.  Ligands with the F-atom in γ-position possess higher GluN2B affinity than analogs bearing the F-atom in β-position.  This effect was attributed to the reduced basicity of β-fluoro amines.  3-Benzazepines with a benzylic OH moiety show moderate GluN2B affinity, but considerable selectivity over the σ2 receptor.  However, removal of the benzylic OH moiety led to increased GluN2B affinity, but reduced GluN2B/σ2 selectivity.  With respect to GluN2B affinity the phenol 17b (I) with a γ-fluorophenylbutyl moiety in 3-position represents the most interesting fluorinated ligand (Ki(GluN2B) = 16 nM).  Most of the synthesized ligands reveal either similar GluN2B and σ1 affinity or higher σ1 affinity than GluN2B affinity.  The Me ether 16b (II) shows high σ1 affinity (Ki(σ1) = 6.6 nM) and high selectivity over a broad panel of receptors and transporters.  The high antiallodynic activity in the mouse capsaicin assay proved the σ1 antagonistic activity of 16b.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4JVguOHkxBrVg90H21EOLACvtfcHk0ljiEoKhgyxz4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnI&md5=6d3d234ecb41991803484736ae7bf512</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DThum%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DAyet%26aufirst%3DE.%26aulast%3DPujol%26aufirst%3DM.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DTetrahydro-3-benzazepines%2520with%2520fluorinated%2520side%2520chains%2520as%2520NMDA%2520and%2520%25CF%25831%2520receptor%2520antagonists%253A%2520Synthesis%252C%2520receptor%2520affinity%252C%2520selectivity%2520and%2520antiallodynic%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D177%26spage%3D47%26epage%3D62%26doi%3D10.1016%2Fj.ejmech.2019.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgueño, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, J.</span></span> <span> </span><span class="NLM_article-title">A complementary scale of biased agonism for agonists with differing maximal responses</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15389</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-15258-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1038%2Fs41598-017-15258-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=29133887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A280%3ADC%252BC1M3gvVegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=15389&author=J.+Burgue%C3%B1oauthor=M.+Pujolauthor=X.+Monroyauthor=D.+Rocheauthor=M.+J.+Varelaauthor=M.+Merlosauthor=J.+Giraldo&title=A+complementary+scale+of+biased+agonism+for+agonists+with+differing+maximal+responses&doi=10.1038%2Fs41598-017-15258-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses</span></div><div class="casAuthors">Burgueno Javier; Pujol Marta; Monroy Xavier; Merlos Manuel; Roche David; Giraldo Jesus; Roche David; Giraldo Jesus; Roche David; Varela Maria Jose</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15389</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Compelling data in the literature from the recent years leave no doubt about the pluridimensional nature of G protein-coupled receptor function and the fact that some ligands can couple with different efficacies to the multiple pathways that a receptor can signal through, a phenomenon most commonly known as functional selectivity or biased agonism.  Nowadays, transduction coefficients (log(τ/KA)), based on the Black and Leff operational model of agonism, are widely used to calculate bias.  Nevertheless, combining both affinity and efficacy in a single parameter can result in compounds showing a defined calculated bias of one pathway over other though displaying varying experimental bias preferences.  In this paper, we present a novel scale (log(τ)), that attempts to give extra substance to different compound profiles in order to better classify compounds and quantify their bias.  The efficacy-driven log(τ) scale is not proposed as an alternative to the affinity&efficacy-driven log(τ/KA) scale but as a complement in those situations where partial agonism is present.  Both theoretical and practical approaches using μ-opioid receptor agonists are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8ACsymX9-Ay-bLEOO4dYpfW6udTcc2eZMpc08l-dN17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3gvVegsg%253D%253D&md5=8c43e0cc2e5e1fe47fa40c2c3d50b7f6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-15258-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-15258-z%26sid%3Dliteratum%253Aachs%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DPujol%26aufirst%3DM.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DVarela%26aufirst%3DM.%2BJ.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGiraldo%26aufirst%3DJ.%26atitle%3DA%2520complementary%2520scale%2520of%2520biased%2520agonism%2520for%2520agonists%2520with%2520differing%2520maximal%2520responses%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D15389%26doi%3D10.1038%2Fs41598-017-15258-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitza, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G. A.</span></span> <span> </span><span class="NLM_article-title">The [<sup>3</sup>H]-dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K<sup>+</sup>]<sub>o</sub></span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2004.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.vascn.2004.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15519905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=187-199&author=G.+J.+Diazauthor=K.+Daniellauthor=S.+T.+Leitzaauthor=R.+L.+Martinauthor=Z.+Suauthor=J.+S.+McDermottauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+%5B3H%5D-dofetilide+binding+assay+is+a+predictive+screening+tool+for+hERG+blockade+and+proarrhythmia%3A+Comparison+of+intact+cell+and+membrane+preparations+and+effects+of+altering+%5BK%2B%5Do&doi=10.1016%2Fj.vascn.2004.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span></div><div class="casAuthors">Diaz, Gilbert J.; Daniell, Katina; Leitza, Sandra T.; Martin, Ruth L.; Su, Zhi; McDermott, Jeffrey S.; Cox, Bryan F.; Gintant, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: The human ether-a-go-go-related gene (hERG) encodes a potassium channel responsible for the cardiac delayed rectifier current (IKr) involved in ventricular repolarization.  Drugs that block hERG have been assocd. with QT interval prolongation and serious, sometimes fatal, cardiac arrhythmias (including torsade de pointes).  While displacement of [3H]dofetilide, a potent methanesulfonanilide hERG blocker, from cells heterologously expressing hERG has been suggested as a screening assay, questions have been raised about its predictive value.Methods: To validate the utility of this assay as a screening tool, we performed a series of satn. and competition binding studies using [3H]dofetilide as ligand and either intact cells or membrane prepns. from HEK 293 cells stably transfected with hERG K+ channels.  The object of these expts. was to (1) compare binding Ki values for 22 hERG blockers using intact cells or membrane homogenates to det. whether maintaining cell integrity enhanced assay reliability; (2) evaluate the ability of different K+ concns. (2, 5, 10, 20, and 60 mM) to modulate hERG binding; and (3) to establish the predictive value of the assay by comparing Ki values from binding studies at 5 and 60 mM [K+]o to functional IC50 values for hERG current block using 56 structurally diverse drugs.Results: We found (a) comparable Ki values in the intact cell and isolated membrane binding assays, although there were some differences in rank order; (b) increasing [K+]o lowered the Kd and increased the Bmax for [3H]dofetilide, particularly in the membrane assay; and (c) good correlation between binding Ki values and functional IC50 values for hERG current block.Discussion: In conclusion, increasing K+ concns. results in an increase in both [3H]dofetilide affinity for hERG and available binding sites, particularly when using membrane homogenates.  There are no meaningful differences between Ki values when comparing intact cell vs. membrane assay, neither are there meaningful trends with increasing [K+]o within assays.  There is good correlation between binding Ki values and functional (whole-cell patch clamp) IC50 values at both 5 and 60 mM K+ concns. (R2 values of .824 and .863, resp.).  The simplicity, predictability, and adaptability to high-throughput platforms make the [3H]dofetilide membrane binding assay a useful tool for screening and ranking compds. for their potential to block the hERG K+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJEs_DWLzvI7Vg90H21EOLACvtfcHk0li3ik99OoC5vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D&md5=28c925ef02404c53443dc90eae961ed1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DDaniell%26aufirst%3DK.%26aulast%3DLeitza%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520%255B3H%255D-dofetilide%2520binding%2520assay%2520is%2520a%2520predictive%2520screening%2520tool%2520for%2520hERG%2520blockade%2520and%2520proarrhythmia%253A%2520Comparison%2520of%2520intact%2520cell%2520and%2520membrane%2520preparations%2520and%2520effects%2520of%2520altering%2520%255BK%252B%255Do%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2004%26volume%3D50%26spage%3D187%26epage%3D199%26doi%3D10.1016%2Fj.vascn.2004.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0li3ik99OoC5vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span> <span> </span><span class="NLM_article-title">Minimizing the potential for metabolic activation in Drug Discovery</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1517/17425255.1.1.91</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1517%2F17425255.1.1.91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=16922655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=91-142&author=A.+S.+Kalgutkarauthor=J.+R.+Soglia&title=Minimizing+the+potential+for+metabolic+activation+in+Drug+Discovery&doi=10.1517%2F17425255.1.1.91"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Minimising the potential for metabolic activation in drug discovery</span></div><div class="casAuthors">Kalgutkar, Amit S.; Soglia, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-142</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Investigations into the role of bioactivation in the pathogenesis of xeno-biotic-induced toxicity have been a major area of research since the link between reactive metabolites and carcinogenesis was first reported in the 1930s.  Circumstantial evidence suggests that bioactivation of relatively inert functional groups to reactive metabolites may contribute towards certain drug-induced adverse reactions.  Reactive metabolites, if not detoxified, can covalently modify essential cellular targets.  The identity of the susceptible biomacromol.(s), and the physiol. consequence of its covalent modification, will dictate the resulting toxicol. response (e.g., covalent modification of DNA by reactive intermediates derived from procarcinogens that potentially leads to carcinogenesis).  The formation of drug-protein adducts often carries a potential risk of clin. toxicities that may not be predicted from preclin. safety studies.  Animal models used to reliably predict idio-syncratic drug toxicity are unavailable at present.  Furthermore, considering that the frequency of occurrence of idiosyncratic adverse drug reactions (IADRs) is fairly rare (1 in 1000 to 1 in 10,000), it is impossible to detect such phenomena in early clin. trials.  Thus, the occurrence of IADRs during late clin. trials or after a drug has been released can lead to an unanticipated restriction in its use and even in its withdrawal.  Major themes explored in this review include a comprehensive cataloguing of bioactivation pathways of functional groups commonly utilized in drug design efforts with appropriate strategies towards detection of corresponding reactive intermediates.  Several instances wherein replacement of putative structural alerts in drugs assocd. with IADRs with a latent functionality eliminates the underlying liability are also presented.  Examples of where bioactivation phenomenon in drug candidates can be successfully abrogated via iterative chem. interventions are also discussed.  Finally, appropriate strategies that aid in potentially mitigating the risk of IADRs are explored, esp. in circumstances in which the structural alert is also responsible for the primary pharmacol. of the drug candidate and cannot be replaced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryrPwGKBtP3rVg90H21EOLACvtfcHk0lgdrLqLlyer9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVGhs7s%253D&md5=15a3312335273663b6ef1222534f5428</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1517%2F17425255.1.1.91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.1.1.91%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26atitle%3DMinimizing%2520the%2520potential%2520for%2520metabolic%2520activation%2520in%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2005%26volume%3D1%26spage%3D91%26epage%3D142%26doi%3D10.1517%2F17425255.1.1.91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48aR"><div class="casContent"><span class="casTitleNuber">48a</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lgdrLqLlyer9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit48a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit48b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span>. <i>Am. Soc. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DAm.%2520Soc.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates. Methodology for 25 enzyme/substrate pairs</span>. In  <i>Optimization in Drug Discovery: In Vitro Methods</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span>, <span class="NLM_string-name">Caldwell, G. W.</span></span>; Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>, <span class="NLM_year">2004</span>; pp  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">230</span>;</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1385%2F1-59259-800-5%3A215" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=215-230&author=D.+M.+Stresserauthor=Z.+Yan&author=G.+W.+Caldwell&title=Optimization+in+Drug+Discovery%3A+In+Vitro+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1385%2F1-59259-800-5%3A215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1385%252F1-59259-800-5%253A215%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26atitle%3DHigh-throughput%2520screening%2520of%2520human%2520cytochrome%2520P450%2520inhibitors%2520using%2520fluorometric%2520substrates.%2520Methodology%2520for%252025%2520enzyme%252Fsubstrate%2520pairs%26btitle%3DOptimization%2520in%2520Drug%2520Discovery%253A%2520In%2520Vitro%2520Methods%26aulast%3DYan%26aufirst%3DZ.%26pub%3DHumana%2520Press%26date%3D2004%26spage%3D215%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit49b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span>, <span class="NLM_string-name">Caldwell, G. W.</span></span> <i>Evaluation of Cytochrome P450 Inhibition in Human Liver Microsomes</i>; <span class="NLM_publisher-name">Idem</span>, pp  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">244</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Yan%2C+Z.%2C+Caldwell%2C+G.+W.+Evaluation+of+Cytochrome+P450+Inhibition+in+Human+Liver+Microsomes%3B+Idem%2C+pp+231%E2%80%93244%3B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DZ.%26jtitle%3DEvaluation%2520of%2520Cytochrome%2520P450%2520Inhibition%2520in%2520Human%2520Liver%2520Microsomes%26pub%3DIdem%26spage%3D231%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit49c"><span><span class="NLM_label">(c) </span> <i>Drug Interaction Studies—Study Design, Data Analysis,
Implications for Dosing and Labeling</i>; <span class="NLM_publisher-name">Center
for Drug Evaluation and Research (CDER), Food and Drug Administration</span>, September <span class="NLM_year">2006</span> and February <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Interaction+Studies%E2%80%94Study+Design%2C+Data+Analysis%2C%0AImplications+for+Dosing+and+Labeling%3B+Center%0Afor+Drug+Evaluation+and+Research+%28CDER%29%2C+Food+and+Drug+Administration%2C+September+2006+and+February+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDrug%2520Interaction%2520Studies%25E2%2580%2594Study%2520Design%252C%2520Data%2520Analysis%252C%250AImplications%2520for%2520Dosing%2520and%2520Labeling%26pub%3DCenter%250Afor%2520Drug%2520Evaluation%2520and%2520Research%2520%2528CDER%2529%252C%2520Food%2520and%2520Drug%2520Administration%26date%3D2006%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Modality-specific peripheral antinociceptive effects of μ-opioid agonists on heat and mechanical stimuli: Contribution of sigma-1 receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.neuropharm.2018.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=29580951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslKmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2018&pages=328-342&author=A.+Montilla-Garc%C3%ADaauthor=G.+Perazzoliauthor=M.+A.+Tejadaauthor=R.+Gonz%C3%A1lez-Canoauthor=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=E.+J.+Cobosauthor=J.+M.+Baeyens&title=Modality-specific+peripheral+antinociceptive+effects+of+%CE%BC-opioid+agonists+on+heat+and+mechanical+stimuli%3A+Contribution+of+sigma-1+receptors&doi=10.1016%2Fj.neuropharm.2018.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Modality-specific peripheral antinociceptive effects of μ-opioid agonists on heat and mechanical stimuli: Contribution of sigma-1 receptors</span></div><div class="casAuthors">Montilla-Garcia, Angeles; Perazzoli, Gloria; Tejada, Miguel A.; Gonzalez-Cano, Rafael; Sanchez-Fernandez, Cristina; Cobos, Enrique J.; Baeyens, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">328-342</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Morphine induces peripherally μ-opioid-mediated antinociception to heat but not to mech. stimulation.  Peripheral sigma-1 receptors tonically inhibit μ-opioid antinociception to mech. stimuli, but it is unknown whether they modulate μ-opioid heat antinociception.  We hypothesized that sigma-1 receptors might play a role in the modality-specific peripheral antinociceptive effects of morphine and other clin. relevant μ-opioid agonists.  Mech. nociception was assessed in mice with the paw pressure test (450 g), and heat nociception with the unilateral hot plate (55 °C) test.  Local peripheral (intraplantar) administration of morphine, buprenorphine or oxycodone did not induce antinociception to mech. stimulation but had dose-dependent antinociceptive effects on heat stimuli.  Local sigma-1 antagonism unmasked peripheral antinociception by μ-opioid agonists to mech. stimuli, but did not modify their effects on heat stimulation.  TRPV1+ and IB4+ cells are segregated populations of small neurons in the dorsal root ganglia (DRG) and the d. of sigma-1 receptors was higher in IB4+ cells than in the rest of small nociceptive neurons.  The in vivo ablation of TRPV1-expressing neurons with resiniferatoxin did not alter IB4+ neurons in the DRG, mech. nociception, or the effects of sigma-1 antagonism on local morphine antinociception in this type of stimulus.  However, it impaired the responses to heat stimuli and the effect of local morphine on heat nociception.  In conclusion, peripheral opioid antinociception to mech. stimuli is limited by sigma-1 tonic inhibitory actions, whereas peripheral opioid antinociception to heat stimuli (produced in TRPV1-expressing neurons) is not.  Therefore, sigma-1 receptors contribute to the modality-specific peripheral effects of opioid analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAy-RHQXgtw7Vg90H21EOLACvtfcHk0ljTRucSrXASzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslKmu7w%253D&md5=3b35eba44d61705f5326cf9762e9fcaa</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DGonz%25C3%25A1lez-Cano%26aufirst%3DR.%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DModality-specific%2520peripheral%2520antinociceptive%2520effects%2520of%2520%25CE%25BC-opioid%2520agonists%2520on%2520heat%2520and%2520mechanical%2520stimuli%253A%2520Contribution%2520of%2520sigma-1%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D135%26spage%3D328%26epage%3D342%26doi%3D10.1016%2Fj.neuropharm.2018.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho-Cordón, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of peripheral μ-opioid analgesia by sigma-1 receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1124%2Fjpet.113.208272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=24155346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=32-45&author=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=A.+Montilla-Garc%C3%ADaauthor=R.+Gonz%C3%A1lez-Canoauthor=F.+R.+Nietoauthor=L.+Romeroauthor=A.+Artacho-Cord%C3%B3nauthor=R.+Montesauthor=B.+Fern%C3%A1ndez-Pastorauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=J.+M.+Entrenaauthor=E.+J.+Cobos&title=Modulation+of+peripheral+%CE%BC-opioid+analgesia+by+sigma-1+receptors&doi=10.1124%2Fjpet.113.208272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of peripheral μ-opioid analgesia by σ1 receptors</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Montilla-Garcia, Angeles; Gonzalez-Cano, Rafael; Nieto, Francisco Rafael; Romero, Lucia; Artacho-Cordon, Antonia; Montes, Rosa; Fernandez-Pastor, Begona; Merlos, Manuel; Baeyens, Jose Manuel; Entrena, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the effects of σ1-receptor inhibition on μ-opioid-induced mech. antinociception and constipation. σ1-Knockout mice exhibited marked mech. antinociception in response to several μ-opioid analgesics (fentanyl, oxycodone, morphine, buprenorphine, and tramadol) at systemic (s.c.) doses that were inactive in wild-type mice and even unmasked the antinociceptive effects of the peripheral μ-opioid agonist loperamide.  Likewise, systemic (s.c.) or local (intraplantar) treatment of wild-type mice with the selective σ1 antagonists BD-1063 [1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride] or S1RA [4-[2-[[5-methyl-1-(2-naphthalenyl)1H-pyrazol-3-yl]oxy]ethyl] morpholine hydrochloride] potentiated μ-opioid antinociception; these effects were fully reversed by the σ1 agonist PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate) hydrochloride], showing the selectivity of the pharmacol. approach.  The μ-opioid antinociception potentiated by σ1 inhibition (by σ1-receptor knockout or σ1-pharmacol. antagonism) was more sensitive to the peripherally restricted opioid antagonist naloxone methiodide than opioid antinociception under normal conditions, indicating a key role for peripheral opioid receptors in the enhanced antinociception.  Direct interaction between the opioid drugs and σ1 receptor cannot account for our results, since the former lacked affinity for σ1 receptors (labeled with [3H](+)-pentazocine).  A peripheral role for σ1 receptors was also supported by their higher d. (Western blot results) in peripheral nervous tissue (dorsal root ganglia) than in several central areas involved in opioid antinociception (dorsal spinal cord, basolateral amygdala, periaqueductal gray, and rostroventral medulla).  In contrast to its effects on nociception, σ1-receptor inhibition did not alter fentanyl- or loperamide-induced constipation, a peripherally mediated nonanalgesic opioid effect.  Therefore, σ1-receptor inhibition may be used as a systemic or local adjuvant to enhance peripheral μ-opioid analgesia without affecting opioid-induced constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXDUF69QHTL7Vg90H21EOLACvtfcHk0ljTRucSrXASzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D&md5=3448ecaf8c215210a48a8413b89db2a5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208272%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez-Cano%26aufirst%3DR.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DArtacho-Cord%25C3%25B3n%26aufirst%3DA.%26aulast%3DMontes%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez-Pastor%26aufirst%3DB.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DModulation%2520of%2520peripheral%2520%25CE%25BC-opioid%2520analgesia%2520by%2520sigma-1%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D32%26epage%3D45%26doi%3D10.1124%2Fjpet.113.208272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.2165/00023210-200418050-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.2165%2F00023210-200418050-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15089113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Sgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=269-284&author=T.+Hayashiauthor=T.+P.+Su&title=Sigma-1+receptor+ligands%3A+potential+in+the+treatment+of+neuropsychiatric+disorders&doi=10.2165%2F00023210-200418050-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">σ-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders</span></div><div class="casAuthors">Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">269-284</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The σ receptor was originally proposed to be a subtype of the opioid receptor.  However, it is now clear that σ receptors are unique non-opioid, non-phencyclidine brain proteins.  Two types of σ receptor exist, the σ-1 receptor and the σ-2 receptor.  σ-1 Receptors have been cloned and their distribution, physiol. functions and roles in signal transduction were recently characterized.  Certain sex hormones in the brain (neurosteroids) are known to interact with σ-1 receptors.  σ-1 Receptors regulate glutamate NMDA receptor function and the release of neurotransmitters such as dopamine.  They are thus proposed to be involved in learning and memory as well as in certain neuropsychiatric disorders.  Selective σ-1 receptor ligands have been suggested to represent a new class of therapeutic agents for neuropsychiatric disorders, although none have yet been introduced into therapeutic use.  Early studies showed that psychotomimetic benzomorphans, as well as several antipsychotics, can bind to σ-1 receptors.  As a result of these findings, σ-1 receptor ligands have been proposed as being of potential use in the treatment of schizophrenia.  Nevertheless, the relation of σ-1 receptors to the underlying pathogenesis of schizophrenia is still unclear.  σ-1 Receptor ligands have failed to improve acute psychotic symptoms of schizophrenia in clin. trials, but, interestingly, a few studies have shown an improvement in neg. symptoms in schizophrenic patients.  A no. of preclin. studies have shown that selective agonists of σ-1 receptors affect higher-ordered brain functions such as learning and memory, cognition and mood.  These studies indicate that σ-1 receptor agonists may exert therapeutic effects in depression and senile dementia.  Indeed, the σ-1 receptor agonist igmesine, has been shown to improve depression in a clin. trial.  The most distinctive feature of the action of σ-1 receptor ligands is their "modulatory" role.  In behavioral studies of depression and memory, they exert beneficial effects only when brain functions are perturbed.  Given the recently accumulated preclin. and clin. data, it is time to reconstruct the concept of σ-1 receptors and the assocd. pathophysiol. conditions that ligands of these receptors target.  This would allow clin. trials to be performed more efficiently, and the results may confirm a long-speculated possibility that σ-1 receptor ligands represent a new class of therapeutic agents for neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8ZblhgvXqLVg90H21EOLACvtfcHk0ljTRucSrXASzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Sgu7w%253D&md5=08d5da331525ae7d7fe5be8665fff0fd</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2165%2F00023210-200418050-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200418050-00001%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DSigma-1%2520receptor%2520ligands%253A%2520potential%2520in%2520the%2520treatment%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DCNS%2520Drugs%26date%3D2004%26volume%3D18%26spage%3D269%26epage%3D284%26doi%3D10.2165%2F00023210-200418050-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of Pan Assay Interference Compounds (PAINS) from screening libraries and their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+screening+libraries+and+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljP_mYKm4zvaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Box, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E. A.</span></span> <span> </span><span class="NLM_article-title">Using measured p<i>K</i><sub>a</sub>, log <i>P</i> and solubility to investigate supersaturation and predict BCS class</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.2174/138920008786485155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.2174%2F138920008786485155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=18991583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=869-878&author=K.+J.+Boxauthor=E.+A.+Comer&title=Using+measured+pKa%2C+log+P+and+solubility+to+investigate+supersaturation+and+predict+BCS+class&doi=10.2174%2F138920008786485155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class</span></div><div class="casAuthors">Box, K. J.; Comer, J. E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">869-878</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ionization, lipophilicity and soly. have a profound influence on the transport properties of drug mols.  We will present an overview of why physicochem. properties are important, before discussing how the properties are related to each other.  Findings are based on research in our own labs. using our com. instruments and software to measure the pKa, lipophilicity (LogP) and intrinsic soly. (LogS0) of 84 marketed ionizable drugs.  In general, the most lipophilic mols. were the least sol. in water.  Plots of LogP vs. LogS0 show results for these drugs clustered according to other properties, including m.p., no. of H-bond donors and acceptors, ability to supersaturate, and BCS class.  Mols. with high m.p. tended to have a larger no. of H-bond donors and acceptors, and to be less sol. than predicted from their LogP.  Mols. with low m.p. tended to have little H-bond donor capacity, and tended to be more sol. than predicted from their LogP.  Mols. that could form supersatd. solns. tended to have higher m.ps., and to be less sol. than predicted from their LogP.  Mols. in BCS Classes I - III tended to cluster in different parts of the plot.  It is proposed that comparing measured LogP and LogS0 of new mols. with these plots will facilitate a quick assessment of their likely BCS Class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjSonznQUhwbVg90H21EOLACvtfcHk0ljP_mYKm4zvaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb4%253D&md5=d330301b360589feb67aa92fc0227ea6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F138920008786485155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485155%26sid%3Dliteratum%253Aachs%26aulast%3DBox%26aufirst%3DK.%2BJ.%26aulast%3DComer%26aufirst%3DE.%2BA.%26atitle%3DUsing%2520measured%2520pKa%252C%2520log%2520P%2520and%2520solubility%2520to%2520investigate%2520supersaturation%2520and%2520predict%2520BCS%2520class%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D869%26epage%3D878%26doi%3D10.2174%2F138920008786485155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lastra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baamonde, A.</span></span> <span> </span><span class="NLM_article-title">Analgesic effects of loperamide in bone cancer pain in mice</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2005.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.pbb.2005.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15894068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1KqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2005&pages=114-121&author=L.+Men%C3%A9ndezauthor=A.+Lastraauthor=A.+Meanaauthor=A.+Hidalgoauthor=A.+Baamonde&title=Analgesic+effects+of+loperamide+in+bone+cancer+pain+in+mice&doi=10.1016%2Fj.pbb.2005.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic effects of loperamide in bone cancer pain in mice</span></div><div class="casAuthors">Menendez, Luis; Lastra, Ana; Meana, Alvaro; Hidalgo, Agustin; Baamonde, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-121</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The intratibial inoculation of NCTC 2472 cells induces an osteosarcoma in C3H/HeJ mice.  These mice show thermal hyperalgesic responses which may be blocked by the local administration of opiates over the tibial tumoral mass (Menendez L, Lastra A, Hidalgo A, Meana A, Garcia E, Baamonde A. Peripheral opioids act as analgesics in bone cancer pain in mice. NeuroReport 2003b;14:867-9).  The aim of this report was to characterize the analgesic responses obtained by activating peripheral opioid receptors in bone cancer pain.  Here, we initially describe that this osteosarcoma induces mech. as well as thermal hyperalgesia.  Loperamide, an opioid agonist unable to cross the blood-brain barrier, inhibits both thermal and mech. hyperalgesia when s.c. injected, locally over the tibial tumoral mass (7.5-75 μg) or distantly, under the fur of the neck (4 mg/kg).  These analgesic effects seem peripherally mediated since they are reverted by the administration of naloxone methiodide (10 mg/kg) and because the withdrawal latencies of the contralateral, non-affected, paws remain unaltered.  Furthermore, only cyprodime (1 mg/kg) but not naltrindole (0.1 mg/kg) or nor-binaltorphimine (10 mg/kg) blocked these effects, showing the involvement of μ-opioid receptors in the peripheral analgesia induced by loperamide on thermal and mech. hyperalgesia.  The advantages of using peripheral acting opiates - devoid of central collateral effects - for the treatment of cancer related pain are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofeiy9O9hOBbVg90H21EOLACvtfcHk0li6BKrTPy7m-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1KqtL8%253D&md5=6f4a46690f0d0e599d23e2c3d969e218</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2005.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2005.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DMen%25C3%25A9ndez%26aufirst%3DL.%26aulast%3DLastra%26aufirst%3DA.%26aulast%3DMeana%26aufirst%3DA.%26aulast%3DHidalgo%26aufirst%3DA.%26aulast%3DBaamonde%26aufirst%3DA.%26atitle%3DAnalgesic%2520effects%2520of%2520loperamide%2520in%2520bone%2520cancer%2520pain%2520in%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2005%26volume%3D81%26spage%3D114%26epage%3D121%26doi%3D10.1016%2Fj.pbb.2005.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48a','cit48b'],'ref49':['cit49a','cit49b','cit49c'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mónica García, Virginia Llorente, Lourdes Garriga, Ute Christmann, Sergi Rodríguez-Escrich, Marina Virgili, Begoña Fernández, Magda Bordas, Eva Ayet, Javier Burgueño, Marta Pujol, Albert Dordal, Enrique Portillo-Salido, Georgia Gris, José Miguel Vela, <span class="NLM_string-name hlFld-ContribAuthor">Carmen Almansa</span>. </span><span class="cited-content_cbyCitation_article-title">Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 10139-10154. <a href="https://doi.org/10.1021/acs.jmedchem.1c00417" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00417%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPropionamide%252BDerivatives%252Bas%252BDual%252B%2525CE%2525BC-Opioid%252BReceptor%252BAgonists%252Band%252B%2525CF%2525831%252BReceptor%252BAntagonists%252Bfor%252Bthe%252BTreatment%252Bof%252BPain%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM%25C3%25B3nica%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D08072021%26volume%3D64%26issue%3D14%26spage%3D10139%26epage%3D10154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nattawadee Chaisan, Sureeporn Ruengsangtongkul, Jumreang Tummatorn, Somsak Ruchirawat, Kittipong Chainok, <span class="NLM_string-name hlFld-ContribAuthor">Charnsak Thongsornkleeb</span>. </span><span class="cited-content_cbyCitation_article-title">Dibrominative Spirocyclization of 2-Butynolyl Anilides: Synthesis of gem-Dibromospirocyclic Benzo[d][1,3]oxazines and Their Application in the Synthesis of 4H-Furo[3,2-b]indoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (6)
                                     , 4671-4698. <a href="https://doi.org/10.1021/acs.joc.1c00086" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00086%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDibrominative%252BSpirocyclization%252Bof%252B2-Butynolyl%252BAnilides%25253A%252BSynthesis%252Bof%252Bgem-Dibromospirocyclic%252BBenzo%25255Bd%25255D%25255B1%25252C3%25255Doxazines%252Band%252BTheir%252BApplication%252Bin%252Bthe%252BSynthesis%252Bof%252B4H-Furo%25255B3%25252C2-b%25255Dindoles%26aulast%3DChaisan%26aufirst%3DNattawadee%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D12012021%26date%3D10032021%26volume%3D86%26issue%3D6%26spage%3D4671%26epage%3D4698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kerstin Hiesinger, Dmitry Dar’in, Ewgenij Proschak, <span class="NLM_string-name hlFld-ContribAuthor">Mikhail Krasavin</span>. </span><span class="cited-content_cbyCitation_article-title">Spirocyclic Scaffolds in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 150-183. <a href="https://doi.org/10.1021/acs.jmedchem.0c01473" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSpirocyclic%252BScaffolds%252Bin%252BMedicinal%252BChemistry%26aulast%3DHiesinger%26aufirst%3DKerstin%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D24082020%26date%3D31122020%26volume%3D64%26issue%3D1%26spage%3D150%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mónica García, Marina Virgili, Mònica Alonso, Carles Alegret, Joan Farran, Begoña Fernández, Magda Bordas, Rosalia Pascual, Javier Burgueño, Alba Vidal-Torres, Antonio R. Fernández de Henestrosa, Eva Ayet, Manuel Merlos, Jose Miguel Vela, Carlos R. Plata-Salamán, <span class="NLM_string-name hlFld-ContribAuthor">Carmen Almansa</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1 Receptor Antagonist Clinical Candidate for the Treatment of Pain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15508-15526. <a href="https://doi.org/10.1021/acs.jmedchem.0c01127" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01127%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BEST73502%25252C%252Ba%252BDual%252B%2525CE%2525BC-Opioid%252BReceptor%252BAgonist%252Band%252B%2525CF%2525831%252BReceptor%252BAntagonist%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BPain%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM%25C3%25B3nica%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01072020%26date%3D16102020%26volume%3D63%26issue%3D24%26spage%3D15508%26epage%3D15526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Na Ye, Wangzhi Qin, Sheng Tian, Qingfeng Xu, Eric A. Wold, Jia Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Xue-Chu Zhen</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15187-15217. <a href="https://doi.org/10.1021/acs.jmedchem.0c01192" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01192%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecules%252BSelectively%252BTargeting%252BSigma-1%252BReceptor%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurological%252BDiseases%26aulast%3DYe%26aufirst%3DNa%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09072020%26date%3D28102020%26volume%3D63%26issue%3D24%26spage%3D15187%26epage%3D15217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Zhuang</span>, <span class="hlFld-ContribAuthor ">Jiaying  Xiong</span>, <span class="hlFld-ContribAuthor ">Shuaishuai  Hao</span>, <span class="hlFld-ContribAuthor ">Wei  Du</span>, <span class="hlFld-ContribAuthor ">Zhenming  Liu</span>, <span class="hlFld-ContribAuthor ">Bifeng  Liu</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhang</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional μ opioid and σ1 receptor ligands as novel analgesics with reduced side effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113658. <a href="https://doi.org/10.1016/j.ejmech.2021.113658" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113658%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBifunctional%252B%2525CE%2525BC%252Bopioid%252Band%252B%2525CF%2525831%252Breceptor%252Bligands%252Bas%252Bnovel%252Banalgesics%252Bwith%252Breduced%252Bside%252Beffects%26aulast%3DZhuang%26aufirst%3DTao%26date%3D2021%26volume%3D223%26spage%3D113658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca Serena  Abatematteo</span>, <span class="hlFld-ContribAuthor ">Mauro  Niso</span>, <span class="hlFld-ContribAuthor ">Marialessandra  Contino</span>, <span class="hlFld-ContribAuthor ">Marcello  Leopoldo</span>, <span class="hlFld-ContribAuthor ">Carmen  Abate</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (12)
                                     , 6359. <a href="https://doi.org/10.3390/ijms22126359" title="DOI URL">https://doi.org/10.3390/ijms22126359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22126359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22126359%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMulti-Target%252BDirected%252BLigands%252B%252528MTDLs%252529%252BBinding%252Bthe%252B%2525CF%2525831%252BReceptor%252Bas%252BPromising%252BTherapeutics%25253A%252BState%252Bof%252Bthe%252BArt%252Band%252BPerspectives%26aulast%3DAbatematteo%26aufirst%3DFrancesca%2BSerena%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D12%26spage%3D6359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva  Ayet</span>, <span class="hlFld-ContribAuthor ">Sandra  Yeste</span>, <span class="hlFld-ContribAuthor ">Raquel F.  Reinoso</span>, <span class="hlFld-ContribAuthor ">María José  Pretel</span>, <span class="hlFld-ContribAuthor ">Ariadna  Balada</span>, <span class="hlFld-ContribAuthor ">Maria Teresa  Serafini</span>. </span><span class="cited-content_cbyCitation_article-title">Preliminary
              in vitro
              approach to evaluate the drug-drug interaction potential of EST73502, a dual µ-opioid receptor partial agonist and σ1 receptor antagonist. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2021,</strong> <em>51 </em>
                                    (5)
                                     , 501-512. <a href="https://doi.org/10.1080/00498254.2021.1877850" title="DOI URL">https://doi.org/10.1080/00498254.2021.1877850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2021.1877850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2021.1877850%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DPreliminary%252Bin%2525C2%2525A0vitro%252Bapproach%252Bto%252Bevaluate%252Bthe%252Bdrug-drug%252Binteraction%252Bpotential%252Bof%252BEST73502%25252C%252Ba%252Bdual%252B%2525C2%2525B5-opioid%252Breceptor%252Bpartial%252Bagonist%252Band%252B%2525CF%2525831%252Breceptor%252Bantagonist%26aulast%3DAyet%26aufirst%3DEva%26date%3D2021%26date%3D2021%26volume%3D51%26issue%3D5%26spage%3D501%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashish J.  Radia</span>, <span class="hlFld-ContribAuthor ">Jaydeep N.  Lalpara</span>, <span class="hlFld-ContribAuthor ">Ishita J.  Modasiya</span>, <span class="hlFld-ContribAuthor ">Gaurang G.  Dubal</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel 1,3,4‐oxadiazole based azaspirocycles catalyzed by
              NaI
              under mild condition and evaluated their antidiabetic and antibacterial activities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2021,</strong> <em>58 </em>
                                    (2)
                                     , 612-621. <a href="https://doi.org/10.1002/jhet.4200" title="DOI URL">https://doi.org/10.1002/jhet.4200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252B1%25252C3%25252C4%2525E2%252580%252590oxadiazole%252Bbased%252Bazaspirocycles%252Bcatalyzed%252Bby%252BNaI%252Bunder%252Bmild%252Bcondition%252Band%252Bevaluated%252Btheir%252Bantidiabetic%252Band%252Bantibacterial%252Bactivities%26aulast%3DRadia%26aufirst%3DAshish%2BJ.%26date%3D2021%26date%3D2020%26volume%3D58%26issue%3D2%26spage%3D612%26epage%3D621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna  Matalińska</span>, <span class="hlFld-ContribAuthor ">Piotr F. J.  Lipiński</span>, <span class="hlFld-ContribAuthor ">Piotr  Kosson</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kosińska</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Misicka</span>. </span><span class="cited-content_cbyCitation_article-title">In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (20)
                                     , 7738. <a href="https://doi.org/10.3390/ijms21207738" title="DOI URL">https://doi.org/10.3390/ijms21207738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21207738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21207738%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DIn%252BVivo%25252C%252BIn%252BVitro%252Band%252BIn%252BSilico%252BStudies%252Bof%252Bthe%252BHybrid%252BCompound%252BAA3266%25252C%252Ban%252BOpioid%252BAgonist%25252FNK1R%252BAntagonist%252Bwith%252BSelective%252BCytotoxicity%26aulast%3DMatali%25C5%2584ska%26aufirst%3DJoanna%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D20%26spage%3D7738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Valenza</span>, <span class="hlFld-ContribAuthor ">Angelo  Blasio</span>, <span class="hlFld-ContribAuthor ">Alyssa  DiLeo</span>, <span class="hlFld-ContribAuthor ">Pietro  Cottone</span>, <span class="hlFld-ContribAuthor ">Valentina  Sabino</span>. </span><span class="cited-content_cbyCitation_article-title">Sigma receptor-induced heavy drinking in rats: Modulation by the opioid receptor system. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Biochemistry and Behavior</span><span> <strong>2020,</strong> <em>192 </em>, 172914. <a href="https://doi.org/10.1016/j.pbb.2020.172914" title="DOI URL">https://doi.org/10.1016/j.pbb.2020.172914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pbb.2020.172914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pbb.2020.172914%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Biochemistry%2520and%2520Behavior%26atitle%3DSigma%252Breceptor-induced%252Bheavy%252Bdrinking%252Bin%252Brats%25253A%252BModulation%252Bby%252Bthe%252Bopioid%252Breceptor%252Bsystem%26aulast%3DValenza%26aufirst%3DMarta%26date%3D2020%26volume%3D192%26spage%3D172914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative MOR agonists (<b>1</b>–<b>3</b>) and σ<sub>1</sub>R antagonists (<b>4</b>, <b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TMSOI, NaH, DMSO, rt to 50 °C, 1 h; (b) EtOH–water 9:1, 100 °C, 16 h; (c) TEA, DCM, 0 °C, 2 h; (d) <sup>t</sup>BuOK, THF, −78 to −30 °C, 1–4 h; (e) TFA, DCM, rt or reflux; (f) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TMSOI, NaH, DMSO, rt to 50 °C, 1 h; (b) EtOH–water 9:1, 100 °C, 16 h; (c) TEA, DCM, 0 °C, 2 h; (d) <sup>t</sup>BuOK, THF, −78 to −30 °C, 1–4 h; (e) CDI, THF, reflux, 16 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>3,</sub> MeOH, rt, 16 h; (b) K<sub>2</sub>CO<sub>3</sub>, EtOAc–water, 0 °C, 30 min; (c) <sup>t</sup>BuOK, THF, rt, 16 h; (d) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>trans</i>-1,2-cyclohexanediamine, 1,4-dioxane, 110 °C, 16 h; (e) for compounds <b>15ab</b>, <b>15as</b>, <b>15ar</b>, and <b>15at</b>: Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 16 h; (f) TFA, DCM, rt, 3 h; (g) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH–water 9:1, 100 °C, 16 h; (b) TEA, DCM, 0 °C, 2 h; (c) <sup>t</sup>BuOK, THF, 0 °C, 2 h; (d) TFA, DCM, rt, 3 h; (e) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h; (f) CAN, acetonitrile–water, rt, 16 h; (g) Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 16 h; (h) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>trans</i>-1,2-cyclohexanediamine, 1,4-dioxane, 110 °C, 16 h.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, 80 °C, 16 h; (b) Pd/C, MeOH, 3 bar H<sub>2</sub>, rt, 16 h; (c) AcCl, TEA, DCM, rt, 16 h.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) MOR pharmacophore with aligned morphine (<b>1</b>); (B) σ<sub>1</sub>R pharmacophore with aligned E-52862 (<b>5</b>); (C) superposition of both models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Fitting of compounds <b>15b</b> (A), <b>20</b> (B), and <b>21</b> (C) into the overlapped MOR and σ<sub>1</sub>R pharmacophores. <b>20</b> and <b>21</b> do not match HBA2, as shown by the unhighlighted green spheres, automatically set by the Discovery Studio Ligand–Pharmacophore Mapping protocol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/medium/jm9b01256_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose–response antinociception curves of compound <b>15au</b> (A) and oxycodone (<b>2</b> (B) in the paw pressure test in mice. Each point and vertical line represents the mean ± SEM percentage of antinociception (<i>n</i> = 8–12 per group). (C) Comparative effect of <b>15au</b> and <b>2</b> on the intestinal transit inhibition in the charcoal test in mice at equianalgesic doses (20 mg/kg ip and 10 mg/kg po, respectively) in the paw pressure test in mice. The bars and vertical lines represent the mean ± SEM percentage of antinociception or intestinal transit inhibition (<i>n</i> = 5–7). (D) Antinociception induced by ipl administration of <b>15au</b> (25 μg, ipl) in the paw pressure test in mice in comparison to the σ<sub>1</sub>R agonist PRE-084 (32 mg/kg, sc) and the concomitant administration of both <b>15au</b> and PRE-084. The bars and vertical lines represent the mean ± SEM struggle response latency during stimulation with 450 g of pressure on the hindpaw of mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01256/20200306/images/large/jm9b01256_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01256&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahana, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic non-cancer pain</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2235</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60402-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2FS0140-6736%2811%2960402-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=21704872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=2226-2235&author=D.+C.+Turkauthor=H.+D.+Wilsonauthor=A.+Cahana&title=Treatment+of+chronic+non-cancer+pain&doi=10.1016%2FS0140-6736%2811%2960402-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic non-cancer pain</span></div><div class="casAuthors">Turk, Dennis C.; Wilson, Hilary D.; Cahana, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9784</span>),
    <span class="NLM_cas:pages">2226-2235</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Chronic pain is a pervasive problem that affects the patient, their significant others, and society in many ways.  The past decade has seen advances in our understanding of the mechanisms underlying pain and in the availability of tech. advanced diagnostic procedures; however, the most notable therapeutic changes have not been the development of novel evidenced-based methods, but rather changing trends in applications and practices within the available clin. armamentarium.  We provide a general overview of empirical evidence for the most commonly used interventions in the management of chronic non-cancer pain, including pharmacol., interventional, phys., psychol., rehabilitative, and alternative modalities.  Overall, currently available treatments provide modest improvements in pain and min. improvements in phys. and emotional functioning.  The quality of evidence is mediocre and has not improved substantially during the past decade.  There is a crucial need for assessment of combination treatments, identification of indicators of treatment response, and assessment of the benefit of matching of treatments to patient characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxyG7QutTErVg90H21EOLACvtfcHk0ljWdURH8i1cwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D&md5=55b3b3e920ec253406736fcee3337754</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960402-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960402-9%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DD.%2BC.%26aulast%3DWilson%26aufirst%3DH.%2BD.%26aulast%3DCahana%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520chronic%2520non-cancer%2520pain%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D2226%26epage%3D2235%26doi%3D10.1016%2FS0140-6736%2811%2960402-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, S. J.</span></span> <span> </span><span class="NLM_article-title">Pain as a global public health priority</span>. <i>BMC Public Health</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">770</span>, <span class="refDoi"> DOI: 10.1186/1471-2458-11-770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1186%2F1471-2458-11-770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=21978149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A280%3ADC%252BC3MbjvFChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=770&author=D.+S.+Goldbergauthor=S.+J.+McGee&title=Pain+as+a+global+public+health+priority&doi=10.1186%2F1471-2458-11-770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pain as a global public health priority</span></div><div class="casAuthors">Goldberg Daniel S; McGee Summer J</div><div class="citationInfo"><span class="NLM_cas:title">BMC public health</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">770</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pain is an enormous problem globally.  Estimates suggest that 20% of adults suffer from pain globally and 10% are newly diagnosed with chronic pain each year.  Nevertheless, the problem of pain has primarily been regarded as a medical problem, and has been little addressed by the field of public health.  DISCUSSION:  Despite the ubiquity of pain, whether acute, chronic or intermittent, public health scholars and practitioners have not addressed this issue as a public health problem.  The importance of viewing pain through a public health lens allows one to understand pain as a multifaceted, interdisciplinary problem for which many of the causes are the social determinants of health.  Addressing pain as a global public health issue will also aid in priority setting and formulating public health policy to address this problem, which, like most other chronic non-communicable diseases, is growing both in absolute numbers and in its inequitable distribution across the globe.  SUMMARY:  The prevalence, incidence, and vast social and health consequences of global pain requires that the public health community give due attention to this issue.  Doing so will mean that health care providers and public health professionals will have a more comprehensive understanding of pain and the appropriate public health and social policy responses to this problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3b5yAa6dhG-IHSmpohpd0fW6udTcc2eYPxyE2iQLlU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbjvFChtQ%253D%253D&md5=ef3530eca2039dd5bb7073816b0127c6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2F1471-2458-11-770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2458-11-770%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BS.%26aulast%3DMcGee%26aufirst%3DS.%2BJ.%26atitle%3DPain%2520as%2520a%2520global%2520public%2520health%2520priority%26jtitle%3DBMC%2520Public%2520Health%26date%3D2011%26volume%3D11%26spage%3D770%26doi%3D10.1186%2F1471-2458-11-770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meldrum, M. L.</span></span>, Ed. <span> </span><span class="NLM_article-title">Opioids and Pain Relief: A Historical Perspective</span>. In  <i>Progress in Pain Research and Management</i>; <span class="NLM_publisher-name">IASP Press</span>: <span class="NLM_publisher-loc">Seattle, WA</span>, <span class="NLM_year">2003</span>; Vol.  <span class="NLM_volume">25</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+L.+Meldrum&title=Progress+in+Pain+Research+and+Management"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeldrum%26aufirst%3DM.%2BL.%26atitle%3DOpioids%2520and%2520Pain%2520Relief%253A%2520A%2520Historical%2520Perspective%26btitle%3DProgress%2520in%2520Pain%2520Research%2520and%2520Management%26pub%3DIASP%2520Press%26date%3D2003%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickenson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span> <span> </span><span class="NLM_article-title">Opioids in neuropathic pain: Clues from animal studies</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.ejpain.2004.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejpain.2004.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15737797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslWrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=113-116&author=A.+H.+Dickensonauthor=R.+Suzuki&title=Opioids+in+neuropathic+pain%3A+Clues+from+animal+studies&doi=10.1016%2Fj.ejpain.2004.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids in neuropathic pain: clues from animal studies</span></div><div class="casAuthors">Dickenson, Anthony H.; Suzuki, Rie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-116</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1090-3801</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  For many years the clin. consensus was that opioids were ineffective in neuropathic pain.  However this view is changing and here we discuss the mechanisms of opioid analgesia in terms of the changes that can occur in preclin. models of nerve injury.  We argue that opioid mechanisms can be perturbed by neuropathy but in most cases these neg. influences can be overcome by dose-escalation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcGfiK-MHKLLVg90H21EOLACvtfcHk0lihqJcTwFlP-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslWrsro%253D&md5=edcad0356537b8256e5cb6152a06126e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpain.2004.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpain.2004.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DDickenson%26aufirst%3DA.%2BH.%26aulast%3DSuzuki%26aufirst%3DR.%26atitle%3DOpioids%2520in%2520neuropathic%2520pain%253A%2520Clues%2520from%2520animal%2520studies%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2005%26volume%3D9%26spage%3D113%26epage%3D116%26doi%3D10.1016%2Fj.ejpain.2004.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanath, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simopoulos, T. T.</span></span> <span> </span><span class="NLM_article-title">A Brief history of the opioid epidemic and strategies for pain medicine</span>. <i>Pain Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/s40122-018-0097-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1007%2Fs40122-018-0097-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=29691801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmtlekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=13-21&author=M.+R.+Jonesauthor=O.+Viswanathauthor=J.+Peckauthor=A.+D.+Kayeauthor=J.+S.+Gillauthor=T.+T.+Simopoulos&title=A+Brief+history+of+the+opioid+epidemic+and+strategies+for+pain+medicine&doi=10.1007%2Fs40122-018-0097-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A Brief History of the Opioid Epidemic and Strategies for Pain Medicine</span></div><div class="casAuthors">Jones Mark R; Viswanath Omar; Gill Jatinder S; Simopoulos Thomas T; Peck Jacquelin; Kaye Alan D</div><div class="citationInfo"><span class="NLM_cas:title">Pain and therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-21</span>
        ISSN:<span class="NLM_cas:issn">2193-8237</span>.
    </div><div class="casAbstract">The opioid epidemic has resulted from myriad causes and will not be solved by any simple solution.  Consequent to a staggering increase in opioid-related deaths in the USA, various governmental inputs and stakeholder strategies have been proposed and implemented with varying success.  This article summarizes the history of opioid use and explores the causes for the present day epidemic.  Recent trends in opioid-related data demonstrate an almost fourfold increase in overdose deaths from 1999 to 2008.  Tragically, opioids claimed over 64,000 lives just last year.  Some solutions have undergone legislation, including the limitation of numbers of opioids postsurgery, as well as growing national prevalence of enhanced recovery after surgery protocols which focus on reduced postoperative opioid consumption and shortened hospital stays.  Stricter prescribing practices and prescription monitoring programs have been instituted in the recent past.  Improvement in abuse deterrent strategies which is a major focus of the Food and Drug Administration (FDA) for all opioid preparations will likely play an important role by increasing the safety of these medications.  Future potential strategies such as additional legislative policies, public awareness, and physician education are also detailed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUyZ-LWOyWCEbxh97K6Vt6fW6udTcc2eYPxyE2iQLlU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmtlekuw%253D%253D&md5=386633388006687ea4c304927a1625bb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs40122-018-0097-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40122-018-0097-6%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DM.%2BR.%26aulast%3DViswanath%26aufirst%3DO.%26aulast%3DPeck%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DA.%2BD.%26aulast%3DGill%26aufirst%3DJ.%2BS.%26aulast%3DSimopoulos%26aufirst%3DT.%2BT.%26atitle%3DA%2520Brief%2520history%2520of%2520the%2520opioid%2520epidemic%2520and%2520strategies%2520for%2520pain%2520medicine%26jtitle%3DPain%2520Ther.%26date%3D2018%26volume%3D7%26spage%3D13%26epage%3D21%26doi%3D10.1007%2Fs40122-018-0097-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burford, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">10830</span>– <span class="NLM_lpage">10835</span>, <span class="refDoi"> DOI: 10.1073/pnas.1300393110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1073%2Fpnas.1300393110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23754417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=10830-10835&author=N.+T.+Burfordauthor=M.+J.+Clarkauthor=T.+S.+Wehrmanauthor=S.+W.+Gerritzauthor=M.+Banksauthor=J.+O%E2%80%99Connellauthor=J.+R.+Traynorauthor=A.+Alt&title=Discovery+of+positive+allosteric+modulators+and+silent+allosteric+modulators+of+the+%CE%BC-opioid+receptor&doi=10.1073%2Fpnas.1300393110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor</span></div><div class="casAuthors">Burford, Neil T.; Clark, Mary J.; Wehrman, Tom S.; Gerritz, Samuel W.; Banks, Martyn; O'Connell, Jonathan; Traynor, John R.; Alt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">10830-10835,S10830/1-S10830/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">μ-Opioid receptors are among the most studied G protein-coupled receptors because of the therapeutic value of agonists, such as morphine, that are used to treat chronic pain.  However, these drugs have significant side effects, such as respiratory suppression, constipation, allodynia, tolerance, and dependence, as well as abuse potential.  Efforts to fine tune pain control while alleviating the side effects of drugs, both physiol. and psychol., have led to the development of a wide variety of structurally diverse agonist ligands for the μ-opioid receptor, as well as compds. that target κ- and δ-opioid receptors.  In recent years, the identification of allosteric ligands for some G protein-coupled receptors has provided breakthroughs in obtaining receptor subtype-selectivity that can reduce the overall side effect profiles of a potential drug.  However, pos. allosteric modulators (PAMs) can also have the specific advantage of only modulating the activity of the receptor when the orthosteric agonist occupies the receptor, thus maintaining spatial and temporal control of receptor signaling in vivo.  This second advantage of allosteric modulators may yield breakthroughs in opioid receptor research and could lead to drugs with improved side-effect profiles or fewer tolerance and dependence issues compared with orthosteric opioid receptor agonists.  Here, the authors describe the discovery and characterization of μ-opioid receptor PAMs and silent allosteric modulators, identified from high-throughput screening using a β-arrestin-recruitment assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdiTL5ko3pr7Vg90H21EOLACvtfcHk0lj2JVT63L74qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7nJ&md5=5fd64e5ae56607fa2396fdd3f32caf54</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1300393110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1300393110%26sid%3Dliteratum%253Aachs%26aulast%3DBurford%26aufirst%3DN.%2BT.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DWehrman%26aufirst%3DT.%2BS.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DBanks%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DAlt%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520positive%2520allosteric%2520modulators%2520and%2520silent%2520allosteric%2520modulators%2520of%2520the%2520%25CE%25BC-opioid%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D10830%26epage%3D10835%26doi%3D10.1073%2Fpnas.1300393110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeomans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobczyk-Kojiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span> <span> </span><span class="NLM_article-title">Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3148</span>– <span class="NLM_lpage">3153</span>, <span class="refDoi"> DOI: 10.1021/jm5002088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2it7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3148-3153&author=H.+I.+Mosbergauthor=L.+Yeomansauthor=J.+P.+Anandauthor=V.+Porterauthor=K.+Sobczyk-Kojiroauthor=J.+R.+Traynorauthor=E.+M.+Jutkiewicz&title=Development+of+a+bioavailable+%CE%BC+opioid+receptor+%28MOPr%29+agonist%2C+%CE%B4+opioid+receptor+%28DOPr%29+antagonist+peptide+that+evokes+antinociception+without+development+of+acute+tolerance&doi=10.1021%2Fjm5002088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance</span></div><div class="casAuthors">Mosberg, Henry I.; Yeomans, Larisa; Anand, Jessica P.; Porter, Vanessa; Sobczyk-Kojiro, Katarzyna; Traynor, John R.; Jutkiewicz, Emily M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3148-3153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors have previously described a cyclic tetrapeptide, KSK-103, that displays μ opioid receptor (MOPr) agonist and δ opioid receptor (DOPr) antagonist activity, a profile assocd. with a reduced incidence of opioid tolerance and dependence.  Like many peptides KSK-103 has poor bioavailability.  The authors describe here an analog of KSK-103 with an added C-terminal β-glucosylserine residue, Ser(β-Glc)NH2, a modification that has previously been shown to improve bioavailability of opioid peptides.  The resulting peptide exhibits full antinociceptive efficacy in the mouse warm water tail withdrawal assay after i.p. administration with potency similar to that of morphine.  Further, the peptide analog does not give rise to acute tolerance and thus represents a promising lead for the development of opioid analgesics with reduced side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe9qN8vLm1lrVg90H21EOLACvtfcHk0lj2JVT63L74qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2it7Y%253D&md5=02801871402feaa30e4268cd137dbbe9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm5002088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002088%26sid%3Dliteratum%253Aachs%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DYeomans%26aufirst%3DL.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DPorter%26aufirst%3DV.%26aulast%3DSobczyk-Kojiro%26aufirst%3DK.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520bioavailable%2520%25CE%25BC%2520opioid%2520receptor%2520%2528MOPr%2529%2520agonist%252C%2520%25CE%25B4%2520opioid%2520receptor%2520%2528DOPr%2529%2520antagonist%2520peptide%2520that%2520evokes%2520antinociception%2520without%2520development%2520of%2520acute%2520tolerance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3148%26epage%3D3153%26doi%3D10.1021%2Fjm5002088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rouzic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polikar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagakura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocampo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6352</span>– <span class="NLM_lpage">6362</span>, <span class="refDoi"> DOI: 10.1021/jm300305c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300305c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2nsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6352-6362&author=S.+Majumdarauthor=J.+Subrathauthor=V.+Le+Rouzicauthor=L.+Polikarauthor=M.+Burgmanauthor=K.+Nagakuraauthor=J.+Ocampoauthor=N.+Haseltonauthor=A.+R.+Pasternakauthor=S.+Grinnellauthor=Y.+X.+Panauthor=G.+W.+Pasternak&title=Synthesis+and+evaluation+of+aryl-naloxamide+opiate+analgesics+targeting+truncated+exon+11-associated+%CE%BC+opioid+receptor+%28MOR-1%29+splice+variants&doi=10.1021%2Fjm300305c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Aryl-Naloxamide Opiate Analgesics Targeting Truncated Exon 11-Associated μ Opioid Receptor (MOR-1) Splice Variants</span></div><div class="casAuthors">Majumdar, Susruta; Subrath, Joan; Le Rouzic, Valerie; Polikar, Lisa; Burgman, Maxim; Nagakura, Kuni; Ocampo, Julie; Haselton, Nathan; Pasternak, Anna R.; Grinnell, Steven; Pan, Ying-Xian; Pasternak, Gavril W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6352-6362</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Iodobenzoylnaltrexamide (IBNtxA) is a potent analgesic acting through a novel receptor target that lack many side-effects of traditional opiates composed, in part, of exon 11-assocd. truncated six transmembrane domain MOR-1 (6TM/E11) splice variants.  To better understand the SAR of this drug target, a no. of 4,5-epoxymorphinan analogs were synthesized.  Results show the importance of a free 3-phenolic group, a Ph ring at the 6 position, an iodine at the 3' or 4' position of the Ph ring, and an N-allyl or c-propylmethyl group to maintain high 6TM/E11 affinity and activity.  3-Iodobenzoylnaloxamide (I; IBNalA) with a N-allyl group displayed lower δ opioid receptor affinity than its naltrexamine analog, was 10-fold more potent an analgesic than morphine, elicited no respiratory depression or phys. dependence, and only limited inhibition of gastrointestinal transit.  Thus, the aryl-naloxamide scaffold can generate a potent analgesic acting through the 6TM/E11 sites with advantageous side-effect profile and greater selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdeU2T8NJ1bVg90H21EOLACvtfcHk0lj2JVT63L74qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2nsbw%253D&md5=bc0d7f9897b58833cec1ef633e89a8ec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm300305c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300305c%26sid%3Dliteratum%253Aachs%26aulast%3DMajumdar%26aufirst%3DS.%26aulast%3DSubrath%26aufirst%3DJ.%26aulast%3DLe%2BRouzic%26aufirst%3DV.%26aulast%3DPolikar%26aufirst%3DL.%26aulast%3DBurgman%26aufirst%3DM.%26aulast%3DNagakura%26aufirst%3DK.%26aulast%3DOcampo%26aufirst%3DJ.%26aulast%3DHaselton%26aufirst%3DN.%26aulast%3DPasternak%26aufirst%3DA.%2BR.%26aulast%3DGrinnell%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DY.%2BX.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520aryl-naloxamide%2520opiate%2520analgesics%2520targeting%2520truncated%2520exon%252011-associated%2520%25CE%25BC%2520opioid%2520receptor%2520%2528MOR-1%2529%2520splice%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6352%26epage%3D6362%26doi%3D10.1021%2Fjm300305c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbotham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agaiby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimbel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doberstein, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagliaferri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddhanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, M.</span></span> <span> </span><span class="NLM_article-title">SUMMIT-07, a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000001517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1097%2Fj.pain.0000000000001517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=30747908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVOqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2019&pages=1374-1382&author=J.+Markmanauthor=J.+Gudinauthor=R.+Rauckauthor=C.+Argoffauthor=M.+Rowbothamauthor=E.+Agaibyauthor=J.+Gimbelauthor=N.+Katzauthor=S.+K.+Dobersteinauthor=M.+Tagliaferriauthor=L.+Luauthor=S.+Siddhantiauthor=M.+Hale&title=SUMMIT-07%2C+a+randomized+trial+of+NKTR-181%2C+a+new+molecular+entity%2C+full+mu-opioid+receptor+agonist+for+chronic+low-back+pain&doi=10.1097%2Fj.pain.0000000000001517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain</span></div><div class="casAuthors">Markman, John; Gudin, Jeffrey; Rauck, Richard; Argoff, Charles; Rowbotham, Michael; Agaiby, Eva; Gimbel, Joseph; Katz, Nathaniel; Doberstein, Stephen K.; Tagliaferri, Mary; Lu, Lin; Siddhanti, Suresh; Hale, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1374-1382</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">NKTR-181, a new mol. entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide analgesia while reducing abuse potential.  This phase 3, enriched-enrollment, randomized-withdrawal trial evaluated the analgesic efficacy, safety, and tolerability of NKTR-181 in patients with chronic low-back pain (CLBP).  Adults with moderate-to-severe CLBP refractory to nonopioid analgesics achieving an analgesic NKTR-181 dosage (100-400 mg twice daily) during the open-label titrn. period were randomized to continued NKTR-181 treatment, double-blind, or switched to placebo.  The study was conducted at 55 sites in the United States.  Of 1189 patients exposed to NKTR-181 during the titrn. period, 610 were randomized to NKTR-181 100 to 400 mg every 12 h or placebo for 12 wk.  The primary outcome measure was change in weekly pain score (scale, 0-10) at 12 wk from randomization baseline.  Secondary outcome measures included responder rates defined by ≥30% and ≥50% improvement in pain score from screening to 12 wk.  Among 610 randomized patients, the mean pain score decreased from 6.73 to 2.32 during open-label titrn.  After randomization, the least-squares mean change in pain score was +0.92 for NKTR-181 vs +1.46 for placebo (P = 0.002).  The ≥30%-improvement responder rate of NKTR-181 vs placebo was 71.2% vs 57.1% (P < 0.001), and the ≥50%-improvement responder rate was 51.1% vs 37.9% (P = 0.001).  NKTR-181 was well tolerated with a low incidence (<3%) of CNS-related adverse events during the randomized treatment phase.  In patients with moderate-to-severe CLBP, NKTR-181 demonstrated significant analgesic efficacy and a favorable safety/tolerability profile, with a low incidence of CNS adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9IZqMh58nibVg90H21EOLACvtfcHk0liRzMx41F2ywQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVOqurk%253D&md5=8a0a5d976021ac32036ee644e355e851</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000001517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000001517%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DJ.%26aulast%3DGudin%26aufirst%3DJ.%26aulast%3DRauck%26aufirst%3DR.%26aulast%3DArgoff%26aufirst%3DC.%26aulast%3DRowbotham%26aufirst%3DM.%26aulast%3DAgaiby%26aufirst%3DE.%26aulast%3DGimbel%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DN.%26aulast%3DDoberstein%26aufirst%3DS.%2BK.%26aulast%3DTagliaferri%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DSiddhanti%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DM.%26atitle%3DSUMMIT-07%252C%2520a%2520randomized%2520trial%2520of%2520NKTR-181%252C%2520a%2520new%2520molecular%2520entity%252C%2520full%2520mu-opioid%2520receptor%2520agonist%2520for%2520chronic%2520low-back%2520pain%26jtitle%3DPain%26date%3D2019%26volume%3D160%26spage%3D1374%26epage%3D1382%26doi%3D10.1097%2Fj.pain.0000000000001517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&author=X.+T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+DeWireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure%E2%80%93activity+relationships+and+discovery+of+a+G+protein+biased+%CE%BC+opioid+receptor+ligand%2C+%5B%283-methoxythiophen-2-yl%29methyl%5D%28%7B2-%5B%289R%29-9-%28pyridin-2-yl%29-6-oxaspiro-%5B4.5%5Ddecan-9-yl%5Dethyl%7D%29amine+%28TRV130%29%2C+for+the+treatment+of+acute+severe+pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain</span></div><div class="casAuthors">Chen, Xiao-Tao; Pitis, Philip; Liu, Guodong; Yuan, Catherine; Gotchev, Dimitar; Cowan, Conrad L.; Rominger, David H.; Koblish, Michael; DeWire, Scott M.; Crombie, Aimee L.; Violin, Jonathan D.; Yamashita, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8019-8031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another.  There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs.  The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events.  Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 (I).  This novel mol. demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clin. development.  It is currently being evaluated in human clin. trials for the treatment of acute severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rI0Et_vFqrVg90H21EOLACvtfcHk0liRzMx41F2ywQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK&md5=c80bd62062f31418f18392f97c880bea</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520and%2520discovery%2520of%2520a%2520G%2520protein%2520biased%2520%25CE%25BC%2520opioid%2520receptor%2520ligand%252C%2520%255B%25283-methoxythiophen-2-yl%2529methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528pyridin-2-yl%2529-6-oxaspiro-%255B4.5%255Ddecan-9-yl%255Dethyl%257D%2529amine%2520%2528TRV130%2529%252C%2520for%2520the%2520treatment%2520of%2520acute%2520severe%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graczyk, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">A G Protein-biased ligand at the m-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1124%2Fjpet.112.201616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23300227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=708-717&author=S.+W.+DeWireauthor=D.+S.+Yamashitaauthor=D.+H.+Romingerauthor=G.+Liuauthor=C.+L.+Cowanauthor=T.+M.+Graczykauthor=X.+T.+Chenauthor=P.+M.+Pitisauthor=D.+Gotchevauthor=C.+Yuanauthor=M.+Koblishauthor=M.+W.+Larkauthor=J.+D.+Violin&title=A+G+Protein-biased+ligand+at+the+m-opioid+receptor+is+potently+analgesic+with+reduced+gastrointestinal+and+respiratory+dysfunction+compared+with+morphine&doi=10.1124%2Fjpet.112.201616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span></div><div class="casAuthors">DeWire, Scott M.; Yamashita, Dennis S.; Rominger, David H.; Liu, Guodong; Cowan, Conrad L.; Graczyk, Thomas M.; Chen, Xiao-Tao; Pitis, Philip M.; Gotchev, Dimitar; Yuan, Catherine; Koblish, Michael; Lark, Michael W.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics.  Morphine pharmacol. in β-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the μ-opioid receptor (MOR) to G proteins, but not β-arrestins, would result in higher analgesic efficacy, less gastrointestinal dysfunction, and less respiratory suppression than morphine.  Here we report the discovery of TRV130 ([(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine), a novel MOR G protein-biased ligand.  In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization.  In mice and rats, TRV130 is potently analgesic while causing less gastrointestinal dysfunction and respiratory suppression than morphine at equianalgesic doses.  TRV130 successfully translates evidence that analgesic and adverse MOR signaling pathways are distinct into a biased ligand with differentiated pharmacol.  These preclin. data suggest that TRV130 may be a safer and more tolerable therapeutic for treating severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3tTP2BOOKrVg90H21EOLACvtfcHk0lhsTWSEagT-RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D&md5=33a685cd1952dd9cb1fb82afe78452af</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201616%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DGraczyk%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%2BM.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520G%2520Protein-biased%2520ligand%2520at%2520the%2520m-opioid%2520receptor%2520is%2520potently%2520analgesic%2520with%2520reduced%2520gastrointestinal%2520and%2520respiratory%2520dysfunction%2520compared%2520with%2520morphine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D708%26epage%3D717%26doi%3D10.1124%2Fjpet.112.201616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span> <span> </span><span class="NLM_article-title">Abuse potential of biased mu opioid receptor agonists</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2018.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.tips.2018.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=30343727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=916-919&author=S.+S.+Negusauthor=K.+B.+Freeman&title=Abuse+potential+of+biased+mu+opioid+receptor+agonists&doi=10.1016%2Fj.tips.2018.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Abuse Potential of Biased Mu Opioid Receptor Agonists</span></div><div class="casAuthors">Negus, S. Stevens; Freeman, Kevin B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">916-919</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-biased mu opioid receptor (GPB-MOR) agonists constitute an emerging class of opioid analgesics.  The first-in-class GPB-MOR agonist TRV130 (oliceridine) produces typical opioid-like abuse-related effects in rodents and humans.  Although GPB-MOR agonists may be safer than conventional opioids on some endpoints, prevailing evidence suggests that they will retain opioid-like abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg0Xf3TNu4LrVg90H21EOLACvtfcHk0lhsTWSEagT-RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF&md5=b33e27478c5d58a4232fffad6de7412f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2018.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2018.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26atitle%3DAbuse%2520potential%2520of%2520biased%2520mu%2520opioid%2520receptor%2520agonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2018%26volume%3D39%26spage%3D916%26epage%3D919%26doi%3D10.1016%2Fj.tips.2018.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span> <i>Anesthetic
and Analgesic Drug Products Advisory Committee (AADPAC)</i>; <span class="NLM_series">FDA Briefing Document</span>; <span class="NLM_publisher-name">U.S. Food and Drug
Administration</span>, October 11, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/media/121233/download" class="extLink">https://www.fda.gov/media/121233/download</a> (accessed July, 4, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Anesthetic%0Aand+Analgesic+Drug+Products+Advisory+Committee+%28AADPAC%29%3B+FDA+Briefing+Document%3B+U.S.+Food+and+Drug%0AAdministration%2C+October+11%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F121233%2Fdownload+%28accessed+July%2C+4%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs%26jtitle%3DAnesthetic%250Aand%2520Analgesic%2520Drug%2520Products%2520Advisory%2520Committee%2520%2528AADPAC%2529%26pub%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schunk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frormann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberbörsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundermann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemolka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kless, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenschein, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent analgesic NOP and opioid receptor agonist: cebranopadol</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1021/ml500117c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500117c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=857-862&author=S.+Schunkauthor=K.+Linzauthor=C.+Hinzeauthor=S.+Frormannauthor=S.+Oberb%C3%B6rschauthor=B.+Sundermannauthor=S.+Zemolkaauthor=W.+Englbergerauthor=T.+Germannauthor=T.+Christophauthor=B.+K%C3%B6gelauthor=W.+Schr%C3%B6derauthor=S.+Harlfingerauthor=D.+Saundersauthor=A.+Klessauthor=H.+Schickauthor=H.+Sonnenschein&title=Discovery+of+a+potent+analgesic+NOP+and+opioid+receptor+agonist%3A+cebranopadol&doi=10.1021%2Fml500117c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol</span></div><div class="casAuthors">Schunk, Stefan; Linz, Klaus; Hinze, Claudia; Frormann, Sven; Oberboersch, Stefan; Sundermann, Bernd; Zemolka, Saskia; Englberger, Werner; Germann, Tieno; Christoph, Thomas; Koegel, Babette-Y.; Schroeder, Wolfgang; Harlfinger, Stephanie; Saunders, Derek; Kless, Achim; Schick, Hans; Sonnenschein, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">857-862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous communication, our efforts leading from 1 to the identification of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amine 2a as analgesic NOP and opioid receptor agonist were disclosed and their favorable in vitro and in vivo pharmacol. properties revealed.  We herein report our efforts to further optimize lead 2a, toward trans-6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine (cebranopadol, 3a), which is currently in clin. development for the treatment of severe chronic nociceptive and neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_oo_6lpPHoLVg90H21EOLACvtfcHk0lgFDOYAP01zZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL&md5=270b1eef8252dcae7ce2e84c17d78b81</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fml500117c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500117c%26sid%3Dliteratum%253Aachs%26aulast%3DSchunk%26aufirst%3DS.%26aulast%3DLinz%26aufirst%3DK.%26aulast%3DHinze%26aufirst%3DC.%26aulast%3DFrormann%26aufirst%3DS.%26aulast%3DOberb%25C3%25B6rsch%26aufirst%3DS.%26aulast%3DSundermann%26aufirst%3DB.%26aulast%3DZemolka%26aufirst%3DS.%26aulast%3DEnglberger%26aufirst%3DW.%26aulast%3DGermann%26aufirst%3DT.%26aulast%3DChristoph%26aufirst%3DT.%26aulast%3DK%25C3%25B6gel%26aufirst%3DB.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DW.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DSaunders%26aufirst%3DD.%26aulast%3DKless%26aufirst%3DA.%26aulast%3DSchick%26aufirst%3DH.%26aulast%3DSonnenschein%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520analgesic%2520NOP%2520and%2520opioid%2520receptor%2520agonist%253A%2520cebranopadol%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D857%26epage%3D862%26doi%3D10.1021%2Fml500117c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Sigma 1 receptor: A new therapeutic target for pain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>716</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.01.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejphar.2013.01.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23500210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt12ju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=716&publication_year=2013&pages=78-93&author=D.+Zamanilloauthor=L.+Romeroauthor=M.+Merlosauthor=J.+M.+Vela&title=Sigma+1+receptor%3A+A+new+therapeutic+target+for+pain&doi=10.1016%2Fj.ejphar.2013.01.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma 1 receptor: A new therapeutic target for pain</span></div><div class="casAuthors">Zamanillo, Daniel; Romero, Luz; Merlos, Manuel; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">716</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">78-93</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sigma 1 receptor (σ1 receptor) is a unique ligand-regulated mol. chaperone located mainly in the endoplasmic reticulum and the plasma membrane. σ1 receptor is activated under stress or pathol. conditions and interacts with several neurotransmitter receptors and ion channels to modulate their function.  The effects reported preclinically with σ1 receptor ligands are consistent with a role for σ1 receptor in central sensitization and pain hypersensitivity and suggest a potential therapeutic use of σ1 receptor antagonists for the management of neuropathic pain as monotherapy.  Moreover, data support their use in opioid adjuvant therapy: combination of σ1 receptor antagonists and opioids results in potentiation of opioid analgesia, without significant increases in opioid-related unwanted effects.  Results from clin. trials using selective σ1 receptor antagonists in several pain conditions are eagerly awaited to ascertain the potential of σ1 receptor modulation in pain therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZl3UX9-U94rVg90H21EOLACvtfcHk0lgFDOYAP01zZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt12ju70%253D&md5=7eba2c57ef558fbc50fb90d7067ab2e8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.068%26sid%3Dliteratum%253Aachs%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSigma%25201%2520receptor%253A%2520A%2520new%2520therapeutic%2520target%2520for%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D716%26spage%3D78%26epage%3D93%26doi%3D10.1016%2Fj.ejphar.2013.01.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocasalbas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touriño, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bura, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>711</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejphar.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=23632394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=711&publication_year=2013&pages=63-72&author=A.+Vidal-Torresauthor=B.+de+la+Puenteauthor=M.+Rocasalbasauthor=C.+Touri%C3%B1oauthor=S.+A.+Buraauthor=B.+Fern%C3%A1ndez-Pastorauthor=L.+Romeroauthor=X.+Codonyauthor=D.+Zamanilloauthor=H.+Buschmannauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=R.+Maldonadoauthor=J.+M.+Vela&title=Sigma-1+receptor+antagonism+as+opioid+adjuvant+strategy%3A+Enhancement+of+opioid+antinociception+without+increasing+adverse+effects&doi=10.1016%2Fj.ejphar.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects</span></div><div class="casAuthors">Vidal-Torres, Alba; de la Puente, Beatriz; Rocasalbas, Maria; Tourino, Clara; Andreea Bura, Simona; Fernandez-Pastor, Begona; Romero, Luz; Codony, Xavier; Zamanillo, Daniel; Buschmann, Helmut; Merlos, Manuel; Manuel Baeyens, Jose; Maldonado, Rafael; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">711</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">While opioids are potent analgesics widely used in the management of pain, a no. of well-known adverse effects limit their use.  The sigma-1 receptor is a ligand-regulated mol. chaperone involved in pain processing, including modulation of opioid antinociception.  However, data supporting the potential use of sigma-1 receptor ligands as suitable opioid adjuvants are based on studies that use non selective ligands.  Also, safety issues derived from combination therapy are poorly addressed.  In this study we used the new selective sigma-1 receptor antagonist S1RA (E-52862) to characterize the effect of selective sigma-1 receptor blockade on opioid-induced efficacy- and safety-related outcomes in mice.  S1RA (40 mg/kg) had no effect in the tail-flick test but did enhance the antinociceptive potency of several opioids by a factor between 2 and 3.3.  The potentiating effect of S1RA on morphine antinociception did not occur in sigma-1 receptor knockout mice, which supports the selective involvement of the sigma-1 receptor.  Interestingly, S1RA co-administration restored morphine antinociception in tolerant mice and reverted the reward effects of morphine in the conditioned place preference paradigm.  In addn., enhancement of antinociception was not accompanied by potentiation of other opioid-induced effects, such as the development of morphine analgesic tolerance, phys. dependence, inhibition of gastrointestinal transit, or mydriasis.  The use of sigma-1 receptor antagonists as opioid adjuvants could represent a promising pharmacol. strategy to enhance opioid potency and, most importantly, to increase the safety margin of opioids.  S1RA is currently in phase II clin. trials for the treatment of several pain conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVTGE08MufobVg90H21EOLACvtfcHk0lgFDOYAP01zZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D&md5=c2cd0eb6fe5a9232bff11fe1539f74d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DB.%26aulast%3DRocasalbas%26aufirst%3DM.%26aulast%3DTouri%25C3%25B1o%26aufirst%3DC.%26aulast%3DBura%26aufirst%3DS.%2BA.%26aulast%3DFern%25C3%25A1ndez-Pastor%26aufirst%3DB.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSigma-1%2520receptor%2520antagonism%2520as%2520opioid%2520adjuvant%2520strategy%253A%2520Enhancement%2520of%2520opioid%2520antinociception%2520without%2520increasing%2520adverse%2520effects%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D711%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.ejphar.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backonja, M.</span></span> <span> </span><span class="NLM_article-title">Combination drug therapy for chronic pain: a call for more clinical studies</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.jpain.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=20851058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=157-166&author=J.+Maoauthor=M.+S.+Goldauthor=M.+Backonja&title=Combination+drug+therapy+for+chronic+pain%3A+a+call+for+more+clinical+studies&doi=10.1016%2Fj.jpain.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Therapy for Chronic Pain: A Call for More Clinical Studies</span></div><div class="casAuthors">Mao, Jianren; Gold, Michael S.; Backonja, Miroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic pain is a debilitating clin. condition assocd. with a variety of disease entities including diabetic neuropathy, postherpetic neuralgia, low back pathol., fibromyalgia, and neurol. disorders.  For many general practitioners and specialists, managing chronic pain has become a daunting challenge.  As a modality of multidisciplinary chronic pain management, medications are often prescribed in combinations, an approach referred to as combination drug therapy (CDT).  However, many medications for pain therapy, including antidepressants and opioid analgesics, have significant side effects that can compd. when used in combination and impact the effectiveness of CDT.  To date, clin. practice of CDT for chronic pain has been based largely on clin. experiences.  In this article, we will focus on (1) the scientific basis and rationales for CDT, (2) current clin. data on CDT, and (3) the need for more clin. studies to establish a framework for the use of CDT.  Perspective: More preclin., clin., and translational studies are needed to improve the efficacy of combination drug therapy that is an integral part of a comprehensive approach to the management of chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDPNs-xJvEbVg90H21EOLACvtfcHk0lhmMKCqC-2sJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D&md5=955711ac2946dd44adc0e8b96b6ee423</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DGold%26aufirst%3DM.%2BS.%26aulast%3DBackonja%26aufirst%3DM.%26atitle%3DCombination%2520drug%2520therapy%2520for%2520chronic%2520pain%253A%2520a%2520call%2520for%2520more%2520clinical%2520studies%26jtitle%3DJ.%2520Pain%26date%3D2011%26volume%3D12%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.jpain.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lhmMKCqC-2sJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of sigma-1 receptors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.pharmthera.2009.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=19619582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2009&pages=195-206&author=T.+Mauriceauthor=T.+P.+Su&title=The+pharmacology+of+sigma-1+receptors&doi=10.1016%2Fj.pharmthera.2009.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of sigma-1 receptors</span></div><div class="casAuthors">Maurice, Tangui; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Originally considered an enigmatic protein, the sigma-1 receptor has recently been identified as a unique ligand-regulated mol. chaperone in the endoplasmic reticulum of cells.  This discovery causes us to look back at the many proposed roles of this receptor, even before its mol. function was identified, in many diseases such as methamphetamine or cocaine addiction, amnesia, pain, depression, Alzheimer's disease, stroke, retinal neuroprotection, HIV infection, and cancer.  In this review, we examine the reports that have clearly shown an agonist-antagonist relationship regarding sigma-1 receptors in models of those diseases and also review the relatively known mechanisms of action of sigma-1 receptors in an attempt to spur the speculation of readers on how the sigma-1 receptor at the endoplasmic reticulum might relate to so many diseases.  We found that the most prominent action of sigma-1 receptors in biol. systems including cell lines, primary cultures, and animals is the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca2+-, K+-, Na+, Cl-, and SK channels, and NMDA and IP3 receptors.  We found that the final output of the action of sigma-1 receptor agonists is to inhibit all above-mentioned voltage-gated ion channels, while they potentiate ligand-gated channels.  The inhibition or potentiation induced by agonists is blocked by sigma-1 receptor antagonists.  Other mechanisms of action of sigma-1 receptors, and to some extent those of sigma-2 receptors, were also considered.  We conclude that the sigma-1 and sigma-2 receptors represent potential fruitful targets for therapeutic developments in combating many human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4d_UAy6J4KbVg90H21EOLACvtfcHk0ljDNZkuznBxOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM&md5=7b5e251decc29edef42ffef1d65dd487</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DThe%2520pharmacology%2520of%2520sigma-1%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D124%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.pharmthera.2009.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span> <span> </span><span class="NLM_article-title">Sigma antagonists potentiate opioid analgesia in rats</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(95)11504-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2F0304-3940%2895%2911504-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=7644123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaK2MXls12nsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=1995&pages=137-139&author=C.+C.+Chienauthor=G.+W.+Pasternak&title=Sigma+antagonists+potentiate+opioid+analgesia+in+rats&doi=10.1016%2F0304-3940%2895%2911504-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma antagonists potentiate opioid analgesia in rats</span></div><div class="casAuthors">Chien, Chih-Cheng; Pasternak, Gavril W.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-9</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In mice, activation of sigma1 receptors antagonizes opioid analgesia.  Sigma antagonists potentiate opioid analgesia, implying that the anti-opioid sigma system is tonically active.  Co-administration of haloperidol with the mu opioid morphine, the kappa1 analgesic U 50488H or the kappa3 agonist naloxone benzoylhydrazone enhances the analgesic activity of all agents.  The effect results from sigma receptor blockade since (-)sulpiride, a selective D2 antagonist which does not block sigma receptors, is inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7Y-iEDEl3bVg90H21EOLACvtfcHk0ljDNZkuznBxOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls12nsr8%253D&md5=66ace8f372aca6d388626a9d9ba09728</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2895%2911504-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252895%252911504-P%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DC.%2BC.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26atitle%3DSigma%2520antagonists%2520potentiate%2520opioid%2520analgesia%2520in%2520rats%26jtitle%3DNeurosci.%2520Lett.%26date%3D1995%26volume%3D190%26spage%3D137%26epage%3D139%26doi%3D10.1016%2F0304-3940%2895%2911504-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cendán, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujalte, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montoliu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Formalin-induced pain is reduced in sigma(1) receptor knockout mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>511</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2005.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejphar.2005.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15777781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2005&pages=73-74&author=C.+M.+Cend%C3%A1nauthor=J.+M.+Pujalteauthor=E.+Portillo-Salidoauthor=L.+Montoliuauthor=J.+M.+Baeyens&title=Formalin-induced+pain+is+reduced+in+sigma%281%29+receptor+knockout+mice&doi=10.1016%2Fj.ejphar.2005.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Formalin-induced pain is reduced in σ1 receptor knockout mice</span></div><div class="casAuthors">Cendan, Cruz Miguel; Pujalte, Jose Miguel; Portillo-Salido, Enrique; Montoliu, Lluis; Baeyens, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-74</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The role of σ1 receptors in non-acute pain has not been explored.  In this study we show that both phases of formalin-induced pain were reduced by approx. 55% in σ1 receptor knockout mice in comparison to wild-type animals.  These results suggest that the tonic pain induced by formalin is altered in mice lacking σ1 receptors, and highlight the potential usefulness of further studies of the role of σ1 receptors in models of non-acute pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLfs5SOcqYY7Vg90H21EOLACvtfcHk0lgQWaceyb-6bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCjsLs%253D&md5=71d93bc7957c3f85824ab4a63d174a6b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DCend%25C3%25A1n%26aufirst%3DC.%2BM.%26aulast%3DPujalte%26aufirst%3DJ.%2BM.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DMontoliu%26aufirst%3DL.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DFormalin-induced%2520pain%2520is%2520reduced%2520in%2520sigma%25281%2529%2520receptor%2520knockout%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D511%26spage%3D73%26epage%3D74%26doi%3D10.1016%2Fj.ejphar.2005.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuberes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrocal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contijoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueño, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the 1-arylpyrazole class of σ<sub>1</sub> receptor antagonists: Identification of 4-{2-[5-methyl-1-(naphtalen-2-yl)-1<i>H</i>-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8211</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1021/jm3007323</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3007323" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8211-8224&author=J.+L.+D%C3%ADazauthor=R.+Cuberesauthor=J.+Berrocalauthor=M.+Contijochauthor=U.+Christmannauthor=A.+Fern%C3%A1ndezauthor=A.+Portauthor=J.+Holenzauthor=H.+Buschmannauthor=C.+Laggnerauthor=M.+T.+Serafiniauthor=J.+Burgue%C3%B1oauthor=D.+Zamanilloauthor=M.+Merlosauthor=J.+M.+Velaauthor=C.+Almansa&title=Synthesis+and+biological+evaluation+of+the+1-arylpyrazole+class+of+%CF%831+receptor+antagonists%3A+Identification+of+4-%7B2-%5B5-methyl-1-%28naphtalen-2-yl%29-1H-pyrazol-3-yloxy%5Dethyl%7Dmorpholine+%28S1RA%2C+E-52862%29&doi=10.1021%2Fjm3007323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of σ1 Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span></div><div class="casAuthors">Diaz, Jose Luis; Cuberes, Rosa; Berrocal, Joana; Contijoch, Montserrat; Christmann, Ute; Fernandez, Ariadna; Port, Adriana; Holenz, Jorg; Buschmann, Helmut; Laggner, Christian; Serafini, Maria Teresa; Burgueno, Javier; Zamanillo, Daniel; Merlos, Manuel; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8211-8224</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-arylpyrazoles as potent σ1 receptor (σ1R) antagonists are reported.  The new compds. were evaluated in vitro in human σ1R and guinea pig σ2 receptor (σ2R) binding assays.  The nature of the pyrazole substituents was crucial for activity, and a basic amine was shown to be necessary, in accordance with known receptor pharmacophores.  A wide variety of amines and spacer lengths between the amino and pyrazole groups was tolerated, but only the ethylenoxy spacer and small cyclic amines provided compds. with sufficient selectivity for σ1R vs σ2R.  The most selective compds. were further profiled, and 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862, I), which showed high activity in the mouse capsaicin model of neurogenic pain, emerged as the most interesting candidate.  In addn., compd. I exerted dose-dependent antinociceptive effects in several neuropathic pain models.  This, together with its good physicochem., safety, and ADME properties, led compd. I to be selected as clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQxd7-vnvc7Vg90H21EOLACvtfcHk0lgQWaceyb-6bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI&md5=0d6a5c8008d27635117c3901ec1db3c4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm3007323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3007323%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BL.%26aulast%3DCuberes%26aufirst%3DR.%26aulast%3DBerrocal%26aufirst%3DJ.%26aulast%3DContijoch%26aufirst%3DM.%26aulast%3DChristmann%26aufirst%3DU.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSerafini%26aufirst%3DM.%2BT.%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%25201-arylpyrazole%2520class%2520of%2520%25CF%25831%2520receptor%2520antagonists%253A%2520Identification%2520of%25204-%257B2-%255B5-methyl-1-%2528naphtalen-2-yl%2529-1H-pyrazol-3-yloxy%255Dethyl%257Dmorpholine%2520%2528S1RA%252C%2520E-52862%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8211%26epage%3D8224%26doi%3D10.1021%2Fjm3007323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyriou, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalofonos, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaqué, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: A randomized, double-blind, placebo-controlled phase IIa clinical trial</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s13311-017-0572-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1007%2Fs13311-017-0572-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=28924870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=178-189&author=J.+Brunaauthor=S.+Videlaauthor=A.+A.+Argyriouauthor=R.+Velascoauthor=J.+Villoriaauthor=C.+Santosauthor=C.+Nadalauthor=G.+Cavalettiauthor=P.+Albertiauthor=C.+Brianiauthor=H.+P.+Kalofonosauthor=D.+Cortinovisauthor=M.+Sustauthor=A.+Vaqu%C3%A9author=T.+Kleinauthor=C.+Plata-Salam%C3%A1n&title=Efficacy+of+a+novel+sigma-1+receptor+antagonist+for+oxaliplatin-induced+neuropathy%3A+A+randomized%2C+double-blind%2C+placebo-controlled+phase+IIa+clinical+trial&doi=10.1007%2Fs13311-017-0572-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span></div><div class="casAuthors">Bruna, Jordi; Videla, Sebastian; Argyriou, Andreas A.; Velasco, Roser; Villoria, Jesus; Santos, Cristina; Nadal, Cristina; Cavaletti, Guido; Alberti, Paola; Briani, Chiara; Kalofonos, Haralabos P.; Cortinovis, Diego; Sust, Mariano; Vaque, Anna; Klein, Thomas; Plata-Salaman, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn).  A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer receiving FOLFOX in a phase II, randomized, double-blind, placebo-controlled, multicenter clin. trial.  Outcome measures included changes in 24-wk quant. measures of thermal sensitivity and total neuropathy score.  In total, 124 patients were randomized (1:1) to MR309 or placebo.  Sixty-three (50.8%) patients withdrew prematurely before completing 12 planned oxaliplatin cycles.  Premature withdrawal because of cancer progression was less frequent in the MR309 group (7.4% vs 25.0% with placebo; p = 0.054).  MR309 significantly reduced cold pain threshold temp. [mean treatment effect difference (SE) vs placebo: 5.29 (1.60)°C; p = 0.001] and suprathreshold cold stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032].  Total neuropathy score, health-related quality-of-life measures, and nerve-conduction parameters changed similarly in both arms, whereas the proportion of patients with severe chronic neuropathy (National Cancer Institute Common Terminol. Criteria for Adverse Events ≥ 3) was significantly lower in the MR309 group (3.0% vs 18.2% with placebo; p = 0.046).  The total amt. of oxaliplatin delivered was greater in the active arm (1618.9 mg vs 1453.8 mg with placebo; p = 0.049).  Overall, 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, resp.).  Intermittent treatment with MR309 was assocd. with reduced acute oxaipn and higher oxaliplatin exposure, and showed a potential neuroprotective role for chronic cumulative oxaipn.  Furthermore, MR309 showed an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkVyo1fPRe7Vg90H21EOLACvtfcHk0lj__iJkVfwufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E&md5=78eac14b1175a004af19c4c9a53af1be</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs13311-017-0572-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-017-0572-5%26sid%3Dliteratum%253Aachs%26aulast%3DBruna%26aufirst%3DJ.%26aulast%3DVidela%26aufirst%3DS.%26aulast%3DArgyriou%26aufirst%3DA.%2BA.%26aulast%3DVelasco%26aufirst%3DR.%26aulast%3DVilloria%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DNadal%26aufirst%3DC.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DAlberti%26aufirst%3DP.%26aulast%3DBriani%26aufirst%3DC.%26aulast%3DKalofonos%26aufirst%3DH.%2BP.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DVaqu%25C3%25A9%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520for%2520oxaliplatin-induced%2520neuropathy%253A%2520A%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520clinical%2520trial%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs13311-017-0572-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span> <span> </span><span class="NLM_article-title">S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freund’s adjuvant models in mice</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1097/FBP.0000000000000038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1097%2FFBP.0000000000000038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=24776490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlGitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=226-235&author=G.+Grisauthor=M.+Merlosauthor=J.+M.+Velaauthor=D.+Zamanilloauthor=E.+Portillo-Salido&title=S1RA%2C+a+selective+sigma-1+receptor+antagonist%2C+inhibits+inflammatory+pain+in+the+carrageenan+and+complete+Freund%E2%80%99s+adjuvant+models+in+mice&doi=10.1097%2FFBP.0000000000000038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freund's adjuvant models in mice</span></div><div class="casAuthors">Gris, Georgia; Merlos, Manuel; Vela, Jose M.; Zamanillo, Daniel; Portillo-Salido, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The therapeutic potential of S1RA (E-52862), a selective sigma-1 receptor (σ1R) antagonist, has been explored in exptl. neuropathic pain, but not in inflammatory pain models.  The present study investigated the effect of the i.p. administration of S1RA on the hind paw withdrawal response to thermal and mech. stimulation following an intraplantar injection of carrageenan (CARR) and complete Freund's adjuvant (CFA), which are two well-characterized models of acute and chronic inflammatory pain, resp.  S1RA fully reversed both mech. [dose of drug that produced half of its maximal response (ED50)=35.9 and 42.1 mg/kg for CARR-induced and CFA-induced pain, resp.] and thermal (ED50=27.9 mg/kg, CARR) hypersensitivity, whereas ibuprofen (CARR, mech. allodynia) and celecoxib (CARR, thermal hyperalgesia; CFA, mech. allodynia) failed to reach max. efficacy.  Morphine also showed max. efficacy in all tests.  Unlike celecoxib and ibuprofen, which decreased paw vol. significantly, CARR-induced paw edema was not reduced by S1RA and morphine, thus suggesting that the antinociceptive effect of S1RA does not involve a major anti-inflammatory (antioedema) action.  S1RA was devoid of efficacy when administered to σ1R knockout mice, thus suggesting the involvement of σ1R in the antinociceptive effects exerted by S1RA.  We conclude that S1RA represents a promising novel analgesic therapy for inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVw_rDFuxlmrVg90H21EOLACvtfcHk0lj__iJkVfwufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlGitbc%253D&md5=4582585803d7d15b7e9b6aae886c3793</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000038%26sid%3Dliteratum%253Aachs%26aulast%3DGris%26aufirst%3DG.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26atitle%3DS1RA%252C%2520a%2520selective%2520sigma-1%2520receptor%2520antagonist%252C%2520inhibits%2520inflammatory%2520pain%2520in%2520the%2520carrageenan%2520and%2520complete%2520Freund%25E2%2580%2599s%2520adjuvant%2520models%2520in%2520mice%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2014%26volume%3D25%26spage%3D226%26epage%3D235%26doi%3D10.1097%2FFBP.0000000000000038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1007/s00213-014-3524-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1007%2Fs00213-014-3524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=24639046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=3855-3869&author=M.+A.+Tejadaauthor=A.+Montilla-Garc%C3%ADaauthor=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=J.+M.+Entrenaauthor=G.+Perazzoliauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptor+inhibition+reverses+acute+inflammatory+hyperalgesia+in+mice%3A+role+of+peripheral+sigma-1+receptors&doi=10.1007%2Fs00213-014-3524-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span></div><div class="casAuthors">Tejada, M. A.; Montilla-Garcia, A.; Sanchez-Fernandez, C.; Entrena, J. M.; Perazzoli, G.; Baeyens, J. M.; Cobos, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Sigma-1 (σ1) receptor inhibition ameliorates neuropathic pain by inhibiting central sensitization.  However, it is unknown whether σ1 receptor inhibition also decreases inflammatory hyperalgesia, or whether peripheral σ1 receptors are involved in this process.  Objective: The purpose of this study was to det. the role of σ1 receptors in carrageenan-induced inflammatory hyperalgesia, particularly at the inflammation site.  Results: The s.c. (s.c.) administration of the selective σ1 antagonists BD-1063 and S1RA to wild-type mice dose-dependently and fully reversed inflammatory mech. (paw pressure) and thermal (radiant heat) hyperalgesia.  These antihyperalgesic effects were abolished by the s.c. administration of the σ1 agonist PRE-084 and also by the intraplantar (i.pl.) administration of this compd. in the inflamed paw, suggesting that blockade of peripheral σ1 receptors in the inflamed site is involved in the antihyperalgesic effects induced by σ1 antagonists.  In fact, the i.pl. administration of σ1 antagonists in the inflamed paw (but not in the contralateral paw) was sufficient to completely reverse inflammatory hyperalgesia. σ1 knockout (σ1-KO) mice did not develop mech. hyperalgesia but developed thermal hypersensitivity; however, the s.c. administration of BD-1063 or S1RA had no effect on thermal hyperalgesia in σ1-KO mice, supporting on-target mechanisms for the effects of both drugs.  The antiedematous effects of σ1 inhibition do not account for the decreased hyperalgesia, since carrageenan-induced edema was unaffected by σ1 knockout or systemic σ1 pharmacol. antagonism.  Conclusions: σ1 receptors play a major role in inflammatory hyperalgesia.  Targeting σ1 receptors in the inflamed tissue may be useful for the treatment of inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvS0b6PcEhLVg90H21EOLACvtfcHk0lgE15VdBdlDGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D&md5=b62ff92aeee8ae0fbc9a4c1c4d272c82</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3524-3%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptor%2520inhibition%2520reverses%2520acute%2520inflammatory%2520hyperalgesia%2520in%2520mice%253A%2520role%2520of%2520peripheral%2520sigma-1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D3855%26epage%3D3869%26doi%3D10.1007%2Fs00213-014-3524-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span> <i>EU Clinical Trials</i>; <span class="NLM_publisher-name">European
Medicines Agency</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2019</span>; <a href="http://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003302-24/results" class="extLink">www.clinicaltrialsregister.eu/ctr-search/trial/2011-003302-24/results</a> (accessed Nov, 14, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+EU+Clinical+Trials%3B+European%0AMedicines+Agency%3A+Amsterdam%2C+2019%3B+www.clinicaltrialsregister.eu%2Fctr-search%2Ftrial%2F2011-003302-24%2Fresults+%28accessed+Nov%2C+14%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEU%2520Clinical%2520Trials%26pub%3DEuropean%250AMedicines%2520Agency%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0lgE15VdBdlDGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Selective sigma-1 receptor antagonists for the treatment of pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.4155%2Ffmc.14.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=25078137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1179-1199&author=C.+Almansaauthor=J.+M.+Vela&title=Selective+sigma-1+receptor+antagonists+for+the+treatment+of+pain&doi=10.4155%2Ffmc.14.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Selective sigma-1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Almansa, Carmen; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1179-1199</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The sigma-1 receptor (σ1R) is located in areas of the CNS key for pain control and belongs to a unique target class with chaperoning functions over different mol. targets involved in transmission and amplification of nociceptive messages.  Preclin. evidence supports a role for σ1R antagonists in the treatment of pain states where hypersensitivity develops as hyperalgesia and allodynia, two common symptoms encountered in neuropathic and other chronic pain conditions.  Addnl., σ1R antagonists increase opioid analgesia without increasing opioid-related unwanted effects, which point to their potential use as opioid adjuvant therapy.  This review summarizes the structure and function of the σ1R as well as the medicinal chem. and pharmacol. studies directed to the identification of σ1R antagonists for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ0qGYS21i37Vg90H21EOLACvtfcHk0lgfNG4-VxctLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK&md5=3ced452012e44f478a377f0fa52995d4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.54%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSelective%2520sigma-1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1179%26epage%3D1199%26doi%3D10.4155%2Ffmc.14.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dvoracsko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, A.</span></span> <span> </span><span class="NLM_article-title">The design of multitarget ligands for chronic and neuropathic pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.4155%2Ffmc.15.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=26652942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2469-2483&author=S.+Dvoracskoauthor=A.+Stefanucciauthor=E.+Novellinoauthor=A.+Mollica&title=The+design+of+multitarget+ligands+for+chronic+and+neuropathic+pain&doi=10.4155%2Ffmc.15.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The design of multitarget ligands for chronic and neuropathic pain</span></div><div class="casAuthors">Dvoracsko, Szabolcs; Stefanucci, Azzurra; Novellino, Ettore; Mollica, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2469-2483</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Monodrug therapy has been used with success to fight various pathologies.  When one medicine fails, co-administration of two or more drugs at the same time may be successfully applied in the treatment of infections, hypertension, HIV and in many other fields.  Discussion: This approach has some weakness related to the pharmacokinetic of the two different substances administered, side effects, possible drug-drug interaction.  Bivalent ligand approach would maintain the strength of the multidrug therapy (synergistic effect, lower doses, and little side effects) and overcome the weakness of a co-administration.  Conclusion: In this review we have described the state-of-the-art of the multitarget approach for the control of pain.  Several approaches adopted by different research groups and future perspectives have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEdmKaU-Blf7Vg90H21EOLACvtfcHk0lgfNG4-VxctLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K&md5=04d64c3fd3e5f442094cbd40ebf25303</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.156%26sid%3Dliteratum%253Aachs%26aulast%3DDvoracsko%26aufirst%3DS.%26aulast%3DStefanucci%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMollica%26aufirst%3DA.%26atitle%3DThe%2520design%2520of%2520multitarget%2520ligands%2520for%2520chronic%2520and%2520neuropathic%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2469%26epage%3D2483%26doi%3D10.4155%2Ffmc.15.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhosle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharambe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gairola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaneshwar, S. S.</span></span> <span> </span><span class="NLM_article-title">Mutual prodrug concept: fundamentals and applications</span>. <i>Indian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.4103/0250-474X.26654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.4103%2F0250-474X.26654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2006&pages=286-294&author=D.+Bhosleauthor=S.+Bharambeauthor=N.+Gairolaauthor=S.+S.+Dhaneshwar&title=Mutual+prodrug+concept%3A+fundamentals+and+applications&doi=10.4103%2F0250-474X.26654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mutual prodrug concept: fundamentals and applications</span></div><div class="casAuthors">Bhosle, D.; Bharambe, S.; Gairola, Neha; Dhaneshwar, Suneela S.</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-294</span>CODEN:
                <span class="NLM_cas:coden">IJSIDW</span>;
        ISSN:<span class="NLM_cas:issn">0250-474X</span>.
    
            (<span class="NLM_cas:orgname">Indian Pharmaceutical Association</span>)
        </div><div class="casAbstract">A review.  A therapeutically significant drug may have limited utilization in clin. practice because of poor organoleptic properties, poor bioavailability, short duration of action, nonspecificity, incomplete absorption, poor aq. soly., high first-pass metab. or other adverse effects.  There is a great emphasis on research to discover methods aimed at improving their therapeutic efficacy by minimizing or eliminating these undesirable properties.  Sometimes, an adequate pharmaceutical formulation can overcome these drawbacks, but often the galenic formulation is inoperant and a chem. modification of active mol. is necessary to correct its pharmacokinetic insufficiencies.  This chem. formulation process, whose objective is to convert an interesting active mol. into a clin. acceptable drug, often involves the so-called 'Prodrug design.'.  Mutual prodrug is a type of carrier-linked prodrug, where the carrier used is another biol. active drug instead of some inert mol.  A mutual prodrug consists of two pharmacol. active agents coupled together so that each acts as a promoiety for the other agent and vice versa.  Mutual prodrug design is really no different from the general drug discovery process, in which a unique substance is obsd. to have desirable pharmacol. effects, and studies of its properties lead to the design of better drugs.  It is a very fruitful area of research, and its introduction in human therapy has given successful results in improving the clin. and therapeutic effectiveness of drugs suffering from some undesirable properties that otherwise hinder their clin. usefulness.  The present article takes a review of various applications of mutual prodrugs and the developments in this field during the last few decades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH3cW1cvTkVLVg90H21EOLACvtfcHk0lgfNG4-VxctLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D&md5=3dcaac61d251a1027fe9d212d0aef51c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4103%2F0250-474X.26654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0250-474X.26654%26sid%3Dliteratum%253Aachs%26aulast%3DBhosle%26aufirst%3DD.%26aulast%3DBharambe%26aufirst%3DS.%26aulast%3DGairola%26aufirst%3DN.%26aulast%3DDhaneshwar%26aufirst%3DS.%2BS.%26atitle%3DMutual%2520prodrug%2520concept%253A%2520fundamentals%2520and%2520applications%26jtitle%3DIndian%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D68%26spage%3D286%26epage%3D294%26doi%3D10.4103%2F0250-474X.26654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Design strategies for bivalent ligands targeting GPCRs</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1002%2Fcmdc.201100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=21520422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=963-974&author=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Design+strategies+for+bivalent+ligands+targeting+GPCRs&doi=10.1002%2Fcmdc.201100101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design Strategies for Bivalent Ligands Targeting GPCRs</span></div><div class="casAuthors">Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Specifically designed bivalent ligands targeting G protein-coupled receptor (GPCR) dimeric structures have become increasingly popular in recent literature.  The advantages of the bivalent approach are numerous, including enhanced potency and receptor subtype specificity.  However, the use of bivalent ligands as potential pharmacotherapeutics is limited by problematic mol. properties, such as high mol. wt. and lipophilicity.  This Minireview focuses on the design of bivalent ligands recently described in the literature; discussing the choice of lead pharmacophore, the position and nature of the attachment point for linking the two pharmacophore units, and the length and compn. of the spacer group.  Furthermore, this Minireview distills the mol. descriptors of the bivalent ligands that exhibit in vivo activity, as well as highlights their ability to access the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7uDrMXq0sprVg90H21EOLACvtfcHk0lha4ULRL1SyoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D&md5=569a8a988cdd9d2daf8f492211303934</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100101%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DDesign%2520strategies%2520for%2520bivalent%2520ligands%2520targeting%2520GPCRs%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D963%26epage%3D974%26doi%3D10.1002%2Fcmdc.201100101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2259</span>– <span class="NLM_lpage">2269</span>, <span class="refDoi"> DOI: 10.1021/jm010158+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010158%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Oit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2259-2269&author=P.+S.+Portoghese&title=From+models+to+molecules%3A+opioid+receptor+dimers%2C+bivalent+ligands%2C+and+selective+opioid+receptor+probes&doi=10.1021%2Fjm010158%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">From Models to Molecules: Opioid Receptor Dimers, Bivalent Ligands, and Selective Opioid Receptor Probes</span></div><div class="casAuthors">Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2259-2269</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opiates have been the most widely investigated class of natural products.  The development of totally synthetic analgesics subsequently led to the development of diverse structural classes of ligands that mimic the actions of the opiates.  Compds. with mixed agonist-antagonist activity during that period represented a new approach to reducing the abuse potential and some of the side effects assocd. with the classical opiates, and several of the analgesics in this group are presently employed clin.  In this presentation I will draw on selected examples from my research to illustrate how key conceptual models have led to the design of selective ligands, some of which are widely employed as pharmacol. tools for the investigation of opioid receptors.  I will also illustrate how site-directed mutagenesis, when combined with the classical structure-activity relationship (SAR) approach, has led to the identification of amino acid residues on opioid receptors and groups on ligands that participate in mol. recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJApX5SmJarVg90H21EOLACvtfcHk0lha4ULRL1SyoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Oit7s%253D&md5=95afe28e1417088a0a934aafa689bb83</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm010158%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010158%252B%26sid%3Dliteratum%253Aachs%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DFrom%2520models%2520to%2520molecules%253A%2520opioid%2520receptor%2520dimers%252C%2520bivalent%2520ligands%252C%2520and%2520selective%2520opioid%2520receptor%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2259%26epage%3D2269%26doi%3D10.1021%2Fjm010158%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Naour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akgün, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yekkirala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunzer, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyuzhny, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5513</span>, <span class="refDoi"> DOI: 10.1021/jm4005219</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4005219" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5505-5513&author=M.+Le%0ANaourauthor=E.+Akg%C3%BCnauthor=A.+Yekkiralaauthor=M.+M.+Lunzerauthor=M.+D.+Powersauthor=A.+E.+Kalyuzhnyauthor=P.+S.+Portoghese&title=Bivalent+ligands+that+target+%CE%BC+opioid+%28MOP%29+and+cannabinoid1+%28CB1%29+receptors+are+potent+analgesics+devoid+of+tolerance&doi=10.1021%2Fjm4005219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid 1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance</span></div><div class="casAuthors">Le Naour, Morgan; Akgun, Eyup; Yekkirala, Ajay; Lunzer, Mary M.; Powers, Mike D.; Kalyuzhny, Alexander E.; Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5505-5513</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given that μ opioid (MOP) and cannabinoid (CB1) receptors are colocalized in various regions of the central nervous system and have been reported to assoc. as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP-CB1 in nociception and other pharmacol. effects has been raised.  As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo.  Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer.  Antinociceptive testing in mice revealed 5 to be the most potent member of the series.  As neither a mixt. of monovalent ligands 9+10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdqGOG4RA1RLVg90H21EOLACvtfcHk0lhk7r-nL0W_qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D&md5=b3df3237bfebc84448056724c3cfca4d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm4005219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005219%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BNaour%26aufirst%3DM.%26aulast%3DAkg%25C3%25BCn%26aufirst%3DE.%26aulast%3DYekkirala%26aufirst%3DA.%26aulast%3DLunzer%26aufirst%3DM.%2BM.%26aulast%3DPowers%26aufirst%3DM.%2BD.%26aulast%3DKalyuzhny%26aufirst%3DA.%2BE.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DBivalent%2520ligands%2520that%2520target%2520%25CE%25BC%2520opioid%2520%2528MOP%2529%2520and%2520cannabinoid1%2520%2528CB1%2529%2520receptors%2520are%2520potent%2520analgesics%2520devoid%2520of%2520tolerance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5505%26epage%3D5513%26doi%3D10.1021%2Fjm4005219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Virgili-Bernardo, M.</span>; <span class="NLM_string-name">Alonso-Xalma, M.</span>; <span class="NLM_string-name">Alegret-Molina, C.</span>; <span class="NLM_string-name">Almansa_Rosales, C.</span>; <span class="NLM_string-name">García Lopez, M.</span></span> <span> </span><span class="NLM_article-title">Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain</span>. PCT Int. Appl. <span class="NLM_patent">WO2015185207A1</span> 20151012, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Virgili-Bernardo&author=M.+Alonso-Xalma&author=C.+Alegret-Molina&author=C.+Almansa_Rosales&author=M.+Garc%C3%ADa+Lopez&title=Alkyl+and+aryl+derivatives+of+1-oxa-4%2C9-diazaspiro+undecane+compounds+having+multimodal+activity+against+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVirgili-Bernardo%26aufirst%3DM.%26atitle%3DAlkyl%2520and%2520aryl%2520derivatives%2520of%25201-oxa-4%252C9-diazaspiro%2520undecane%2520compounds%2520having%2520multimodal%2520activity%2520against%2520pain%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caroon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repke, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strosberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, R. L.</span></span> <span> </span><span class="NLM_article-title">Antihypertensive 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1021/jm00360a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00360a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaL3sXhvFWhurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1983&pages=855-861&author=R.+D.+Clarkauthor=J.+M.+Caroonauthor=D.+B.+Repkeauthor=A.+M.+Strosbergauthor=S.+M.+Bitterauthor=M.+D.+Okadaauthor=A.+D.+Michelauthor=R.+L.+Whiting&title=Antihypertensive+9-substituted+1-oxa-4%2C9-diazaspiro%5B5.5%5Dundecan-3-ones&doi=10.1021%2Fjm00360a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Antihypertensive 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones</span></div><div class="casAuthors">Clark, Robin D.; Caroon, Joan M.; Repke, David B.; Strosberg, Arthur M.; Bitter, Susan M.; Okada, Marlys D.; Michel, Anton D.; Whiting, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title compds. I (R = H, Me, Et, Ph; R1 = H, C1-3 alkyl, Ph, substituted Ph, or benzyl; R2 = H, Me, or Et; R3 = indolylethyl, benzodioxanylmethyl, substituted phenethyl, etc.) prepd. by stepwise reactions from the substituted 6-carbobenzoxy-1-oxa-6-azaspiro[2.5]octane and I ring-opened analogs II (R = Me, Et, MeOCH2, or Ph; R1 = H or MeO) prepd. either by acylation of 3-[2-[4-(aminomethyl)piperidino]ethyl]indole  [85151-25-3] or from benzyl 4-(azidomethyl)-4-hydroxy-1-piperidinecarboxylate  [85151-24-2], as HCl salts were evaluated as antihypertensives in spontaneously hypertensive rats.  9-(2-indol-3-ylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one-HCl  [85151-27-5] Was the most effective antihypertensive, its activity apparently due to peripheral α1-adrenoceptor blockade.  Structure activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCtn48e407MbVg90H21EOLACvtfcHk0lhk7r-nL0W_qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhvFWhurk%253D&md5=91b65ec71c690bb9765b7ad7e306ae51</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00360a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00360a013%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DCaroon%26aufirst%3DJ.%2BM.%26aulast%3DRepke%26aufirst%3DD.%2BB.%26aulast%3DStrosberg%26aufirst%3DA.%2BM.%26aulast%3DBitter%26aufirst%3DS.%2BM.%26aulast%3DOkada%26aufirst%3DM.%2BD.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DWhiting%26aufirst%3DR.%2BL.%26atitle%3DAntihypertensive%25209-substituted%25201-oxa-4%252C9-diazaspiro%255B5.5%255Dundecan-3-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1983%26volume%3D26%26spage%3D855%26epage%3D861%26doi%3D10.1021%2Fjm00360a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyloxosulfonium methylide ((CH<sub>3</sub>)<sub>2</sub>SOCH<sub>2</sub>) and dimethylsulfonium methylide ((CH<sub>3</sub>)<sub>2</sub>SCH<sub>2</sub>). Formation and application to organic synthesis</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/ja01084a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01084a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1965&pages=1353-1364&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethyloxosulfonium+methylide+%28%28CH3%292SOCH2%29+and+dimethylsulfonium+methylide+%28%28CH3%292SCH2%29.+Formation+and+application+to+organic+synthesis&doi=10.1021%2Fja01084a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyloxosulfonium methylide and dimethylsulfonium methylide. Formation and application to organic synthesis</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-64</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The generation of dimethyloxosulfonium methylide (Me2SOCH2) and dimethylsulfonium methylide (Me2SCH2) as reactive intermediates is described.  Both ylides are nucleophiles and both function to transfer methylene to certain electrophilic unsatd. linkages, including C:O, C:N, C:S, and in certain cases, C:C.  The less reactive oxosulfonium ylide interacts with the carbonyl function of aromatic and nonconjugated aldehydes and ketones to form oxiranes and with α,β-unsatd. ketones which are Michael receptors to form cyclopropyl ketones.  The sulfonium ylide reacts with the same substrates to give oxiranes exclusively even with the α,β-unsatd. carbonyl systems.  These reactions are quite general and, therefore, of considerable practical value.  The stereochemistry of carbonyl addn. to cyclohexanones varies depending on the ylide; the oxosulfonium ylide reacts by equatorial addn. (i.e., of methylene) and the sulfonium ylide shows a preference for axial addn.  A no. of other reactions of these ylides are described including "over-all methylene insertion," and a differential comparison of their chem. properties is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt0xfN-tNfFLVg90H21EOLACvtfcHk0ljV3r0_108ZMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D&md5=ae22573e36db50409c7832e5950df7f1</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fja01084a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01084a034%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethyloxosulfonium%2520methylide%2520%2528%2528CH3%25292SOCH2%2529%2520and%2520dimethylsulfonium%2520methylide%2520%2528%2528CH3%25292SCH2%2529.%2520Formation%2520and%2520application%2520to%2520organic%2520synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1965%26volume%3D87%26spage%3D1353%26epage%3D1364%26doi%3D10.1021%2Fja01084a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. S.</span></span> <span> </span><span class="NLM_article-title">Concise and versatile syntheses of <i>N</i>-arylalkylpiperidines as potential intermediates for 4-anilidopiperidine analgesics</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.3987/COM-97-8056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.3987%2FCOM-97-8056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaK1cXitVemu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1998&pages=239-242&author=Y.+G.+Suhauthor=D.+Y.+Shinauthor=K.+H.+Choauthor=J.+S.+Ryu&title=Concise+and+versatile+syntheses+of+N-arylalkylpiperidines+as+potential+intermediates+for+4-anilidopiperidine+analgesics&doi=10.3987%2FCOM-97-8056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Concise and versatile syntheses of N-arylalkylpiperidines as potential intermediates for 4-anilidopiperidine analgesics</span></div><div class="casAuthors">Suh, Young-Ger; Shin, Dong-Yun; Cho, Kyung-Ho; Ryu, Jae-Sang</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    
            (<span class="NLM_cas:orgname">Japan Institute of Heterocyclic Chemistry</span>)
        </div><div class="casAbstract">N-(Arylalkyl)piperidones I (R = Ph, 2-thienyl) and the (arylalkyl)spiroepoxypiperidine II, potential intermediates for 4-anilidopiperidine analgesics and their structural analogs, were efficiently synthesized from arylalkylamines by two- and three-step sequences, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm0W0FqhD7yrVg90H21EOLACvtfcHk0ljV3r0_108ZMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVemu7Y%253D&md5=420100137985a2849e29e94e122db544</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3987%2FCOM-97-8056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-97-8056%26sid%3Dliteratum%253Aachs%26aulast%3DSuh%26aufirst%3DY.%2BG.%26aulast%3DShin%26aufirst%3DD.%2BY.%26aulast%3DCho%26aufirst%3DK.%2BH.%26aulast%3DRyu%26aufirst%3DJ.%2BS.%26atitle%3DConcise%2520and%2520versatile%2520syntheses%2520of%2520N-arylalkylpiperidines%2520as%2520potential%2520intermediates%2520for%25204-anilidopiperidine%2520analgesics%26jtitle%3DHeterocycles%26date%3D1998%26volume%3D48%26spage%3D239%26epage%3D242%26doi%3D10.3987%2FCOM-97-8056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caroon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strosberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, R. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1320</span>– <span class="NLM_lpage">1328</span>, <span class="refDoi"> DOI: 10.1021/jm00143a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00143a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaL3MXls1WktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1320-1328&author=J.+M.+Caroonauthor=R.+D.+Clarkauthor=A.+F.+Klugeauthor=J.+T.+Nelsonauthor=A.+M.+Strosbergauthor=S.+H.+Ungerauthor=A.+D.+Michelauthor=R.+L.+Whiting&title=Synthesis+and+antihypertensive+activity+of+a+series+of+8-substituted+1-oxa-3%2C8-diazaspiro%5B4.5%5Ddecan-2-ones&doi=10.1021%2Fjm00143a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones</span></div><div class="casAuthors">Caroon, Joan M.; Clark, Robin D.; Kluge, Arthur F.; Nelson, Janis T.; Strosberg, Arthur M.; Unger, Stefan H.; Michel, Anton D.; Whiting, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1320-8</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Forty-three title compds. I, II, and III (R and R1 = H, Me, CH2Ph, etc.; R2 = H, Et, or Pr) were synthesized and tested as antihypertensive agents in the spontaneous hypertensive rat.  I substituted in the 4 position were the most active I.  III were less active than their corresponding II.  II (R = R2 = H, R1 = Et)  [79053-05-7] and III (R = Me, R1 = R2 = H)  [79053-04-6], designed as mixed α- and β-adrenergic receptor blockers, lowered blood pressure but gave no evidence of working as β-adrenergic blockers.  I (R = R1 = R2 = H)  [78741-66-9] and II (R = Me, R1 = R2 = H)  [79101-49-8] were α-adrenergic blockers in dogs, and in tilt-response studies for evaluating the potential for producing orthostatic hypotension both compds. had little potential for avoiding orthostatic hypotension at therapeutically EDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzT_RyPEUqSbVg90H21EOLACvtfcHk0lheobjSFSistQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXls1WktLs%253D&md5=5f55f46d792fcf59bccd3fb0101cc65a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm00143a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00143a012%26sid%3Dliteratum%253Aachs%26aulast%3DCaroon%26aufirst%3DJ.%2BM.%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26aulast%3DNelson%26aufirst%3DJ.%2BT.%26aulast%3DStrosberg%26aufirst%3DA.%2BM.%26aulast%3DUnger%26aufirst%3DS.%2BH.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DWhiting%26aufirst%3DR.%2BL.%26atitle%3DSynthesis%2520and%2520antihypertensive%2520activity%2520of%2520a%2520series%2520of%25208-substituted%25201-oxa-3%252C8-diazaspiro%255B4.5%255Ddecan-2-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D1320%26epage%3D1328%26doi%3D10.1021%2Fjm00143a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrecht, S.</span></span> <span> </span><span class="NLM_article-title">Method for the preparation of alpha-bromo-lactam derivatives</span>. U.S. Patent <span class="NLM_patent">US6,114,541</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=S.+Abrecht&title=Method+for+the+preparation+of+alpha-bromo-lactam+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbrecht%26aufirst%3DS.%26atitle%3DMethod%2520for%2520the%2520preparation%2520of%2520alpha-bromo-lactam%2520derivatives%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span> <i>Discovery Studio
16</i>; <span class="NLM_publisher-name">Dassault Systèmes
BIOVIA</span>: <span class="NLM_publisher-loc">San Diego, CA</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Discovery+Studio%0A16%3B+Dassault+Syst%C3%A8mes%0ABIOVIA%3A+San+Diego%2C+CA%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDiscovery%2520Studio%250A16%26pub%3DDassault%2520Syst%25C3%25A8mes%250ABIOVIA%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieferer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiechtner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, F. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of high-affinity ligands of sigma-1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4754</span>– <span class="NLM_lpage">4764</span>, <span class="refDoi"> DOI: 10.1021/jm049073+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049073%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4754-4764&author=C.+Laggnerauthor=C.+Schiefererauthor=B.+Fiechtnerauthor=G.+Polesauthor=R.+D.+Hoffmannauthor=H.+Glossmannauthor=T.+Langerauthor=F.+F.+Moebius&title=Discovery+of+high-affinity+ligands+of+sigma-1+receptor%2C+ERG2%2C+and+emopamil+binding+protein+by+pharmacophore+modeling+and+virtual+screening&doi=10.1021%2Fjm049073%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of High-Affinity Ligands of σ1 Receptor, ERG2, and Emopamil Binding Protein by Pharmacophore Modeling and Virtual Screening</span></div><div class="casAuthors">Laggner, Christian; Schieferer, Claudia; Fiechtner, Birgit; Poles, Gloria; Hoffmann, Remy D.; Glossmann, Hartmut; Langer, Thierry; Moebius, Fabian F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4754-4764</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ERG2, emopamil binding protein (EBP), and sigma-1 receptor (σ1) are enzymes of sterol metab. and an enzyme-related protein, resp., that share high affinity for various structurally diverse compds.  To discover novel high-affinity ligands, pharmacophore models were built with Catalyst based upon a series of 23 structurally diverse chems. exhibiting Ki values from 10 pM to 100 μM for all three proteins.  In virtual screening expts., we retrieved drugs that were previously reported to bind to one or several of these proteins and also tested 11 new hits exptl., of which three, among them raloxifene, had affinities for σ1 or EBP of <60 nM.  When used to search a database of 3525 biochems. of intermediary metab., a slightly modified ERG2 pharmacophore model successfully retrieved 10 substrate candidates among the top 28 hits.  Our results indicate that inhibitor-based pharmacophore models for σ1, ERG2, and EBP can be used to screen drug and metabolite databases for chem. diverse compds. and putative endogenous ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYGPlSy4wI8rVg90H21EOLACvtfcHk0lheobjSFSistQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb8%253D&md5=f96d318b2e3d5575dfe6bbe98e0f5ef0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm049073%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049073%252B%26sid%3Dliteratum%253Aachs%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSchieferer%26aufirst%3DC.%26aulast%3DFiechtner%26aufirst%3DB.%26aulast%3DPoles%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DR.%2BD.%26aulast%3DGlossmann%26aufirst%3DH.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DMoebius%26aufirst%3DF.%2BF.%26atitle%3DDiscovery%2520of%2520high-affinity%2520ligands%2520of%2520sigma-1%2520receptor%252C%2520ERG2%252C%2520and%2520emopamil%2520binding%2520protein%2520by%2520pharmacophore%2520modeling%2520and%2520virtual%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4754%26epage%3D4764%26doi%3D10.1021%2Fjm049073%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span> <span> </span><span class="NLM_article-title">A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">519</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.3389%2Ffphar.2019.00519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=31214020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=519&author=R.+Pascualauthor=C.+Almansaauthor=J.+M.+Velaauthor=C.+Plata-Salam%C3%A1n&title=A+new+pharmacophore+model+for+the+design+of+sigma-1+ligands+validated+on+a+large+experimental+dataset&doi=10.3389%2Ffphar.2019.00519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset</span></div><div class="casAuthors">Pascual, Rosalia; Almansa, Carmen; Plata-Salaman, Carlos; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The recent publication of the σ1R crystal structure is an important cornerstone for the derivation of more accurate activity prediction models.  We report here a comparative study involving a set of more than 25,000 structures from our internal database that had been screened for σ1R affinity.  Using the recently published crystal structure, 5HK1, two new pharmacophore models were generated.  The first one, 5HK1-Ph.A, was obtained by an algorithm that identifies the most important receptor-ligand interactions including vol. restrictions enforced by the at. structure of the recognition site.  The second, 5HK1-Ph.B, resulted from a manual edition of the first one by the fusion of two hydrophobic (HYD) features.  Finally, we also docked the database using a high throughput docking technique and scored the resulting poses with seven different scoring functions.  Statistical performance measures were obtained for the two models, comparing them with previously published σ1R pharmacophores (Hit Rate, sensitivity, specificity, and Receiver Operator Characteristic) and 5HK1-Ph.B emerged as the best one in discriminating between active and inactive compds., with a ROC-AUC value above 0.8 and enrichment values above 3 at different fractions of screened samples. 5HK1-Ph.B also showed better results than the direct docking, which may be due to the rigidity of the crystal structure in the docking process (i.e., feature tolerances in the pharmacophore model).  Addnl., the impact of the HYD interactions and the penalty for desolvating ligands with polar atoms may be not adequately captured by scoring functions, whereas HYD groups filling up such regions of the binding site are entailed in the pharmacophore model.  Altogether, using annotated data from a large and diverse compd. collection together with crystal structure information provides a sound basis for the generation and validation of predictive models to design new mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGommlNCghqBXrVg90H21EOLACvtfcHk0lh8BQ_BVxlUCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D&md5=156ec236d1cf03779cae199e0716b497</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00519%26sid%3Dliteratum%253Aachs%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26atitle%3DA%2520new%2520pharmacophore%2520model%2520for%2520the%2520design%2520of%2520sigma-1%2520ligands%2520validated%2520on%2520a%2520large%2520experimental%2520dataset%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D519%26doi%3D10.3389%2Ffphar.2019.00519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.ejmech.2019.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=31129453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2019&pages=47-62&author=S.+Thumauthor=D.+Schepmannauthor=E.+Ayetauthor=M.+Pujolauthor=F.+R.+Nietoauthor=S.+M.+Ametameyauthor=B.+W%C3%BCnsch&title=Tetrahydro-3-benzazepines+with+fluorinated+side+chains+as+NMDA+and+%CF%831+receptor+antagonists%3A+Synthesis%2C+receptor+affinity%2C+selectivity+and+antiallodynic+activity&doi=10.1016%2Fj.ejmech.2019.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity</span></div><div class="casAuthors">Thum, Simone; Schepmann, Dirk; Ayet, Eva; Pujol, Marta; Nieto, Francisco R.; Ametamey, Simon M.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-62</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The class of tetrahydro-1H-3-benzazepines was systematically modified in 1-, 3- and 7-position.  In particular, a F-atom was introduced in β- or γ-position of the 4-phenylbutyl side chain in 3-position.  Ligands with the F-atom in γ-position possess higher GluN2B affinity than analogs bearing the F-atom in β-position.  This effect was attributed to the reduced basicity of β-fluoro amines.  3-Benzazepines with a benzylic OH moiety show moderate GluN2B affinity, but considerable selectivity over the σ2 receptor.  However, removal of the benzylic OH moiety led to increased GluN2B affinity, but reduced GluN2B/σ2 selectivity.  With respect to GluN2B affinity the phenol 17b (I) with a γ-fluorophenylbutyl moiety in 3-position represents the most interesting fluorinated ligand (Ki(GluN2B) = 16 nM).  Most of the synthesized ligands reveal either similar GluN2B and σ1 affinity or higher σ1 affinity than GluN2B affinity.  The Me ether 16b (II) shows high σ1 affinity (Ki(σ1) = 6.6 nM) and high selectivity over a broad panel of receptors and transporters.  The high antiallodynic activity in the mouse capsaicin assay proved the σ1 antagonistic activity of 16b.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4JVguOHkxBrVg90H21EOLACvtfcHk0lh8BQ_BVxlUCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnI&md5=6d3d234ecb41991803484736ae7bf512</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DThum%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DAyet%26aufirst%3DE.%26aulast%3DPujol%26aufirst%3DM.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DTetrahydro-3-benzazepines%2520with%2520fluorinated%2520side%2520chains%2520as%2520NMDA%2520and%2520%25CF%25831%2520receptor%2520antagonists%253A%2520Synthesis%252C%2520receptor%2520affinity%252C%2520selectivity%2520and%2520antiallodynic%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D177%26spage%3D47%26epage%3D62%26doi%3D10.1016%2Fj.ejmech.2019.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgueño, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, J.</span></span> <span> </span><span class="NLM_article-title">A complementary scale of biased agonism for agonists with differing maximal responses</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15389</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-15258-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1038%2Fs41598-017-15258-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=29133887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A280%3ADC%252BC1M3gvVegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=15389&author=J.+Burgue%C3%B1oauthor=M.+Pujolauthor=X.+Monroyauthor=D.+Rocheauthor=M.+J.+Varelaauthor=M.+Merlosauthor=J.+Giraldo&title=A+complementary+scale+of+biased+agonism+for+agonists+with+differing+maximal+responses&doi=10.1038%2Fs41598-017-15258-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses</span></div><div class="casAuthors">Burgueno Javier; Pujol Marta; Monroy Xavier; Merlos Manuel; Roche David; Giraldo Jesus; Roche David; Giraldo Jesus; Roche David; Varela Maria Jose</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15389</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Compelling data in the literature from the recent years leave no doubt about the pluridimensional nature of G protein-coupled receptor function and the fact that some ligands can couple with different efficacies to the multiple pathways that a receptor can signal through, a phenomenon most commonly known as functional selectivity or biased agonism.  Nowadays, transduction coefficients (log(τ/KA)), based on the Black and Leff operational model of agonism, are widely used to calculate bias.  Nevertheless, combining both affinity and efficacy in a single parameter can result in compounds showing a defined calculated bias of one pathway over other though displaying varying experimental bias preferences.  In this paper, we present a novel scale (log(τ)), that attempts to give extra substance to different compound profiles in order to better classify compounds and quantify their bias.  The efficacy-driven log(τ) scale is not proposed as an alternative to the affinity&efficacy-driven log(τ/KA) scale but as a complement in those situations where partial agonism is present.  Both theoretical and practical approaches using μ-opioid receptor agonists are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8ACsymX9-Ay-bLEOO4dYpfW6udTcc2eZEm0NUPlub_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3gvVegsg%253D%253D&md5=8c43e0cc2e5e1fe47fa40c2c3d50b7f6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-15258-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-15258-z%26sid%3Dliteratum%253Aachs%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DPujol%26aufirst%3DM.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DVarela%26aufirst%3DM.%2BJ.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGiraldo%26aufirst%3DJ.%26atitle%3DA%2520complementary%2520scale%2520of%2520biased%2520agonism%2520for%2520agonists%2520with%2520differing%2520maximal%2520responses%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D15389%26doi%3D10.1038%2Fs41598-017-15258-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitza, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G. A.</span></span> <span> </span><span class="NLM_article-title">The [<sup>3</sup>H]-dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K<sup>+</sup>]<sub>o</sub></span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2004.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.vascn.2004.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15519905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=187-199&author=G.+J.+Diazauthor=K.+Daniellauthor=S.+T.+Leitzaauthor=R.+L.+Martinauthor=Z.+Suauthor=J.+S.+McDermottauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+%5B3H%5D-dofetilide+binding+assay+is+a+predictive+screening+tool+for+hERG+blockade+and+proarrhythmia%3A+Comparison+of+intact+cell+and+membrane+preparations+and+effects+of+altering+%5BK%2B%5Do&doi=10.1016%2Fj.vascn.2004.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span></div><div class="casAuthors">Diaz, Gilbert J.; Daniell, Katina; Leitza, Sandra T.; Martin, Ruth L.; Su, Zhi; McDermott, Jeffrey S.; Cox, Bryan F.; Gintant, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: The human ether-a-go-go-related gene (hERG) encodes a potassium channel responsible for the cardiac delayed rectifier current (IKr) involved in ventricular repolarization.  Drugs that block hERG have been assocd. with QT interval prolongation and serious, sometimes fatal, cardiac arrhythmias (including torsade de pointes).  While displacement of [3H]dofetilide, a potent methanesulfonanilide hERG blocker, from cells heterologously expressing hERG has been suggested as a screening assay, questions have been raised about its predictive value.Methods: To validate the utility of this assay as a screening tool, we performed a series of satn. and competition binding studies using [3H]dofetilide as ligand and either intact cells or membrane prepns. from HEK 293 cells stably transfected with hERG K+ channels.  The object of these expts. was to (1) compare binding Ki values for 22 hERG blockers using intact cells or membrane homogenates to det. whether maintaining cell integrity enhanced assay reliability; (2) evaluate the ability of different K+ concns. (2, 5, 10, 20, and 60 mM) to modulate hERG binding; and (3) to establish the predictive value of the assay by comparing Ki values from binding studies at 5 and 60 mM [K+]o to functional IC50 values for hERG current block using 56 structurally diverse drugs.Results: We found (a) comparable Ki values in the intact cell and isolated membrane binding assays, although there were some differences in rank order; (b) increasing [K+]o lowered the Kd and increased the Bmax for [3H]dofetilide, particularly in the membrane assay; and (c) good correlation between binding Ki values and functional IC50 values for hERG current block.Discussion: In conclusion, increasing K+ concns. results in an increase in both [3H]dofetilide affinity for hERG and available binding sites, particularly when using membrane homogenates.  There are no meaningful differences between Ki values when comparing intact cell vs. membrane assay, neither are there meaningful trends with increasing [K+]o within assays.  There is good correlation between binding Ki values and functional (whole-cell patch clamp) IC50 values at both 5 and 60 mM K+ concns. (R2 values of .824 and .863, resp.).  The simplicity, predictability, and adaptability to high-throughput platforms make the [3H]dofetilide membrane binding assay a useful tool for screening and ranking compds. for their potential to block the hERG K+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJEs_DWLzvI7Vg90H21EOLACvtfcHk0ljjPsnwxj-WNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D&md5=28c925ef02404c53443dc90eae961ed1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DDaniell%26aufirst%3DK.%26aulast%3DLeitza%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520%255B3H%255D-dofetilide%2520binding%2520assay%2520is%2520a%2520predictive%2520screening%2520tool%2520for%2520hERG%2520blockade%2520and%2520proarrhythmia%253A%2520Comparison%2520of%2520intact%2520cell%2520and%2520membrane%2520preparations%2520and%2520effects%2520of%2520altering%2520%255BK%252B%255Do%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2004%26volume%3D50%26spage%3D187%26epage%3D199%26doi%3D10.1016%2Fj.vascn.2004.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0liD6kgai7MD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span> <span> </span><span class="NLM_article-title">Minimizing the potential for metabolic activation in Drug Discovery</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1517/17425255.1.1.91</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1517%2F17425255.1.1.91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=16922655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=91-142&author=A.+S.+Kalgutkarauthor=J.+R.+Soglia&title=Minimizing+the+potential+for+metabolic+activation+in+Drug+Discovery&doi=10.1517%2F17425255.1.1.91"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Minimising the potential for metabolic activation in drug discovery</span></div><div class="casAuthors">Kalgutkar, Amit S.; Soglia, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-142</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Investigations into the role of bioactivation in the pathogenesis of xeno-biotic-induced toxicity have been a major area of research since the link between reactive metabolites and carcinogenesis was first reported in the 1930s.  Circumstantial evidence suggests that bioactivation of relatively inert functional groups to reactive metabolites may contribute towards certain drug-induced adverse reactions.  Reactive metabolites, if not detoxified, can covalently modify essential cellular targets.  The identity of the susceptible biomacromol.(s), and the physiol. consequence of its covalent modification, will dictate the resulting toxicol. response (e.g., covalent modification of DNA by reactive intermediates derived from procarcinogens that potentially leads to carcinogenesis).  The formation of drug-protein adducts often carries a potential risk of clin. toxicities that may not be predicted from preclin. safety studies.  Animal models used to reliably predict idio-syncratic drug toxicity are unavailable at present.  Furthermore, considering that the frequency of occurrence of idiosyncratic adverse drug reactions (IADRs) is fairly rare (1 in 1000 to 1 in 10,000), it is impossible to detect such phenomena in early clin. trials.  Thus, the occurrence of IADRs during late clin. trials or after a drug has been released can lead to an unanticipated restriction in its use and even in its withdrawal.  Major themes explored in this review include a comprehensive cataloguing of bioactivation pathways of functional groups commonly utilized in drug design efforts with appropriate strategies towards detection of corresponding reactive intermediates.  Several instances wherein replacement of putative structural alerts in drugs assocd. with IADRs with a latent functionality eliminates the underlying liability are also presented.  Examples of where bioactivation phenomenon in drug candidates can be successfully abrogated via iterative chem. interventions are also discussed.  Finally, appropriate strategies that aid in potentially mitigating the risk of IADRs are explored, esp. in circumstances in which the structural alert is also responsible for the primary pharmacol. of the drug candidate and cannot be replaced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryrPwGKBtP3rVg90H21EOLACvtfcHk0liD6kgai7MD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVGhs7s%253D&md5=15a3312335273663b6ef1222534f5428</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1517%2F17425255.1.1.91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.1.1.91%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26atitle%3DMinimizing%2520the%2520potential%2520for%2520metabolic%2520activation%2520in%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2005%26volume%3D1%26spage%3D91%26epage%3D142%26doi%3D10.1517%2F17425255.1.1.91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48aR"><div class="casContent"><span class="casTitleNuber">48a</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0liD6kgai7MD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit48a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit48b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span>. <i>Am. Soc. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DAm.%2520Soc.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates. Methodology for 25 enzyme/substrate pairs</span>. In  <i>Optimization in Drug Discovery: In Vitro Methods</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span>, <span class="NLM_string-name">Caldwell, G. W.</span></span>; Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>, <span class="NLM_year">2004</span>; pp  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">230</span>;</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1385%2F1-59259-800-5%3A215" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=215-230&author=D.+M.+Stresserauthor=Z.+Yan&author=G.+W.+Caldwell&title=Optimization+in+Drug+Discovery%3A+In+Vitro+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1385%2F1-59259-800-5%3A215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1385%252F1-59259-800-5%253A215%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26atitle%3DHigh-throughput%2520screening%2520of%2520human%2520cytochrome%2520P450%2520inhibitors%2520using%2520fluorometric%2520substrates.%2520Methodology%2520for%252025%2520enzyme%252Fsubstrate%2520pairs%26btitle%3DOptimization%2520in%2520Drug%2520Discovery%253A%2520In%2520Vitro%2520Methods%26aulast%3DYan%26aufirst%3DZ.%26pub%3DHumana%2520Press%26date%3D2004%26spage%3D215%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit49b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span>, <span class="NLM_string-name">Caldwell, G. W.</span></span> <i>Evaluation of Cytochrome P450 Inhibition in Human Liver Microsomes</i>; <span class="NLM_publisher-name">Idem</span>, pp  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">244</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Yan%2C+Z.%2C+Caldwell%2C+G.+W.+Evaluation+of+Cytochrome+P450+Inhibition+in+Human+Liver+Microsomes%3B+Idem%2C+pp+231%E2%80%93244%3B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DZ.%26jtitle%3DEvaluation%2520of%2520Cytochrome%2520P450%2520Inhibition%2520in%2520Human%2520Liver%2520Microsomes%26pub%3DIdem%26spage%3D231%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit49c"><span><span class="NLM_label">(c) </span> <i>Drug Interaction Studies—Study Design, Data Analysis,
Implications for Dosing and Labeling</i>; <span class="NLM_publisher-name">Center
for Drug Evaluation and Research (CDER), Food and Drug Administration</span>, September <span class="NLM_year">2006</span> and February <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Interaction+Studies%E2%80%94Study+Design%2C+Data+Analysis%2C%0AImplications+for+Dosing+and+Labeling%3B+Center%0Afor+Drug+Evaluation+and+Research+%28CDER%29%2C+Food+and+Drug+Administration%2C+September+2006+and+February+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDrug%2520Interaction%2520Studies%25E2%2580%2594Study%2520Design%252C%2520Data%2520Analysis%252C%250AImplications%2520for%2520Dosing%2520and%2520Labeling%26pub%3DCenter%250Afor%2520Drug%2520Evaluation%2520and%2520Research%2520%2528CDER%2529%252C%2520Food%2520and%2520Drug%2520Administration%26date%3D2006%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Modality-specific peripheral antinociceptive effects of μ-opioid agonists on heat and mechanical stimuli: Contribution of sigma-1 receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.neuropharm.2018.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=29580951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslKmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2018&pages=328-342&author=A.+Montilla-Garc%C3%ADaauthor=G.+Perazzoliauthor=M.+A.+Tejadaauthor=R.+Gonz%C3%A1lez-Canoauthor=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=E.+J.+Cobosauthor=J.+M.+Baeyens&title=Modality-specific+peripheral+antinociceptive+effects+of+%CE%BC-opioid+agonists+on+heat+and+mechanical+stimuli%3A+Contribution+of+sigma-1+receptors&doi=10.1016%2Fj.neuropharm.2018.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Modality-specific peripheral antinociceptive effects of μ-opioid agonists on heat and mechanical stimuli: Contribution of sigma-1 receptors</span></div><div class="casAuthors">Montilla-Garcia, Angeles; Perazzoli, Gloria; Tejada, Miguel A.; Gonzalez-Cano, Rafael; Sanchez-Fernandez, Cristina; Cobos, Enrique J.; Baeyens, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">328-342</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Morphine induces peripherally μ-opioid-mediated antinociception to heat but not to mech. stimulation.  Peripheral sigma-1 receptors tonically inhibit μ-opioid antinociception to mech. stimuli, but it is unknown whether they modulate μ-opioid heat antinociception.  We hypothesized that sigma-1 receptors might play a role in the modality-specific peripheral antinociceptive effects of morphine and other clin. relevant μ-opioid agonists.  Mech. nociception was assessed in mice with the paw pressure test (450 g), and heat nociception with the unilateral hot plate (55 °C) test.  Local peripheral (intraplantar) administration of morphine, buprenorphine or oxycodone did not induce antinociception to mech. stimulation but had dose-dependent antinociceptive effects on heat stimuli.  Local sigma-1 antagonism unmasked peripheral antinociception by μ-opioid agonists to mech. stimuli, but did not modify their effects on heat stimulation.  TRPV1+ and IB4+ cells are segregated populations of small neurons in the dorsal root ganglia (DRG) and the d. of sigma-1 receptors was higher in IB4+ cells than in the rest of small nociceptive neurons.  The in vivo ablation of TRPV1-expressing neurons with resiniferatoxin did not alter IB4+ neurons in the DRG, mech. nociception, or the effects of sigma-1 antagonism on local morphine antinociception in this type of stimulus.  However, it impaired the responses to heat stimuli and the effect of local morphine on heat nociception.  In conclusion, peripheral opioid antinociception to mech. stimuli is limited by sigma-1 tonic inhibitory actions, whereas peripheral opioid antinociception to heat stimuli (produced in TRPV1-expressing neurons) is not.  Therefore, sigma-1 receptors contribute to the modality-specific peripheral effects of opioid analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAy-RHQXgtw7Vg90H21EOLACvtfcHk0lgb8RamqwZxYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslKmu7w%253D&md5=3b35eba44d61705f5326cf9762e9fcaa</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DGonz%25C3%25A1lez-Cano%26aufirst%3DR.%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DModality-specific%2520peripheral%2520antinociceptive%2520effects%2520of%2520%25CE%25BC-opioid%2520agonists%2520on%2520heat%2520and%2520mechanical%2520stimuli%253A%2520Contribution%2520of%2520sigma-1%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D135%26spage%3D328%26epage%3D342%26doi%3D10.1016%2Fj.neuropharm.2018.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho-Cordón, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of peripheral μ-opioid analgesia by sigma-1 receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1124%2Fjpet.113.208272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=24155346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=32-45&author=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=A.+Montilla-Garc%C3%ADaauthor=R.+Gonz%C3%A1lez-Canoauthor=F.+R.+Nietoauthor=L.+Romeroauthor=A.+Artacho-Cord%C3%B3nauthor=R.+Montesauthor=B.+Fern%C3%A1ndez-Pastorauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=J.+M.+Entrenaauthor=E.+J.+Cobos&title=Modulation+of+peripheral+%CE%BC-opioid+analgesia+by+sigma-1+receptors&doi=10.1124%2Fjpet.113.208272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of peripheral μ-opioid analgesia by σ1 receptors</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Montilla-Garcia, Angeles; Gonzalez-Cano, Rafael; Nieto, Francisco Rafael; Romero, Lucia; Artacho-Cordon, Antonia; Montes, Rosa; Fernandez-Pastor, Begona; Merlos, Manuel; Baeyens, Jose Manuel; Entrena, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the effects of σ1-receptor inhibition on μ-opioid-induced mech. antinociception and constipation. σ1-Knockout mice exhibited marked mech. antinociception in response to several μ-opioid analgesics (fentanyl, oxycodone, morphine, buprenorphine, and tramadol) at systemic (s.c.) doses that were inactive in wild-type mice and even unmasked the antinociceptive effects of the peripheral μ-opioid agonist loperamide.  Likewise, systemic (s.c.) or local (intraplantar) treatment of wild-type mice with the selective σ1 antagonists BD-1063 [1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride] or S1RA [4-[2-[[5-methyl-1-(2-naphthalenyl)1H-pyrazol-3-yl]oxy]ethyl] morpholine hydrochloride] potentiated μ-opioid antinociception; these effects were fully reversed by the σ1 agonist PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate) hydrochloride], showing the selectivity of the pharmacol. approach.  The μ-opioid antinociception potentiated by σ1 inhibition (by σ1-receptor knockout or σ1-pharmacol. antagonism) was more sensitive to the peripherally restricted opioid antagonist naloxone methiodide than opioid antinociception under normal conditions, indicating a key role for peripheral opioid receptors in the enhanced antinociception.  Direct interaction between the opioid drugs and σ1 receptor cannot account for our results, since the former lacked affinity for σ1 receptors (labeled with [3H](+)-pentazocine).  A peripheral role for σ1 receptors was also supported by their higher d. (Western blot results) in peripheral nervous tissue (dorsal root ganglia) than in several central areas involved in opioid antinociception (dorsal spinal cord, basolateral amygdala, periaqueductal gray, and rostroventral medulla).  In contrast to its effects on nociception, σ1-receptor inhibition did not alter fentanyl- or loperamide-induced constipation, a peripherally mediated nonanalgesic opioid effect.  Therefore, σ1-receptor inhibition may be used as a systemic or local adjuvant to enhance peripheral μ-opioid analgesia without affecting opioid-induced constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXDUF69QHTL7Vg90H21EOLACvtfcHk0lgb8RamqwZxYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D&md5=3448ecaf8c215210a48a8413b89db2a5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208272%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez-Cano%26aufirst%3DR.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DArtacho-Cord%25C3%25B3n%26aufirst%3DA.%26aulast%3DMontes%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez-Pastor%26aufirst%3DB.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DModulation%2520of%2520peripheral%2520%25CE%25BC-opioid%2520analgesia%2520by%2520sigma-1%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D32%26epage%3D45%26doi%3D10.1124%2Fjpet.113.208272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.2165/00023210-200418050-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.2165%2F00023210-200418050-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15089113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Sgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=269-284&author=T.+Hayashiauthor=T.+P.+Su&title=Sigma-1+receptor+ligands%3A+potential+in+the+treatment+of+neuropsychiatric+disorders&doi=10.2165%2F00023210-200418050-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">σ-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders</span></div><div class="casAuthors">Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">269-284</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The σ receptor was originally proposed to be a subtype of the opioid receptor.  However, it is now clear that σ receptors are unique non-opioid, non-phencyclidine brain proteins.  Two types of σ receptor exist, the σ-1 receptor and the σ-2 receptor.  σ-1 Receptors have been cloned and their distribution, physiol. functions and roles in signal transduction were recently characterized.  Certain sex hormones in the brain (neurosteroids) are known to interact with σ-1 receptors.  σ-1 Receptors regulate glutamate NMDA receptor function and the release of neurotransmitters such as dopamine.  They are thus proposed to be involved in learning and memory as well as in certain neuropsychiatric disorders.  Selective σ-1 receptor ligands have been suggested to represent a new class of therapeutic agents for neuropsychiatric disorders, although none have yet been introduced into therapeutic use.  Early studies showed that psychotomimetic benzomorphans, as well as several antipsychotics, can bind to σ-1 receptors.  As a result of these findings, σ-1 receptor ligands have been proposed as being of potential use in the treatment of schizophrenia.  Nevertheless, the relation of σ-1 receptors to the underlying pathogenesis of schizophrenia is still unclear.  σ-1 Receptor ligands have failed to improve acute psychotic symptoms of schizophrenia in clin. trials, but, interestingly, a few studies have shown an improvement in neg. symptoms in schizophrenic patients.  A no. of preclin. studies have shown that selective agonists of σ-1 receptors affect higher-ordered brain functions such as learning and memory, cognition and mood.  These studies indicate that σ-1 receptor agonists may exert therapeutic effects in depression and senile dementia.  Indeed, the σ-1 receptor agonist igmesine, has been shown to improve depression in a clin. trial.  The most distinctive feature of the action of σ-1 receptor ligands is their "modulatory" role.  In behavioral studies of depression and memory, they exert beneficial effects only when brain functions are perturbed.  Given the recently accumulated preclin. and clin. data, it is time to reconstruct the concept of σ-1 receptors and the assocd. pathophysiol. conditions that ligands of these receptors target.  This would allow clin. trials to be performed more efficiently, and the results may confirm a long-speculated possibility that σ-1 receptor ligands represent a new class of therapeutic agents for neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8ZblhgvXqLVg90H21EOLACvtfcHk0lgb8RamqwZxYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Sgu7w%253D&md5=08d5da331525ae7d7fe5be8665fff0fd</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2165%2F00023210-200418050-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200418050-00001%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DSigma-1%2520receptor%2520ligands%253A%2520potential%2520in%2520the%2520treatment%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DCNS%2520Drugs%26date%3D2004%26volume%3D18%26spage%3D269%26epage%3D284%26doi%3D10.2165%2F00023210-200418050-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of Pan Assay Interference Compounds (PAINS) from screening libraries and their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+screening+libraries+and+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lihrRyNmmH4qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Box, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E. A.</span></span> <span> </span><span class="NLM_article-title">Using measured p<i>K</i><sub>a</sub>, log <i>P</i> and solubility to investigate supersaturation and predict BCS class</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.2174/138920008786485155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.2174%2F138920008786485155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=18991583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=869-878&author=K.+J.+Boxauthor=E.+A.+Comer&title=Using+measured+pKa%2C+log+P+and+solubility+to+investigate+supersaturation+and+predict+BCS+class&doi=10.2174%2F138920008786485155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class</span></div><div class="casAuthors">Box, K. J.; Comer, J. E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">869-878</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ionization, lipophilicity and soly. have a profound influence on the transport properties of drug mols.  We will present an overview of why physicochem. properties are important, before discussing how the properties are related to each other.  Findings are based on research in our own labs. using our com. instruments and software to measure the pKa, lipophilicity (LogP) and intrinsic soly. (LogS0) of 84 marketed ionizable drugs.  In general, the most lipophilic mols. were the least sol. in water.  Plots of LogP vs. LogS0 show results for these drugs clustered according to other properties, including m.p., no. of H-bond donors and acceptors, ability to supersaturate, and BCS class.  Mols. with high m.p. tended to have a larger no. of H-bond donors and acceptors, and to be less sol. than predicted from their LogP.  Mols. with low m.p. tended to have little H-bond donor capacity, and tended to be more sol. than predicted from their LogP.  Mols. that could form supersatd. solns. tended to have higher m.ps., and to be less sol. than predicted from their LogP.  Mols. in BCS Classes I - III tended to cluster in different parts of the plot.  It is proposed that comparing measured LogP and LogS0 of new mols. with these plots will facilitate a quick assessment of their likely BCS Class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjSonznQUhwbVg90H21EOLACvtfcHk0lihrRyNmmH4qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb4%253D&md5=d330301b360589feb67aa92fc0227ea6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F138920008786485155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485155%26sid%3Dliteratum%253Aachs%26aulast%3DBox%26aufirst%3DK.%2BJ.%26aulast%3DComer%26aufirst%3DE.%2BA.%26atitle%3DUsing%2520measured%2520pKa%252C%2520log%2520P%2520and%2520solubility%2520to%2520investigate%2520supersaturation%2520and%2520predict%2520BCS%2520class%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D869%26epage%3D878%26doi%3D10.2174%2F138920008786485155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lastra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baamonde, A.</span></span> <span> </span><span class="NLM_article-title">Analgesic effects of loperamide in bone cancer pain in mice</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2005.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=10.1016%2Fj.pbb.2005.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=15894068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1KqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2005&pages=114-121&author=L.+Men%C3%A9ndezauthor=A.+Lastraauthor=A.+Meanaauthor=A.+Hidalgoauthor=A.+Baamonde&title=Analgesic+effects+of+loperamide+in+bone+cancer+pain+in+mice&doi=10.1016%2Fj.pbb.2005.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic effects of loperamide in bone cancer pain in mice</span></div><div class="casAuthors">Menendez, Luis; Lastra, Ana; Meana, Alvaro; Hidalgo, Agustin; Baamonde, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-121</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The intratibial inoculation of NCTC 2472 cells induces an osteosarcoma in C3H/HeJ mice.  These mice show thermal hyperalgesic responses which may be blocked by the local administration of opiates over the tibial tumoral mass (Menendez L, Lastra A, Hidalgo A, Meana A, Garcia E, Baamonde A. Peripheral opioids act as analgesics in bone cancer pain in mice. NeuroReport 2003b;14:867-9).  The aim of this report was to characterize the analgesic responses obtained by activating peripheral opioid receptors in bone cancer pain.  Here, we initially describe that this osteosarcoma induces mech. as well as thermal hyperalgesia.  Loperamide, an opioid agonist unable to cross the blood-brain barrier, inhibits both thermal and mech. hyperalgesia when s.c. injected, locally over the tibial tumoral mass (7.5-75 μg) or distantly, under the fur of the neck (4 mg/kg).  These analgesic effects seem peripherally mediated since they are reverted by the administration of naloxone methiodide (10 mg/kg) and because the withdrawal latencies of the contralateral, non-affected, paws remain unaltered.  Furthermore, only cyprodime (1 mg/kg) but not naltrindole (0.1 mg/kg) or nor-binaltorphimine (10 mg/kg) blocked these effects, showing the involvement of μ-opioid receptors in the peripheral analgesia induced by loperamide on thermal and mech. hyperalgesia.  The advantages of using peripheral acting opiates - devoid of central collateral effects - for the treatment of cancer related pain are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofeiy9O9hOBbVg90H21EOLACvtfcHk0lhwh8xOEjTqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1KqtL8%253D&md5=6f4a46690f0d0e599d23e2c3d969e218</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2005.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2005.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DMen%25C3%25A9ndez%26aufirst%3DL.%26aulast%3DLastra%26aufirst%3DA.%26aulast%3DMeana%26aufirst%3DA.%26aulast%3DHidalgo%26aufirst%3DA.%26aulast%3DBaamonde%26aufirst%3DA.%26atitle%3DAnalgesic%2520effects%2520of%2520loperamide%2520in%2520bone%2520cancer%2520pain%2520in%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2005%26volume%3D81%26spage%3D114%26epage%3D121%26doi%3D10.1016%2Fj.pbb.2005.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01256">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_36447"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01256?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01256</a>. <ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical data for all the final compounds and intermediates; chiral preparative HPLC separation data and optical purity of enantiopure compounds; HPLC traces for final compounds of formula <b>15</b>; interfeature distances and tolerance radii for the generated MOR and σ<sub>1</sub>R pharmacophores; experimental methods for affinity measurement in selectivity panel targets (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_001.pdf">jm9b01256_si_001.pdf (2.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01256/suppl_file/jm9b01256_si_002.csv">jm9b01256_si_002.csv (5.34 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01256%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01256" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a09abcb6e3c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
